Novel Ion Channels in Neurogenic Pain by Casula, Maria Anna & Casula, Maria Anna
NOVEL ION CHANNELS IN 
NEUROGENIC PAIN 
Maria Anna Casula 
A thesis submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy of the University of London and the Diploma of 
Imperial College London 
March 2009 % 
uNri! 
Abstract 
Neurogenic pain is defined as pain associated with disease or damage of the nervous 
system, comprising spontaneous and stimulus-evoked pain. A key mechanism is 
increased excitability of primary sensory neurons, with consequent central changes. 
Ion channels specific to nociceptive primary sensory neurons are most interesting 
and their contribution to the generation of neurogenic pain has been the subject of 
much current investigation. Between these, specific subtypes of voltage-gated 
sodium channels, vanilloid and purinergic receptors provide potentially interesting 
analgesic drug targets. 
It was hypothesized that modulation of expression of sensory ion channels and 
receptors by disease or trauma results in spontaneous or ectopic discharges, mediated 
mainly via sodium channels, and hypersensitivity of nerve terminals, mainly via 
receptors of the TRF family and the purinoceptor P2X7. 
Sensory neurons and characterised tissues were studied, using 
immunocytochernistry, in common clinical chronic pain states. 
The key novel findings are: 
1) TRPVI is the most selective pain target of the TRP family - it is abundant in 
pelvic afferents, and TRPVI-positive fibres are increased in vulvodynia; TRPVI 
blockade may be particularly effective in visceral hypersensitivity. Studies in 
cultured human sensory neurons demonstrate that Nerve Growth Factor and other 
neurotrophic factors may regulate the increased expression of TRPVl. 
2) P2X7receptor levels were increased in painful injured human nerves. In mice 
with a disrupted P2X7 gene, inflammatory and neuropathic hyperalgesia was 
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completely absent. P2X7 receptor appears pivotal in chronic inflammatory and 
neuropathic sensitization to noxious stimuli. 
3) There is an up-regulation of theP3 subunit, which modulates sodium channel 
activation, in human peripheral nerves after injury, and thus represents a novel 
selective target for spontaneous pain. 
In conclusion, multiple molecular mechanisms are thus involved in pain states, and 
strategies which combine drugs aimed at these targets may be necessary for 
improved clinical efficacy. 
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CHAPTER I 
Introduction 
1.1. Pain 
The nature of pain has been of interest for centuries. While pain had generally been 
considered as something esoteric, belonging to the sphere of the soul, it is only in 
modem times that a sound scientific approach has developed (see Bonica, 1991). 
1.1.1. Physiological versus pathological pain 
Physiological, nociceptive pain is an essential protective process, acting as an alarm 
for noxious stimuli (mechanical, chemical, thermal), which starts with sensory 
nociceptive nerve fibre tenninals innervating peripheral tissues, and travels via the 
spinal cord to the brain, where it is interpreted as "pain" 
Pain comprises a complex sensory input, which can activate involuntary reflex 
withdrawal at the spinal cord level, autonomic responses, and in the higher brain 
centres becomes a conscious sensation. 
If tissue damage occurs following a noxious stimulus, the release of some 
ins (like bradykinin or kallidin), neurotrophic factors (NTFs), neurotransmitters, kini III 
metabolites (e. g. adenosine triphosphate (ATP) and protons) and the activation of the 
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enzyme Cyclo-oxygenase-2 (Cox-2) cause a temporary potentiation 
(hypersensitivity) of the nociceptive system around the injured area, either by direct 
activation of nerve terminals, or indirectly by reducing their transduction threshold, 
so that normally innocuous stimuli become painful (Kidd and Urban, 2001). At the 
same time, some of these factors activate cascades that initiate repair processes to 
restore tissue homeostasis (Richardson and Vasko, 2002; Woolf and Costigan, 1999). 
This type of pain, inflammatory pain, has a well defined time-course, usually 
delimited by the healing process; it can be acute or sub-chronic, depending on the 
extent of injury, and allows for a minimisation of movement and contact with the 
injured area until healing is under way, thus simultaneously accomplishing a 
protective function and supporting tissue repair. In this respect, acute inflammatory 
pain can be considered a physiological, functionally important, event. 
When changes occur which are maladaptive and become irreversible, spontaneous 
persistent pain and severe hypersensitivity can result, which may last beyond the 
healing period and become chronic. In this case, without having any apparent 
protective or reparative role, pain will constitute a dysfunctional response, therefore 
considered pathological (Scholz and Woolf, 2002; Woolf and Mannion, 1999; Woolf 
and Salter, 2000; Zimmen-nann, 2001). For example, in arthritic syndromes, chronic 
tissue inflammation of various origins, e. g. autoimmune, can give rise to pain, which 
becomes an important symptom of the pathology. 
1.1.2. Neurogenic pain 
The focus of this study will be on neurogenic (called also neuropathic) pain, defined 
by the International Association for the Study of Pain (IASP) as pain origInating 
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from a primary injury or dysfunction of any component of the nervous system 
(Merskey et al., 1994). 
Neuropathic pain can result from a range of diseases including physical injury, such 
as a nerve or root lesion (Campbell, 200 1), metabolic dysfunction as in diabetes 
mellitus (Ziegler et al., 1988), infections such as herpes zoster (Fields et al., 1998) or 
cancer (Kocoglu et al., 2002), resulting from tumour invasion of nervous tissue, 
surgical nerve damage during tumour removal, or radiation-induced nerve damage. 
However in none of these is pain an obligatory symptom, and the pathophysiological 
mechanisms responsible for its presence or absence in such a variety of diseases are 
not yet clearly understood. 
Classification of pain into different categories can be anatomically based, depending 
on which part of the body is involved, or pathology-related, depending upon its 
aetiology (Jensen et al., 200 1). More recently, the idea of a mechanism-related 
classification of pain has been proposed (Woolf et al., 1998) which, once developed, 
could be more appropriate for diagnosis and intervention (Woolf and Max, 2001) 
than other types of subdivisions. 
In the last decades there has been a huge advance in the knowledge of the pain 
process, especially at a molecular level (Julius and Basbaum, 2001), with the cloning 
of receptors for painful stimuli and the study of their functionality in recombinant 
systems. This has stimulated the interest on the subject of neuropathic pain, of 
clinical importance for its frequent resistance to treatment with current common 
analgesics, and the appreciation of the importance of a better understanding of the 
ical diagnosis, treatment and novel mechanisms involved for an improvement of clim I 
drug development. 
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1.1.3. The pain pathway 
The detection of pain originates at the periphery through the activation of specific 
receptors sensitive to stimuli of various kinds, mechanical (e. g. strong pressure, sharp 
objects), chemical (extreme pH, histamine, bradykinin, potassium ions), or thermal 
(i. e. temperatures above 45'C or under 15'C), present on the free nerve endings of a 
subset of fibres of the somatosensory system located at the body surface or within the 
body. Once these receptors are activated, the information is carried up to the cerebral 
cortex through a network of neuronal relays (Willis and Westlund, 1997; Hunt and 
Mantyh, 2001). 
Nociceptive sensory fibres in the periphery originate from a sub-population of 
primary sensory neurons (first-order neurons), located mainly in the dorsal root 
ganglia (DRG) of the spinal cord, trigerninal ganglion (TG) and nodose ganglion. 
Primary sensory neurons, including nociceptors, are pseudo-unipolar neurons, 
characterised by a single stem process originating from the soma which divides into a 
peripheral axon innervating the target organs/tissues (e. g. skin) and a central axon 
which enters the CNS and projects to second-order neurons in the dorsal hom of the 
spinal cord at the level of the most superficial lamine I and 11 and the deeper lamina 
VNI and X (figure 1.1). 
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Figure 1.1 DRG structure and its connections. Cell bodies of primary sensory 
neurons are located in the dorsal root ganglia and project centrally to dorsal horn 
neurons in the spinal cord and peripherally to skin or muscle (from Patapoutian et al., 
2003). 
Some second-order neurons project to supraspinal centres, others are interneurons 
involved in the modulation of the nociceptive signals or part of the circuits mediating 
spinal reflexes. The pattern of neuronal interconnections in the dorsal hom is plastic 
and is a potential site of dysfunction and source of pathological pain. 
Nociceptive information passes from the spinal cord to higher centres, and the 
connections between the above structures are quite complex (figure 1.2a). 
The spinothalamic tract (STT), whose input comes mainly from primary A-6 fibres 
(see paragraph 1.2.1), and the spino-reticulo-diencephalic tract, whose input 
originates mainly from C-fibres (see paragraph 1.2.1), project to the thalamus, and 
from here up to the somatosensory cortex type I and type 11 (S-1 and S-11). 
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Figure 1.2 Main ascending and descending spinal pathways. aI Ascending 
nociceptive pathways: spinoparabrachial pathway (red) and the spinothalamic 
pathway (blue). bIA descending pathway originating from the amygdala and 
hypothalamus and terminating in the periaqueductal grey (PAG). 
A, adrenergic nucleus; bc, brachiurn conjunctivum; cc, corpus callosum; Ce, central 
nucleus of the amygdala; Hip, hippocampus; ic, internal capsule; LC, locus 
coeruleus; PB, parabrachial area; Po, posterior group of thalamic nuclei; Py, 
pyramidal tract; RVM, rostroventral medulla; V, ventricle; VMH, ventral medial 
nucleus of the hypothalamus; VPL, ventral posteriolateral nucleus of the thalamus; 
VPM; ventral posteriomedial nucleus of the thalamus; (from Hunt and Mantyh, 
2001). 
The spinothalamic tract, which projects directly onto third order neurons in the 
lateral thalamus, is a phylogenetically more modem pathway. It synapses into the 
lateral parts of the thalamus, which projects specifically to the S-1. In the cortex, the 
S-1 is topographically organized, with the entire surface of body and internal organs 
mapped, with size of representation determined by density of innervation (lips and 
hand areas are large, the back is small). This pathway is therefore classified as a 
'discriminative' pain pathway, participating in the determination of the localisation of 
the painful stimulus. 
The more primitive spino-reticulo-diencephalic connections project indirectly on to 
the intralarninar nuclei and posterior group of the thalamus, passing via the reticular 
formation. This consists of a network of branched neurons extending through the 
midbrain, pons and medulla oblungata. The input transmitted to this area is non- 
specific, conveying information about the intensity and quality of the stimulus. The 
intralammar nuclei of the thalamus project to the striatum and to wide areas of the 
cerebral cortex and to other centres, subserving the alerting response to painful 
stimuli. Neurons of the posterior nuclei of the thalamus project mainly to the S-Il, 
which has a crude topography. This pathway underlies the dull, poorly localised 
persistent painful sensations. 
Analogous to these pathways, sensory signals from the face send their input to the 
spinal trigeminal nucleus. This is divided into three areas of which one in particular, 
the pars caudalis, has cytoarchitectural similarities to the dorsal horn and is involved 
in the transmission of nociceptive inputs, receiving the central processes of 
nociceptive fibres. From here the ventral trigemino-thalamic tract departs, supplying 
the reticular formation and innervating the ventral posteromedial, posterior and 
intralaminar nuclei of the thalamus, which connect further to the striatum and cortex. 
24 
Another important somatosensory pathways carrying nociceptive information ascend 
from the superficial dorsal horn (lamina 1) to the parabrachial area of the brainstem 
(Bester et al., 2000) and from here to the hypothalamus and to the amygdala, areas 
thought to be involved in the autonomic and affective response to painful 
stimulation. These areas project to the periaqueductal gray, an important modulatory 
centre. The flow of nociceptive information is regulated by local circuits of the 
spinal cord involving interneurons of the lamina 11-111 (Substantia Gelatinosa - SG) 
and descending pathways from the brainstem under the control of the forebrain 
(Fields and Basbaurn, 1978; Basbaurn and Field, 1984). 
Spinal cord regulation Excitatory and inhibitory interneurons are both found 
in the SG, which project on the secondary neurons and upon one another. Inhibitory 
intemeurons receive inhibitory inputs from nociceptive afferents and excitatory 
inputs from non-nociceptive afferences and descending pathways. When nociceptive 
afferents are activated, the simple rubbing of the painful area can activate an 
inhibitory tone over nociception. This action stimulates large myelinated A-0 fibres 
skin mechanoreceptors, which activate enkephalinergic SG neurons (spinal gating 
mechanism) alleviating the intensity of painful sensation. 
Descending pathways These originate mainly from the penaqueductal grey 
area of the midbrain (PAG), the nucleus raphe magnus (NRM) in the medulla and 
from the nucleus coeruleus (NQ at the level of the pons (figure 1.2b). 
The periaqueductal gray area is connected directly to the dorsal hom and via the 
NRM. It receives inputs from the spinal cord and many brain regions, including the 
hypothalamus, cortex and thalamus and has a pivotal role in modulating descending 
facilitation and inhibition of the nociceptive input. The NRM and NC inhibit directly 
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the STT relay cells, while the NRM acts also by exciting the enkephalin intemeurons 
of the SG. 
1.1.4. Symptoms of pain 
Neuropathic pain can be present in two main forms: spontaneous (stimulus- 
independent) pain and evoked (stimulus- dependent) pain (Dworkin, 2002; Jensen et 
al., 2001; Woolf and Mannion, 1999). 
Spontaneous pain is present in the absence of any stimulation. This type of pain can 
be continuous or intermittent (paroxysmal), of variable intensity, and is often 
described by patients as shooting, burning, stabbing or of electric-like quality. 
Spontaneous pain is often present following axotomy of peripheral nociceptive 
neurons. Sodium channel accumulation renders the injured axons electrically 
hyperexcitable, so they become an ectopic source of afferent impulse discharges 
(Matzner and Devor, 1994). These discharges, if sustained, can maintain the spinal 
cord in a sensitised state, and innocuous stimuli from the affected region may lead to 
pain sensation. In these circumstances dorsal root ganglion sensory neurons are also 
known to become spontaneously active (Devor et al., 1992). 
Stimulus evoked pain includes hyperalgesia and allodynia. In hyperalgesia, 
increased pain is perceived in response to a noxious stimulus. This symptom can be 
classified into subgroups on the basis of modality, i. e. mechanical, thermal or 
chemical. Hyperalgesia is caused by both peripheral and central mechanisms: in the 
periphery, by sensitization of nociceptive nerve terminals, due to the action of 
inflammatory agents such as bradykinin and prostaglandin; centrally, by facilitation 
of synaptic transmission at the level of the dorsal horn (McMahon et al., 1993), 
where the phenomenon of wind-up has been well characterised, in which the synaptic 
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potential steadily increases in amplitude with each stimulus when repeated stimuli 
are delivered at physiological frequencies. 
Allodynia refers to pain evoked by non-noxious stimuli, also classified on the basis 
of modality, and generally related to central phenomena mediated by large 
myelinated fibres. 
Other symptoms, both positive and negative, have been characterised in neuropathic 
pain. Positive symptoms are abnormal sensations including dysesthesia (unpleasant 
sensations) and paresthesia (abnormal but not unpleasant). Negative symptoms 
consist in the loss of sensation with impainnent of sensory input (referred as 
numbness by patients) and motor deficit (experienced as weakness). 
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1.2. Anatomy of the peripheral sensory system 
This study has investigated mainly the effect of nerve injury or disease on primary 
sensory neurons and fibres. A more detailed description of peripheral nociceptive 
system anatomy and the physiopathological events that follow some forms of injury 
are given in this section and in the following one (Sections 1.2 and 1.3). 
1.2.1. Primary sensory neurons 
Dorsal root ganglia primary sensory neurons possess a specific set of ion channels 
and receptors, which confer to these cells distinctive electrical properties and 
sensitivity to selective stimuli. These include voltage-gated channels, GABAergic 
and glutammatergic receptors, bradykinin, histamine and vanilloid receptors. Some 
of these, such as ATP-activated P2X3 receptor, thermal and chemical sensors of the 
vanilloid receptor family and specific subtypes of the voltage-gated sodium channel, 
show a relatively selective expression in nociceptive neurons providing potentially 
useful targets for analgesic drugs (Wood and Heath, 2000). 
Nociceptors are characterised by high threshold of activation, in contrast to the low 
threshold of sensory neurons that respond to non-painful stimuli. Shift in nociceptor 
activation threshold is observed in clinical pain syndromes (Woolf and Salter, 2000). 
Human DRG neurons are divided in three subgroups based on size, small (diameter < 
25ýM), medium (diameter between 25-50[tM) and large (diameter > 50[tM) cells. 
All three classes of sensory neurons include both low threshold non-nociceptive and 
high threshold nociceptive neurons (Lawson, 2002), but most nociceptors belong to 
the small and medium diameter subtype. In particular, medium cells express 
neuropeptides and are nerve growth factor (NGF) dependent, while small neurons 
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can be subdivided into non-peptide-expres sing cells, regulated by glial cell line 
derived neurotrophic factor (GDNF), and peptide-expressing cells, which synthesize 
calcitonin gene related peptide (CGRP) and substance P (SP) and are regulated by 
nerve growth factor (NGF) (Priestley et al., 2002). Activation of peptide-expre s sing 
fibres by noxious stimuli evokes the release of neuropeptides from peripheral nerve 
endings inducing neurogenic inflammation (Richardson and Vasko, 2002) and also 
into the spinal cord dorsal hom, which may modulate pain (Basbaum, 1999). 
1.2.2. Peripheral nerve 
Axons originating from sensory neurons travel via the peripheral nerves and 
terminate in muscle (intramuscular connective tissue and walls of blood vessels), 
joint ligaments or skin. The peripheral nerve is composed of nerve fibres surrounded 
by connective tissue (Flores et al., 2000; Ide, 1996). Nerve fibres can be myelinated 
or um-nyelinated. Ummyelinated nerve fibres consist of several nerve axons 
enveloped as a group by Schwann cells (figure 1.3), while myelinated nerve fibres 
consist of a single axon that is enveloped individually by Schwann cells, whose 
membrane wraps around the nerve fibre to form a multilaminated myelin sheath 
(figure 1.3), leaving short unprotected spaces along the myelinated fibre (nodes of 
Ranvier). Because of this structure, the electrical transmission along myelinated 
fibres is faster than in the unmyelinated ones. 
Parallel to the subdivision of sensory neurons into three subgroups, sensory fibres are 
subdivided in unmyelinated C-fibres originating from small neurons, fine myelinated 
A-6 fibres from medium size neurons, and myelinated A-P fibres from large neurons. 
A-6 fibres, with a conduction velocity of 10-15 m/sec, respond to thermal and 
mechanical stimuli and convey the sharp immediate pricking pain called 
"first pain" 
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C-fibres, with a conduction velocity <2 m/sec, are usually associated with 
polymodal nociceptors (sensitive to more than one kind of damaging stimuli) and 
convey a prolonged unpleasant dull burning type of pain. 
A-P fibres, with a conduction velocity up to 60 m/sec, transmit painful sensation 
mostly in pathological states, especially when mechanical allodynia has developed. 
The distinctive conduction velocity of the different types of nerve fibres allows for 
an objective assessment of pain perception and identification of the type of fibres 
involved, useful for clinical diagnosis. 
Peripheral nerves contain also a motor component, axons from motoneurons of the 
spinal cord, which join the dorsal postganglionic root via the spinal ventral root 
shortly near the dorsal ganglia, before extending into the peripheral nerves to reach 
their target organs (voluntary muscles). 
Nerve fibres are supported and protected by different layers of connective tissue 
which organise the fibres first in fascicles and finally in a peripheral nerve trunk, 
maintaining the structural continuity of the nerve (figure 1.3). This connective tissue 
has a great importance in guiding the regeneration of the nerve after injury, and the 
degree of its damage influences greatly the outcome of the repair process. Peripheral 
nerves receive both an external segmental blood supply and an intrinsic longitudinal 
blood supply. 
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Figure 1.3 Cross-sectional anatomy of peripheral nerve. This schematic 
illustration shows the connective tissue and nerve tissue components of a normal 
peripheral nerve. The enlarged sections show in details unmyelinated and myelinated 
fibres (from Birch, Bonney and Wynn-Parry. Surgical disorders of the peripheral 
nerves: Churchill Livingstone, 1998). 
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1.2.3. Skin 
Structure The skin is organised in three layers, epidermis, dermis and 
hypodermis. The matrix of these layers is composed mainly of epithelial cells 
(keratinocytes), connective (collagen) and fatty (adipocytes) tissue respectively. 
Skin is crossed by vascular and nervous components, and contains in each 
compartment different annexa, e. g. fibroblasts, dermal dendrocytes, mast cells in 
dermis and Langerhans cells, melanocytes, Merkel cells, sweat glands and hair 
follicles in epidermis (Kanitakis, 2002). Its composition confers to the skin 
protective function and an important role in thermal regulation. This, together with 
its richness in sensory nerve terminals and receptor bodies, makes of the skin a very 
efficient point of both contact and barrier with the external world. 
Cutaneous innervation The innervation of the skin includes afferent somatic 
sensory fibres and efferent fibres of the autonomic nervous system. 
From the cutaneous nerves in the subcutaneous area, branches depart to enter into the 
dermis where they join the dermal nerve plexus, a grid of dividing and overlapping 
branches of somatic sensory and sympathetic fibres. From here nerve bundles of 
sensory fibres travel towards the epidermis, some fibres terminate at the hair follicles 
and on specialised sensory transducers, such as the tactile corpuscles Meissner and 
Pacini, others form a horizontal subepidermal nerve plexus from which nerve fibres 
separate from the bundles, lose the Schwann cell and collagen sheath and emerge as 
single naked axons to form dermal and epidermal nerve endings (Kennedy, 2004). 
Myelinated nerve fibres are mainly involved in mechano sensation, while 
unmyelinated fibres form thermo- and nociceptive free nerve endings. Intra- 
epidermal fibres consist mainly of unmyelinated C-fibre and rare A-6 sensory fibres 
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and are characterised by the expression of cell adhesive molecule (N-CAM) protein, 
protein gene product 9.5 (PGP9.5) and calcitonin gene-related peptide (CGRP). 
Efferent innervation is comprised of non-myelinated fibres of the sympathetic system 
that regulate vascular tone, sweat secretion and pilo-erection. 
Skin innervation is relevant for the study of some neuropathies, where hyper- or 
hypo-sensitivity occur. In particular, intra-epidennal nerve fibre density in skin 
biopsies, proven to be easy to quantify in a highly reproducible way (Smith et al., 
2005), can be a good indicator for pathologies such as diabetic neuropathy, where 
changes occurring in small fibres can be followed in time, whereas nerve conduction 
studies are indicative of large fibre function. 
Keratinocytes The epidermis is organised in continuous layers of 
keratinocytes (KC) comprising, from bottom to top, a basal germinative layer (single 
KC layer), Malpighian layer (5-15 KC layers), stratum granulosum (1-3 KC layers) 
and a comified layer (5-10 KC layers), with an additional layer, the stratum lucidum, 
between the granular and the cornified layers in the palmoplantar region. These 
epidermal cells originate from mitotic divisions of stem cells of the basal layer which 
progress towards the skin surface whilst undergoing a process of morphological and 
biochemical differentiation (keratinisation), resulting in the production of flattened, 
non-nucleate cells that eventually shed from the skin surface, process which takes 
about 30 days. 
Keratinocytes are an important site of neurotrophic factor production; basal 
keratinocytes synthesize and release nerve growth factor (NGF) while suprabasal 
keratinocytes produce neurotrophin-3 (NT-3) (Anand, 1996; Kennedy et al., 1998). 
NGF stimulates proliferation of keratinocytes and, importantly, acts on cutaneous 
nociceptive fibres to regulate the synthesis and expression of neuropeptides (Lewin 
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and Mendell, 1993; Rice et al., 1998), IncreasIng theIr sensitivity particularly in 
neurogenic inflammation (Koltzenburg et al., 1999). 
Expression of vanilloid receptors (see Section 1.4), whose function is well known in 
sensory neurons, has been detected in keratinocytes (Chung et al., 2004; Denda et al., 
2001; Peier et al., 2002b), where their function is less clear and under investigation. 
1.2.4. Dorsal horn 
The impulses generated at the periphery are relayed on by the primary neurons to the 
secondary neurons in the spinal cord. Some of these neurons show convergence, 
encoding for more than one type of information: some relay both somatic and 
visceral noxious stimuli, other respond to both noxious and mechanical stimuli. 
Projections of the primary sensory neurons to the dorsal horn in the spinal cord 
follow a specific pattern: C-/A6-fibres terminate in the most superficial lamine (I and 
11), with some of the A-6 projecting also to the deeper lamina V, while the A-P fibres 
project widely on neurons between lamine III to VI. 
A-6 and C-fibres expressing neuropeptide project mainly to the most superficial part 
of the dorsal horn, from which the spino-parabrachial tract mainly originates, while 
the other group projects mainly into the deeper parts of the substantia gelatinosa 
(Hunt and Mantyh, 200 1). 
Dorsal hom neurons of lamina I express neurokinin receptor- I (NK-1) for substance 
P, which is released following intense peripheral stimulation. These neurons appear 
to be fundamental for the maintenance of chronic neuropathic pain states (Nichols et 
al., 1999), since their ablation is linked to the loss of pain behavior in some animal 
models of pain (Hunt, 2000). Dorsal horn neurons are known to show abnormal 
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activity after denervation, which would explain the pain that originates after injury or 
avulsion of spinal cord nerve root (Berman et al., 1998). 
1.3 Mechanisms of pain 
Neuropathic pain is initiated by nerve tissue damage of various causes and may be 
accompanied by partial or complete loss of afferent sensory function. The pain can 
result from diverse mechanisms, and multiple mechanisms can be involved in a 
single patient (Woolf and Mannion, 1999). Neuroplasticity of the pain pathway is 
the basis of a series of changes, which can take place both at peripheral and central 
level, including sensitisation, usually reversible, but not when maladaptive chronic 
inflammatory pain or neuropathic pain occurs (Woolf et al., 1998; Woolf and Salter, 
2000). 
After nerve tissue damage in the periphery, sensitisation occurs after a short time via 
modulatory mechanisms such as post-translational modification of receptors or 
cellular proteins, most commonly phosphorylation, as occurs with the Naj. 9 subunit 
of the voltage gated sodium channels (Fitzgerald et al., 1999). After a longer time, 
neuronal components of the pain pathway can change phenotype with alteration in 
transcription of receptors and neuropeptides, such that the functional and signalling 
properties of the neurons are altered. 
Other mechanisms inducing neurophatic pain are related to malfunction at a central 
level, like disinhibitiOn of the inhibitory pathways and temporal summation at 
cortical levels. 
Some of the main types of peripheral injuries and dysfunction leading to neuropathic 
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pain, which have been the focus of this study, are here briefly described. 
1.3.1. Peripheral nerve injury 
Traumatic lesions can be the result of stretch, laceration, compression or a 
combination of these. In traumatic nerve injuries, complete transection of the nerve 
occurs only rarely in laceration injuries, while more often injuries involve some 
degree of nerve continuity. Symptoms can range from paresis or sensory disturbance 
up to paralysis and complete sensory loss, depending on the extent of the lesion. 
After injury and degeneration, peripheral nerves undergo a process of regeneration 
(Ide, 1996), which is at the basis for the possibility of functional recovery. The 
response to injury does not involve proliferation of neuronal cells, but is affected by 
the peripheral nerve milieu, with neurotrophic factors making a major contribution. 
In the proximal segment, near the area of injury, nerve axons and myelin reduce in 
diameter. Transcriptional changes occur in the cell bodies of the lesioned axons, 
with a decrease in neurotransmitter production and an increase in the synthesis of 
RNA, proteins and lipids, including all the structural components necessary for the 
regeneration of the injured nerves. From this site, axonal sprouts appear shortly after 
injury. 
In the nerve distal stump, Wallerian degeneration occurs, which involves myelin 
breakdown and dedifferentiation and proliferation of Schwann cells, which now 
produce NGF (Heumann et al., 1987), supporting axonal growth (Maggi et al., 2003). 
Proliferating Schwann. cells will lead, after removal of the axon and myelin debris, to 
the formation of the Bungner's bands that will receive the regenerating axons from 
the proximal stump, which will eventually grow to reinnervate their original 
peripheral targets in the best outcome. 
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Depending on the severity of the lesion, which could involve just axons or the entire 
nerve trunk, the outcome of the regeneration process can be very different. 
Proximal atrophy can be minimal but it can extend back to the cell body, with 
consequent neuronal death in the most severe cases. This depends also by the level 
of the lesion: the closer the injury to the cell body, the higher the possibility of 
neuronal death (Maggi et al., 2003). 
When regeneration occurs and the axonal sprouts do not reach the distal endoneural 
tube, or the distal tube has become fibrotic, they will form a neuroma, consisting in a 
mass of disorganised regenerating axons embedded in connective tissue. Neuromata 
can present with pain as a symptom, related commonly to mechanical hyperalgesia or 
to abnormal electrical hyperexcitability. 
Specific sodium (Coward et al, 2000) and potassium channels (Boettger et al, 2002) 
are thought to be involved in the emergence of pain after nerve injury and neuroma 
formation (England et al., 1996a; England et al., 1998). A change in density and/or 
functionality of these ion channels may cause abnormal electrical activity in the 
primary neurons and fibres. 
Transcriptional changes that follow axonal injury can also induce phenotypic 
changes in DRG neurons, e. g. large sensory neurons start to produce substance P. 
Changes occur also in the surviving intact nociceptors due to factors present during 
Wallerian degeneration (Campbell, 200 1), which act not only on the injured fibres 
but also on the intact ones. 
Changes in the activity of DRG neurons can lead to a long term increased excitability 
of the secondary dorsal hom neurons (central sensitisation), thought to be partly 
CGRP mediated (Bird et al, 2006; Sun et al., 2004). 
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Structural changes can occur in the DRG, such as sympathetic sprouting onto the 
primary neurons (Chung et al., 1997), possibly induced by NGF (Zhou et al., 1999), 
leading to increased neuronal activity. 
Another consequence of peripheral nerve injury is reorganisation of the sensory 
system, which can occur at different levels and may be associated with adverse 
consequences. As an example, severe loss of small fibres input together with 
phenotype change in damaged A-P fibres can induce sprouting of large myelinated 
fibres into the superficial lamine in the dorsal hom of the SC (Woolf and Mannion, 
1999), causing innocuous stimuli to be felt as painful, thus contributing to 
mechanical allodynia. 
1.3.2. DRG avulsion 
Dorsal root ganglion avulsion consists of a lesion of the brachial plexus system in 
which the dorsal root is disconnected from the dorsal hom. 
Brachial plexus injuries, which usually involve both the ventral and the dorsal root, 
can induce paralysis and sensory dysfunction such as numbness and often severe, 
intractable pain, described frequently as a characteristic constant crushing and 
intenuittent shooting pain (Berman et al., 1998). A central mechanism, involving 
second order neurons, is related to the emergence of the pain, which in animal 
models was seen to be concomitant with the appearance of abnormal activity within 
the damaged dorsal horn (Ovelmen-Levitt, 1988). As a consequence, pain relief can 
be obtained by dorsal root entry zone lesioning (Friedman et al., 1988), but this 
procedure has only a transient effect. 
While peripheral nerves are capable of regeneration, injured dorsal root fibres 
do not 
reconnect onto the second order neurons in the dorsal 
hom (Carlstedt, 1997) so that 
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injury at this level is not naturally repaired by regenerative process, but the 
peripheral nerve of the avulsed DRG can be redirect surgically to a neighbouring 
intact nerve. 
1.3.3. Changes in epidermal innervation 
Conditions which present with a change in function or density of skin innervation 
can be accompanied by neuopathic pain. Some hypersensitivity states such as 
vulvodynia present with an increased density of sensory fibres (Tympanidis et al., 
2004). 
In some conditions, neuropathic pain can be correlated also to a decrease in 
innervation (Oaklander, 2001; Holland et al, 1998), which may reflect their severity. 
A disease which can be often accompanied by neuropathic pain is diabetes. 
The metabolic dysfunction leads to neuropathy via multiple mechanisms, with 
hyperglycernia as a primary factor (Vinik, 1999). Elevated Intracellular glucose 
levels drive secondary pathologies, such as oxidative stress and protein glycation. 
These drive the changes in the microvasculature, staiting possibly with 
vasoconstriction and followed by further vascular abnormalities which are 
accompanied by neural dysfunction (Cameron et al., 2001). 
Depending on which components of the nervous system are affected by the 
pathology, distinct painful syndromes will develop. 
The most common type is distal polyneuropathy. In this case, the manifestation of 
diabetic neuropathy begins from the most distal extremities (fingers and toes). 
Common symptoms are numbness, usually confined to feet and lower legs, and loss 
of temperature sensation, negative symptoms occurring throughout the course of 
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diabetes. Positive symptoms are burning paresthesiae and allodynia and occur in a 
minority of patients. 
Also, with distal polyneuropathy, loss of motor innervation can lead to atrophy of 
essential pedal muscles, which results in deformities and ultimately in foot ulcers, 
responsible for the majority of lower-extremity amputations in patients with diabetes. 
Skin biopsies are considered a valid method to evaluate abnormalities in skin 
innervation, particularly the intraepidermal nociceptor fibres (Kennedy et al., 1996; 
Wendelschafer-Crabb et al., 2006), which are of interest since the loss of small 
sensory fibres has been related in some cases to diabetic neuropathy (Lauria et al., 
1998). 
1.4. Contribution of ion channels in pain sensation 
Ion channels belonging to multiple gene families and responsive to various stimuli, 
allow for passage of ions through the lipophilic cell membrane. Many of these 
channels are located at the nociceptor peripheral terminals, affecting neuronal 
excitability and therefore pain sensation (Eglen et al., 1999). Some are involved in 
the detection of painful stimuli, which gate the receptors inducing changes in 
membrane excitability and second messenger signals, particularly Ca+2 . Others are 
voltage-gated channels, involved in the propagation of painful stimuli, by amplifying 
the changes in membrane voltage and contributing to the initiation and transmission 
of action potentials along the axon. Those channels/receptors selectively expressed 
in components of the pain pathway are of particular interest. Their contribution to 
the generation of neurogenic pain has been the subject of much current investigation 
which has brought exciting advances in this field (Okuse, 2007). 
40 
The following three families of ion channels have shown well recognised importance 
in pain sensation: vanilloid receptors (TRP), purinergic receptors (M) and voltage 
gated sodium channels (VGSC), and therefore have been considered in detail in the 
present study. 
The transient receptor potential (TRP) superfamily includes cation channels 
expressed predominantly in the sensory nervous system. One of these channels in 
particular, the TRPV I receptor, is expressed in a subpopulation of nociceptors and is 
sensitive to heat, low pH and to capsaicin, the active component of chilly pepper. 
TRPVI has been largely studied and its involvement in the generation of 
inflammatory and neurogenic pain is well recognised (Caterina and Julius, 2001). 
Punnergic P2X receptors are cationic channels activated by extracellular ATP (Buell 
et al., 1996), thought to be involved in pain mechanisms both centrally and in the 
periphery (Chizh and Illes, 2001). Large quantities of ATP are released with tissue 
damage and inflammation in the periphery, where nociceptive effects can be 
mediated both by neuronal (Chen et al., 1995; North, 2004) and non-neuronal 
(Colornar et al., 2003) P2X subunits. 
Voltage-gated sodium channels play a critical role in membrane excitability and 
action potential generation. As for the other families of receptors considered in this 
study, DRG neuron-specific sodium channels have been identified (Waxman et al., 
1999a). Altered expression of these subunits has been observed after nerve injury 
and in models of inflammatory pain, indicating a strong involvement of these 
channels in the pathophysiology of pain (Waxman et al., 1999b; Wood et al., 2004). 
More details on each of these ion channels families are given at the beginning of 
each relevant result chapter. 
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1.5. Neurotrophic factor (NTF) regulation of sensory neuron 
phenotype 
Sensory neurons are normally under the influence of NTFs. These are produced in 
peripheral target tissues and retrogradely transported to the neuronal cell bodies, 
where they act via specific receptors. A main source of NTFs is the skin (Anand, 
1996; Kennedy et al., 1998), where basal keratinocytes produce NGF and GDNF, 
and suprabasal keratinocytes produce NT-3, regulating nociceptors. NT-3 is also 
present in muscle tissue supporting large myelinated sensory fibres (propioceptive). 
As described in paragraph 1.2.1, small sensory neurons are subdivided in two 
populations based on the production of neuropeptides, a CGRP-positive group, 
regulated by NGF via the high affinity tyrosine kinase A receptor (TrkA), and the 
CGRP-negative group, regulated by GDNF via the receptor complex of glycosyl- 
phosphatidylinositol (GPI)-linked protein GDNFR-alpha and c-ret, a transmembrane 
orphan tyrosine kinase (Trupp et al., 1996). 
Activation of NTFs' receptors initiates signalling pathways which influence neuronal 
survival and gene expression, maintaining specific neuronal phenotype (Lindsay and 
Harmar, 1989). 
In some of the conditions that present with neuropathic pain, NTFs levels are known 
to be altered (Anand, 2004). 
After peripheral nerve lesion, the synthesis of NGF is induced in non-neuronal cells 
of the nerve sheath (Heumann et al., 1987), included Schwann cells of the distal 
stump (Anand et al., 1997), together with the level of other NTFs (Bar et al., 1998; 
Funakoshi et al., 1993). Also, expression of the NGF-receptors is induced in 
Schwann cells in the distal stump at the level of the Bungner's bands, and it is again 
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suppressed when regeneration from the proximal stump occurs (Taniuchi et al., 
1988). While the proximal stump and cell bodies of lesioned nerves would be 
deprived of NGF, there could be an excess of this factor for the uninjured 
fibres/neurons, thought to be of some importance in the generatlon of paln (Hudson 
et al., 2001). In diabetes, changes of innervation and thickness of epidermis have 
been related to NGF, which is often reduced in diabetic skin and may be involved in 
lack of sensation and neuropathic pain, both of which can be symptoms of diabetes 
(Anand, 1995). An increase in the level of NGF plays also a role in the generation of 
inflammatory hypersensitivity (Woolf et al., 1994; McMahon, 1996). 
The altered levels of NTFs can trigger acute effects in sensory neurons and fibres e. g. 
by affecting the biophysical properties of membrane channels such as TRPVI 
(Chuang et al., 200 1), but they also have long term effects, influencing the 
expression of genes for specific proteins, included some of those belonging to the ion 
channel families mentioned in Section 1.4 (Priestley et al., 2002; Gould et al., 2000; 
Ramer et al., 200 1). 
As pointed out before, altered expression of specific ion channels in sensory neurons 
participate in the emergence of neurogenic pain. Since NTFs are involved in the 
induction of these long-term changes, these factors provide a viable target for the 
treatment of chronic pain. 
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Pain management 
There are different types of strategies that can be applied to obtain some relief in 
patients suffering from chronic neuropathic pain. These include pharmacological 
treatments, which may indicate certain pain mechanisms, as well as surgery or 
stimulation techniques such as TENS and acupuncture. The ones more relevant for 
this study are here examined. 
1.6.1. Pharmacological therapies 
Currently available pharmacological therapies and their effectiveness has been 
comprehensively reviewed (Rasmussen et al., 2004; Jensen et al., 2001). Some of 
the most common drugs in use are here considered. 
Opioids Opioids, such as morphine and codeine, act mainly via the central 
nervous system by the activation of G-protein coupled receptors, which causes a 
series of negative effects on neuronal excitability and transmitter release (Jensen and 
Sindrup, 2002). Opioids are usually effective in acute and chronic pain, but less so 
in neuropathic pain syndromes such as trigeminal neuralgia, phantom limb or other 
types of deafferentation pain. Apart from the potential risk of development of 
dependence, adverse effects are sedation and respiratory depression, constipation, 
nausea and itching. 
NSAID Non-steroidal anti-inflammatory agents (NSAID) such as aspirin, 
ibuprofen and paracetamol, act by inhibiting cyclo-oxygenase (COX- I and -2), 
enzymes expressed both at peripheral and central sites, crucial in the initial synthesis 
of prostaglandins (PGs). These agents are especially used to treat chronic 
inflammatory conditions (inflammatory arthritides, osteoarthritis, dysmenspiorrea) 
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but there is not much evidence of their efficacy in the treatment of neuropathic pain 
(Sindrup and Jensen, 1999). Conventional NSAIDs induce mainly gastrointestinal 
side effects. COX- I is the constitutive variant that makes prostaglandins vital for 
protecting the stomach through mucus production, and maintenance of renal blood 
flow. COX-2 is the inducible form that mediates the pain of inflammation by 
sensitising peripheral nociceptors. Specific COX-2 antagonists have been developed 
and are on the market. 
Local anaesthetics These drugs, e. g. lidocaine, act peripherally by inhibiting 
sodium channels and are used for post-herpetic neuralgia (Attal et al., 1999), 
persistent surgical pain (Fassoulaki et al., 2000), diabetic polyneuropathy (Bach et 
al., 1990) and traumatic peripheral nerve injuries (Chabal et al., 1992), all syndromes 
which often do not respond to treatment with standard oploids and NSAIDs. 
Their use is limited by the onset of adverse, usually CNS-related, side-effects. 
Application of drugs locally may reduce the occurrence of side-effects but the 
obstacle of making drugs which can pass readily the skin barrier can be a challenge. 
Centrally acting agents These include some types of antidepressant and anti- 
epileptics. Tricyclic antidepressants are hypothesised to act as sodium channel 
antagonists and on descending inhibitory serotoninergic pathways. They can be 
effective for various types of neuropathies, but have sedative side-effects (Attal, 
2000; Wallace, 200 1). Antiepileptics such as carbarnazepine are thought to act as 
sodium channel blockers (Tanelian and Brose, 199 1), and are usually effective 
against pain related with abnonnal ectopic activity in peripheral nerves fibres. They 
can be accompanied by side-effects, such as dizziness and somnolence. 
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Gabapentin and Pregabalin More recent antlepileptics are pregabalin and 
the related gabapentin, both exerting their action by binding the alpha(2)-delta 
protein, an auxiliary subunit of voltage-gated calcium channels. They have been 
shown to be effective in treatment of diabetic peripheral neuropathy and postherpetic 
neuralgia (Taylor et al., 2006; Backonja and Glanzman, 2003) and are commonly 
used due their lower side-effects profile. 
Capsaicin Capsaicin is an agonist on the TRPV I receptor, highly expressed on 
primary sensory neurons. In rat it has been shown that its topical application at low 
concentrations produces a reversible impairment of the C-fibres terminals in the skin 
without affecting the properties of cell soma or producing cell death in the adult 
animal (McMahon et al., 199 1). In human, topical capsaicin is by itself painful, 
following the activation of small sensory fibres and release of substance P, but its 
repeated application causes a desensitisation to pain. Mechanism of action depends 
on the time course, short term can involve reversible changes in sensory neurons, 
such as neuropeptide depletion, while prolonged application results in a selective 
degeneration of these fibres, possibly by neurotoxicity (Hautkappe et al., 1998; 
Nolano et al., 1999). 
Capsaicin is used for various pain conditions, included neuropathies such as painful 
diabetic peripheral neuropathy, amputation and postherpetic neuralgia, with some 
contrasting results (Zhang and Li Wan Po, 1994; Low et al., 1995; Biesbroeck et al., 
1995; Nolano et al., 1999). 
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Surgical treatments 
Nerve repair after brachial plexus injury 
Brachial. plexus injury, where DRG avulsion and/or peripheral nerve injury occur, 
can induce a state of constant crushing and intermittent shooting pain, usually 
difficult to treat. After surgical repair, when peripheral connections are re- 
established (Berman et al, 1998), an improvement of motor function, with the 
regeneration of the motor neurons to denervated muscles, can be accompanied by a 
return of sensory function and alleviation of pain (Carlstedt et al., 2000). 
Distal neuroma relocation 
Surgery is perfon-ned to eliminate this nerve mass with ectopic activity and relocate 
the proximal nerve terminals to other tissue, generally muscle or bone, where further 
stimulation is minimised. This procedure is sometime successful in eliminating the 
pain, possibly because of the reduced levels of NGF compared to NT-3 in the target 
tissue (Atherton et al., 2006), but often helps only for a limited period, as the neuroma 
reforms and further surgery becomes necessary. 
1.6.3. Nerve growth factor 
Treatment with NTFs can be intended both as a pharmacological therapy and in 
conjunction with surgery. It appears to be useful especially for pain conditions 
where inflammation is involved, more specifically, block of the endogenous NGF 
has been seen to prevent development of hyperalgesia after tissue inflammation 
(Woolf et al., 1994). NT-3 treatment in rats has been shown to be antinociceptive 
(Malcangio et al., 1997). 
A new strategy has been proposed, with NTFs used in connection with techniques of 
tissue engineering for neuropathic pain related to traumatic injuries (Anand, 2004), in 
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which the ratio between NGF and NT-3 could be altered by implanting a tissue- 
engineered surrogate target at the site of nerve injury. This would favour successful 
nerve regeneration and therefore may ameliorate pain and hypersensitivity. Animal 
studies (Ramer et al., 2000) indicate that local application of NTFs could favour the 
regrowth of damaged axons across the dorsal root entry zone into the spinal cord. 
1.6.4. Conclusion 
Despite the existence of few families of drugs with different mechanisms of action, 
there is still a great need to develop novel treatment, in particular for neuropathic 
pain for which drugs available are mostly inadequate for their low/moderate 
effectiveness and a generally high incidence of side-effects. A better understanding 
of the pathophysiology of pain is providing targets for the development of new 
pharmacological therapies, specific to the mechanism of the pathology. 
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Hypothesis and Aim 
As indicated in Section 1.4, a large body of work strongly indicates for a role of 
specific ion channels in neuropathic pain. However, most of the basic research on 
ion channels' distribution and physiology is based on the use of animal models, 
mainly rodents. This thesis explores the correspondence of some of the current 
knowledge in human neuropathic states. 
In this thesis the hypothesis tested is that changes in the excitability of tenninals and 
DRG neurons in distinct pain states (e. g. painful neuromata, causalgia or burning 
pain, mechanical allodynia, vulvodynia) result from differential expression and 
pathophysiology of key sensory channels and receptors. These changes may then 
drive the altered excitability at different levels of the pathways related to pain. 
It was proposed to test the hypothesis by using immunohistochemical (IHC) 
techniques to study the expression and distribution of novel ion channels which 
regulate the excitability of sensory neurons in human tissues from the above pain 
states, and in vitro systems, particularly culture of human injured sensory neurons 
under different conditions (e. g. with or without neurotrophic factors in the culture 
medium). This thesis focuses on novel sodium channel subunits, and on those novel 
receptors highly expressed in nociceptive neurons or peripheral nerves, such as the 
vanilloid and purinergic receptors. Further understanding of the distribution of these 
channels, and their subunits composition, may lead to a better understanding and 
treatment of chronic pain. 
To test outcomes with regard to the primary hypothesis, statistical analysis was 
performed on experimental results to see if there is significant correlation between 
pain and ion channel subunits, with "non-painful" tissues serving as controls. 
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The next step of the project would be to progress to physiological studies and 
investigate the functionality of selected relevant channels. This kind of work has 
obvious limitations in humans, but the use of cultured sensory neurons from human 
ganglia would allow for it in some extent. Some results obtained from a 
collaborative study will be described (Chapter 3, section 3.5.1) and critical further 
work will be discussed in Chapter 6. 
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CHAPTER 2 
Materials and Methods 
2.1. MATERIALS 
2.1.1. Tissues 
Studies were conducted using tissues from well characterised patients, suffering from 
different conditions associated with pain. 
Where available, tissues were used from painful and non-painful injured or diseased 
corresponding areas (e. g. neuroma and tooth pulps), sometimes from the same 
patient. This provides an effective instrument to investigate mechanisms involved in 
pain and to define novel therapeutic targets. 
Description of the types of human tissues used follows: 
9 Brachial plexus trauma: the ends of injured peripheral nerve bundles or "stumps", 
both proximal and distal to the site of injury (figure 2.1), avulsed DRG (disconnected 
from spinal cord) and spinal roots (figure 2.1), both dorsal and ventral, were obtained 
during surgical repair after trauma to the brachial plexus. Injured nerves, mostly C5- 
C8, were ruptured distally with respect to the DRG, with different degrees of lesion, 
from incomplete to complete (axotomy). The sections of spinal roots were collected 
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distally from the injured site (DRG-Cord), being disconnected from the spinal cord 
but still attached to the DRG. Tissue samples were distinguished into acute and 
chronic', depending on the length of time passed between injury and surgery (acute: < 
3-4 weeks; chronic >4 weeks). 
This type of injury occurs mainly as a result of road traffic accidents, especially 
motorbike accidents, and therefore most of the samples come from young male 
patients. 
DRG Spinal Cord 
Nerve 
Rupture 
prox. stump 
4, ýý 
distal stump 
root 
DRG 
Avtilsimi 
Figure 2.1 Tissue samples from brachial plexus injury. Proximal and d'stal 
nerve stumps are taken from ruptured nerves before the two sides are reconnected by 
grafting. DRG with correspondent dorsal and ventral roots disconnected from the 
spinal cord are taken when avulsion occurs. 
Peripheral neuroma: Neuroma relocation is used as a means of alleviating pain, in 
particular chronic pain that can be lasting for years. Neuromata from peripheral 
nerves, usually from limbs, were used in this study. Most of the specimens were 
from painful neuroma but a few rare non-painful ones were obtained and proved to 
be valuable for comparison and correlation of pain with ion channels expression. In 
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addition, nerves proximal to the neuroma and hyper- and hypo-sensItive target skin 
were collected from some patients. 
e Neuropathic nerves: these were collected from patients with non-traumatic 
neuropathy, with or without pain. 
* Hypersensitive skin: samples were collected from patients with vulvodynia, an 
idiopathic hypersensitivity state, and from control patients undergoing surgery for 
reasons unrelated to pain. 
9 Tooth pulp: Samples were collected from patients with painful and non-painful 
dental caries. 
* Hyposensitive (diabetic) skin: Biopsies of leg (calf) skin were collected from 
control subjects and patients with diabetic neuropathy. 
* Spinal cords: post mortern (PM) spinal cords were available from normal, 
control, subjects or from subjects that had suffered from neuroinflammatory or 
neurodegenerative diseases such as multiple sclerosis (MS) and amyotrophic lateral 
sclerosis (ALS). MS is a chronic, autoimmune disorder of the central nervous 
system where inflammatory demyelination often results in a gradual and progressive 
loss of neurological function, sometimes associated with chronic pain if damage to 
motor and sensory pathways occurs. ALS does not normally present with pain, but 
diseased tissues are useful for the study of neurodegenerative processes. 
Control DRGs and Spinal Cords were obtained at post-mortem (autopsy delay of less 
than 48 hours) from the Netherlands Brain Bank and MRC Brain Bank, King's 
College London. 
All other human tissues were collected in our Department or in collaboration with 
surgeons and physicians, with infonned written consent of the patients, and studied 
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with Research Ethics Committee approvals. Prof R Birch, from the Royal 
Orthopaedic Hospital (Stanmore, UK), provided control and injured nerve tissue 
from brachial plexus repairs (DRG, spinal roots and peripheral nerves); Mr. D Elliot 
(Broomfield Hospital, Chelmsford, UK) provided samples of distal peripheral injured 
nerves, neuromata and hypersensitive skin; Dr. A Sandison (Charing Cross Hospital, 
London, UK) collected neuropathic nerves from patients with non-traumatic 
neuropathy, Prof T Renton (Kings College Dental Institute, London, UK) supplied 
the tooth pulp specimens; Dr. P Tympanidis (UCL Hospitals NHS Trust, London) 
and Dr. D Yarnitsky (Rambam Medical Centre Technion, Faculty of Medicine, 
Israel) provided the vulva skin samples, while the skin biopsies from control and 
diabetic patients were collected at the Peripheral Neuropathy Unit, Hammersmith. 
Number of tissue samples available and patients' information are different in each 
study. The exact number of specimens used will be given in each of the individual 
result chapters in a subsection called 'Materials'. 
2.1.2. Antibodies 
Most of the primary antibodies against novel ion channels used in this study were 
obtained from GlaxoSmithKline (GSK) and few are commercially available. The 
antibodies used as neuronal and glial markers and the secondary antibodies are all 
commercially available. 
Neuronal markers were chosen to recognise and differentiate various components of 
the nerve. Axons were detected using antibodies to PGP9.5, which enables detection 
of fine intra-epidermal nerve fibres, but its use is restricted to fixed tissues owing to 
its solubility. In post-fixed tissue, neurofilaments (68,160 and 200 kDa; NF) or 
peripherin (the intermediate filaments of neuronal cells; PPN) were used, which can 
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detect nerve fibres up to the dermis. In particular, PPN is useful to detect fine calibre 
fibres. Schwann cells were recognised using antibodies against SlOO protein and 
glial fibrillary acidic protein (GFAP). 
Antibo4v Generation: 
A complete list of primary antibodies with donor species and titration used for 
immunohistochernistry is given in table 2.1. More details are given for those primary 
antibodies used which are not commercially available. 
03VGSC A site-directed antibody against the human P3-subunit was generated 
against a synthetic peptide (CSAVPVEE) corresponding to the C-terminal 
cytoplasmic tail of the P3 protein (Casula et al., 2004). 
NavI. 7 (VGSQ Antibody (K241) was generated (Coward et al., 2001 a) against 
a peptide corresponding to amino-acids 444 - 449 of the human Na, 1.7 sequence. 
TRPV1 Antibody against human TRPV I subunit was generated against the c- 
terminus sequence CKPEDAEVEKSPAASGEK (Smith et al., 2002). 
TRPV3 Antibody N63 was raised against an amino-terininal peptide 
LAKEEQRRKKG(C) (Smith et al., 2002), of the human TRPV3 sequence. 
TRPV4 Antibody to the human TRPV4 was raised against the N-terminal 
sequence MADSSEGPRAGPGEVA (Gopinath et al., 2005). 
TRPM8 Antibody to the human TRPM8 (D SEL -2) was raised against 
cysteine tagged N-tenninal peptide CEKVv'NYKKHTKEFPTDAFGD, corresponding 
to amino acids sequences 85-105 (Mukerji et al., 2006). 
TRPAl Antibody - 1962 was raised against the human N-terminus antigenic 
peptide SLRKMWRPGEKKEPQGV. 
P2X7 Monoclonal antibodies were raised against the extracellular loop of 
the human P2X7 receptor (Buell et al., 1998). 
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Table 2.1 List of primary antibodies 
Antibodies to Donor species Source (ref) Titration 
h-P3 VGSC Rabbit GSK (A53) 1: 300 - 1: 500 
CGRP Rabbit Chemicon 1: 2k- 1: 4k 
CD68 Mouse Dako Cytomation (M0718) 1: 3k 
Ferritin Rabbit Abcam (ab7332) 1: 20k 
GFAP Rabbit Dako Cytomation (Z0334) 1: 10k- 1: 20k 
NavI. 7 VGSC Rabbit GSK (K241) 1: 100 
NGF Rabbit Genentech USA 1: 2k- 1: 8k 
NF Mouse Dako Cytomation (M0762) 1: 10k 
NT-3 Rabbit Amgen USA (8C/845) 1: 20k - 1: 40k 
Peripherin Mouse Novocastra (NCL-Periph) 1: 500 
PGP9.5 Rabbit Ultraclone (RA95/06) 1: 50k 
P2X7 Mouse 
Gen Biomed Res. Inst. 
(L4/ ELIO 116/122) 
1: 2k - 1: 8k 
SlOO Rabbit Dako Cytomation (Z31 1) 1: 5k- 1: 10k 
trkA Mouse Genentech USA (4EI21487) 1: 200 - 1: 400 
h-TRPAI Rabbit GSK (1962) Ik-2k 
h-TRPM8 Rabbit GSK/SEL-2(1323 TEA) 1: Ik - 1: 2k 
TRPM8 Rabbit Phoenix Pharmaceutical 
(H-050-50) 
1: 2k 
h-TRPVI Rabbit GSK (C22) 1: 5k- 1: 10k 
h-TRPV3 Rabbit GSK (N63) I: lk- 1: 10k 
h-TRPV4 Rabbit GSK (N42) Ik-5k 
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Buffers 
Phosphate buffer (0.2M, for Zamboni fixative) 
Solution A- dissolve 6.24gm NaH2PO4 2H20* in 200ml water 
Solution B- dissolve 11.36gm Na2HP04* anhydrous in 400ml water 
Mix 115ml A+ 385ml B (pH should be 7.0 - 7.3) 
PBS buffer 
Stock solution (10x concentrate): NaCl (1740g), KH2PO4 (54.4g) and Na2HP04 
(227g) are diluited in 20L of purified water. 
Stock is diluited 1: 10 in purified water for use (pH of I xPBS should be 7.0-7.3). 
TBS buffer (0.05M TRIS-buffered saline pH 8) 
400ml of distilled water are added to 500ml of OAM Tris HCI at pH 7.5 (assay 
buffer). Solution is adjusted to pH=8 with IOM NaOH, 8.7grams of NaCl are added 
and the final volume is brought to I litre with water. 
RIPA Buffer 
I% NP-40ý 0.25% sodium deoxycholate and 0.1% sodium dodecal sulphate (SDS) in 
50mM Tris-HCI at pH 7.4. 
Electrophoresis running buffer 
Trys-Glycine-SDS I OX ultra pure diluted 1: 10 in purified water. 
Transfer solution 
350mL purified water, lOOmL methanol, 50mL Transfer Buffer, ImL SDS. 
Lists of chemicals and equipment are given in Appendices -I and -2. 
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2.2. METHODS 
2.2.1. Tissue collection and preparation 
Upon removal, tissue samples were immediately snap frozen in liquid nitrogen and 
then stored at -80'C until use or fixed in 4% paraformaldehyde or Zamboni's fluid 
(see table 2.2). 
Most specimens of spinal cord and roots, DRGs and peripheral nerves and neuromata 
were stored as frozen, unfixed tissues. Only two pre-fixed DRGS were prepared, 
while samples of calf-skin, vulva skin and dental pulps were available both pre-fixed 
and frozen unfixed. 
Pre-fixed or frozen specimens were chosen depending on the intended antibody. 
Most of the antibodies used in this study gave best results on frozen, post-fixed 
tissue, with the exception of the Na, 1.7 (sodium channel) and the neuronal marker 
PGP9.5 antibodies, which perforin best in pre-fixed tissues. 
For fixation, tissue was immersed in fixative overnight (unless small pieces e. g. 
endoscopic biopsies, in which case 1-4 hours fixation was sufficient), then washed 
and transferred to PBS containing 15 % w/v sucrose cryoprotectant and 0.01% w/v 
sodium azide and stored (4'C). 
Prior to preparation of frozen sections, tissues were embedded in optimum cutting 
tissue (OCT) medium (Tissue Tek, UK) and frozen in melting isopentane suspended 
in liquid nitrogen. 
Samples embedded in OCT were used multiple times for sectioning it the cryostat. 
After use, the samples 1) surface was re-sealed with a small amount of OCT and the 
samples (both pre-fixed and unfixed) stored at -80'C. 
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Table 2.2 Fixatives preparation 
4% Formalin (PF) Paraformaldehyde 4% w/v in PBS 
Zamboni 425mL Formalin + 425mL 0-2M phosphate buffer 
+ 150mL saturated aqueous picric acid 
2.2.2. Immunohistochemistry 
Immun. ohistochernistry (lHQ is a technique widely used in basic research to 
understand the distribution and localization of proteins in different parts of a tissue. It 
exploits the principle of antibodies binding specifically to antigens in biological 
tissues. There are numerous IHC methods that may be used to visualise an antibody- 
antigen interaction in tissue sections. 
The standard method mostly used in this work is the Avidin-Biotin Complex (ABC) 
method, which uses avidin, a large glycoprotein with a very high affinity for biotin, 
and biotin, a low molecular weight vitamin that can be conjugated to biological 
molecules such as antibodies or enzymes. 
This is an indirect method involving three layers. The first layer is the unlabeled 
primary antibody of interest. The second layer is the biotinylated secondary antibody 
against the IgG of the animal species in which the primary antibody has been raised. 
The third layer is a complex of avidin and biotinylated peroxidase (ABC) in which 
the components are mixed in proportion to allow free avidin sites to react with the 
biotin in the second layer. 
Peroxide (H202, from glucose-glucose oxidase reaction) is used to detect site of 
peroxidase with 3,3'diaminobenzidine tetra-hydrochloride di-hydrate (DAB) as 
chromogene precipitated in the presence of nickel ions. 
59 
This method has very high sensitivity since it allows for high amplification of signal 
and has low background respect to other methods because of the lower dilution of 
primary antibody generally needed when using it. 
Details of the protocol used are here described. 
For cryornicrotomy, tissues were embedded in optimum cutting tissue (OCT) 
medium (Tissue Tek, UK) orientated in the appropriate way, nerves longitudinally, 
spinal cord transversally, skin and gut perpendicular with respect to dermal papillae 
and intestinal villi. 
Frozen, unfixed sections (10ýtm) were collected onto poly-L-lysine- coated (Sigma 
Poole Dorset UK) -glass slides and post-fixed in freshly prepared, 4% w/v 
formaldehyde for 30 minutes. When pre-fixed tissue was used, tissue sections were 
collected on to the glass slides and left to dry for at least one hour. After washing in 
PBS, endogenous peroxidases were blocked by incubating tissue sections with 0.3% 
w/v hydrogen peroxide in methanol for 15 minutes. 
After washing in PBS to eliminate any residues of alcohol and peroxide, the tissue 
sections were encircled using PAP pen to prevent spreading of antibody solutions. 
Sections were incubated overnight with primary antibody at room temperature (RT) 
in humidified plastic Petri dishes, to prevent tissue sections from drying out. 
Dilutions of primary antibodies were prepared freshly on the day. Antibodies were 
diluted in PBS containing 1/30 v/v of appropriate blocking serum (goat or horse 
serum for rabbit or mouse primary antibodies respectively), bovine albumin serum 
(BSA; 0.05% w/v) and azide (0.01% w/v). 
On the following day, sections were rinsed in PBS and incubated for 40 minutes in 
the appropriate biotinylated secondary antibodies (see table 2.3) diluted in PBS 
(modified as for primary antibodies dilution). 
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Sites of antibody attachment were revealed using a nickel-enhanced glucose oxidase- 
immunoperoxidase and an avidin-biotinylated peroxidase complex (ABC) method, 
(Vector Laboratories, High Wycombe, Bucks U. K. ). Following this method, avidin 
and biotinylated peroxidase were allowed to combine in antibody diluent (without 
azide, since this inhibits the peroxidase), both at 1: 200 v/v, for at least 30 minutes 
before use. After washing from secondary antibodies with PBS, sections were 
incubated in the AB-complex for one hour, rinsed and then incubated in peroxidase 
developer (see table 2.4) with glucose oxidase (Img/lOOmL final concentration), 
which initiates the reaction. Sections were kept in developer for the time needed to 
observe the immunoreaction, usually up to 10 minutes. During this time they were 
monitored under the microscope at regular intervals and the reaction was stopped 
when the positive specific immunostaining had developed and background was still 
low. The reaction was blocked rinsing the sections in purified water. Preparations 
were counterstained in 0.1% w/v aqueous neutral red to visualise cells' nuclei. After 
rinsing in purified water, sections were dried and coverslipped with DPX mounting 
medium. 
Table 2.3 List of secondary antibodies 
Antibodies to Donor Source Reference Titration 
species 
Biotinylated Goat Vector Laboratories, BA-1000 1: 200 
Anti-Rabbit IgG Peterborough, UK 
Biotinylated Horse Vector Laboratories, BA-2000 1: 100 
Anti-Mouse IgG Peterborough, UK 
Non-biotinylated Goat Dako A/S, Denmark Z0420 1: 25 
Anti-Mouse IgG 
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Table 2.4 Developers for immunohistochemistry 
Peroxide Dilute 40mL of Acetate buffer (IM), brought at pH 6.0 with acetic 
developer acid, in purified water 1: 10 v/v. Dissolve di-Ammonium Nickel (11) 
(400rnL) Sulphate 6-hydrate (7grams) and add ImL of glucose solution (8 
grams/20mL of purified water), 0.5mL of ammonium chloride solution 
(3.2grams per 20mL of purified water) and 4mL of DAB stock 
solution. 
DAB stock 3,3'diaminobenzidine tetra-hydrochloride di-hydrate dissolved in 
solution purified water (25mg/mL), stored frozen in aliquots (-20 'Q. 
APAAP One tablet of Sigma Fast Red Tris-buffer and then one tablet of Fast 
developer red/Naphthol dissolved in ImL of purified water. 
For double staining in co-localisation studies, tissue sections were incubated with 
two different primary antibodies at the same time, one raised in rabbit and the other 
in mouse. To develop the immunoreaction, the standard ABC method, which gives a 
dark product, was used to reveal the rabbit antibodies. Mouse primary antibodies 
were detected using an alkaline-phophatase-anti-alkaline-phosphatase (APAAP) 
complex (Dako A/S, Denmark). 
After overnight incubation with primary antibodies, sections were rinsed in TRIS 
buffer, which was used instead of PBS also to dilute all subsequent antibodies. 
Sections were incubated sequentially in secondary antibody biotynilated anti-rabbit 
(at 1: 200 for 40 minutes) and non-biotynilated mouse IgG (at 1: 25 for 40 min), 
washed in TBS, and then incubated in immunoalkaline phosphatase (APAAP; 1: 25 
for 40 minutes). After washing in TBS, incubations in secondary antibodies and 
APAAP were repeated a second time following the same sequence. Sections were 
washed in TBS to eliminate any residue of azide and ABC peroxidase was applied 
for at least 40 minutes. After washing, the peroxidase (rabbit-ABC-black product) 
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was developed first, as explained before, followed by the alkaline phosphatase 
(mouse-APAAP-red product), developed using Sigma Fast Red reagents (Sigma- 
Aldrich, Steinham, Germany; red product; table 2.4). For double staining, 
counterstaining was not performed to avoid red nuclei conflicting with red APAAP 
immunostaining product and vecta mount was used when coverslipping. 
For the comparison of antigens for which antibodies were raised in the same specie, 
this type of double staining was not possible. Instead, flip-flop sections were 
collected and sequential sections were stained for the two antibodies. Consecutive 
flip-flop sections are taken in such a way that it is possible to identify corresponding 
halves of the same neuron based on similarity of the pattern of the two sections. This 
allows estimating the number of cells immunoreactive to only one or to both 
antibodies. 
Specificity method controls included positive and negative controls. For positive 
controls, an antibody known to show positive staining (e. g. antibody against 
neurofilaments in nerve tissue) was used in each experiment, or specific tissue 
known to show positive staining was included when testing an antibody in a new 
tissue type. Negative controls, to test for the specificity of primary antibodies, 
included omission of primary antibodies, or overnight pre-incubation at 4'C of 
primary antibodies with homologous antigen prior to its use. 
2.2.2. Quantification 
0 Cell diameter and counts: Immuno-positive and negative sensory neurons in 
DRG and motoneurons in the spinal cord were assessed using a microscope. Cell size 
in DRG was assessed using a calibrated microscope eyepiece graticule. Only 
nucleated cells were counted to ensure the measure was closest to maximum 
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diameter, and neurons were divided in small/medium (< 50 microns) and large (>50 
microns) diameter groups. 
Human DRGs are rare and difficult tissues to obtain and therefore used sparingly. 
For individual experiments, a maximum of 10 controls and 8 to 12 avulsion injured 
DRGs, were used. 
Only three sections were taken from each tissue sample and each section incubated 
with the antibody studied at the standard optimal dilution, and a higher and a lower 
dilution. 
The antibody dilution which gave the best results was chosen for cell counting across 
all the specimens, so that only one section per sample was used for quantification. 
The entire section of each DRG sample was analysed, with a total number of neurons 
counted, in the range of 50 - 200 cells per section. The number of positive cells in 
each specimen was expressed as % of total in small/medium neurons and large 
neurons separately. Neurons were subdivided according to immunostaining intensity 
as strongly positive versus weak or negative. To confirm the analysis, cell counts 
were repeated by a second investigator. 
Given the limited number of DRG samples, non-parametric analysis was used to 
evaluate the statistical significance of any difference observed between control and 
neuropathic tissue samples (Mann-Whitney test). This test is appropriate even if 
number of samples is as small as three samples per group. Also, the test is based on 
the ranking of the data, rather than their value, which would be most appropriate 
considering the method used to quantify immuno-reactivity in neurons or fibres. 
0 Density of nerve fibres: Computerized image analysis was used (Seescan 
Cambridge, UK) to quantify immunoreactive nerve fibres. Images were captured via 
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video link to an Olympus BX50 microscope (x20 objective) and scanned by the 
computer. One section per tissue sample (three to five fields per section) was 
analysed, positive immunostaining was highlighted by setting grey-level detection 
limits at threshold, and the area of highlighted fibres was obtained as percentage area 
of the field scanned. The mean value was used in subsequent statistical analysis. 
Visual fields were chosen at intervals along the sections to capture images from 
different sides of the nerve. When computerised image analysis was performed on 
different days and the grey-level detection limits at threshold had to be reset, care 
was taken to divide control and injured specimens equally between the different 
sessions. This helped to minimise the subjectivity effect which might confound the 
comparison of controls and injured tissues. 
For the analysis of peripheral nerves, where the density of total nerve fibres varied 
between samples, values were normalised using the ratio of each marker and a 
general nerve marker (NF or PPN) as a measure of nerve density instead of the 
absolute measurements. 
9 Intensity of immunostaining: Grading by two independent observers on an 
arbitrary scale from negative (0) to maximum (3) was performed to quantify the 
intensity of immunoreaction in basal keratinocytes or when nerve fibres 
immunostaining was too sparse or weak to be quantified by computerised image 
analysis. 
* Intra-epidermal nerve fibre counts: For each tissue sample, a minimum of three 
sections were used to count epidermal nerve fibres. The majority of skin samples 
were from 3-4mm diameter punch biopsies so that the length of sections was 
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approximately 3-4mm. Positive fibres were counted along the entire length of skin 
sections, and for each specimen the numbers of fibres were combined to provide one 
measurement per tissue sample, with number of fibres per specimen being from as 
little as zero in some diabetic samples to 20-25 fibres in normal skin. The length of 
epidermis per section was measured using a calibrated microscope eyepiece graticule 
and nerve fibre counts expressed as fibres per length (mm) of section. 
2.2.4 Immunoblotting 
Western blot (immunoblot; WB) is a method to detect a protein in a sample of tissue 
homogenate or extract. This method gives information about the size and the 
potential existence of different isofonns of the proteins under study, and gives also 
some indication of the amount of specific protein in a given sample respect to 
another. 
Western blotting was performed following standard protocol (Yiangou et al., 2000); 
buffers used are listed in paragraph 2.1.3 and chemicals in Appendix- 1. 
Proteins for western blot were prepared from frozen tissue. This was first pulverized 
with a mortar and pestle pre-cooled in nitrogen liquid and then homogenised with a 
Dounce homogeniser in ice-cold RIPA buffer in the presence of protease inhibitors 
(5mmol/L phenylmethylsuphonyl fluoride, 2mmol/L benzamidine, Immol/L 
iodoacetamide and 50mg/mL aprotinin). Homogenate was left 30 minutes on ice and 
then centrifuged at 50OOg for 15 minutes and the supernatant was collected and 
directly used or stored at -70'C. 
The amount of protein in the supernatant was quantified using a Bradford dye- 
binding protein assay (from Bio-Rad Laboratories, Hertfordshire, UK), following the 
manufacturer's instruction. 
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Proteins with different weights were separated by electrophoresis. For each sample, 
a volume of homogenate containing a fixed amount of protein (about 25pg) was 
mixed with SDS sample buffer and incubated at 100'C for five minutes, spinned for 
two minutes and then loaded onto a 6% SDS-polyacrylamide gel. Diluted marker 
(RPN756, from Amersham, UK) was run at the same time to identify the bands. 
Electrophoresis gel was left to run for about 40 minutes at fix voltage of 200mV. 
Proteins were transferred from gel to pre-wetted polyvinylidene difluoride membrane 
(Hybond P) using a semidry transblotter. The membrane was first left in methanol 
for 5-10 min, washed in distilled water and then wetted in transfer solution together 
with the gel at 4'C for 20 minutes, to stabilise before use. Gel and membrane were 
placed between four sheets of 3MM paper and gauze pads and proteins were 
transferred overnight (about 16 hours) at 150mA at 4'C. 
The day after, the membrane was re-hydrated by transferring it first in methanol, then 
water and finally in a solution of PB S containing 0.1 % v/v of Tween 20 (PB S-T). 
Non-specific antibody binding sites were blocked by incubating the membrane at RT 
for two hours in blocking buffer [5% w/v of non-fat dried milk powder (Biorad) in 
PBS-T]. 
Membrane strips were incubated with primary antibodies diluted in blocking buffer 
for two hours at RT. After few washing with PBS-T, strips were incubated for 45 
minutes with biotinylated secondary antibody diluted in blocking buffer and 
subsequently washed for at least 30 minutes with frequent changes in PBS-T. 
For specificity studies, primary antibodies were pre-incubated with homologous 
antigen for two hours at RT before incubation with blots. 
Sites of attachment of primary antibodies were detected using immunoperoxidase 
reagents. Incubation in AB-complex (10ýtL of A+ 10ýtL of B in 50mL of PBS-T, to 
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prepare at least 30 minutes before use) lasted 30 minutes. After washing, 
immunoreactivity was visualised on Hyperfilm autoradiography film after treatment 
with ECL-plus Western blotting detection system, using manufacturer's instructions. 
2.2.5 Image analysis of western blot band 
Optical density readings of autoradiographs were taken using a Digit-X densitometer 
evenly illuminated on a photography viewer. Background readings were determined 
by measuring optical density outside the sample lanes. After subtraction of 
background, the mean of three consecutive readings of protein immunoreactivity at 
the respective band position for each sample lane was obtained. 
Comparisons of control with diseased/injured specimens were performed on separate 
occasions using the same original extracts. Because of inter-gel variation, only gels 
that were performed on the same day were used in comparison studies. Inter-gel 
variation was corrected by comparing the optical density of the positive control in 
each blot and adjusting the optical density readings accordingly. 
2.2.6 Tissue culture of human DRG neurons 
Cultured primary sensory neurons were done in a collaborative study with the 
Histopathology Unit of Cancer Research UK and GSK Laboratories in Harlow, UK. 
Human avulsed cervical ganglia were used to prepare DRG pellets, on which 
immunochemistry was perforined, and cultured neurons, used for 
immunohistochemistry and calcium imaging (Anand et al., 2006). 
Studies in cultured neurons were mainly aimed to evaluate the effect of NTFs on 
neuronal morphology and on the expression and functionality of the capsaicin 
receptor (TRPV I), in culture. 
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Excised DRGs were finely cut, and enzyme digested in Ham's F 12 nutrient medium 
(GIBCO), containing penicillin (100[tg/ml), streptomycin (100 [tg/ml), 0.5% dispase 
(8U/mg, GIBCO), and 0.2% collagenase (Type IV Worthington, 168 U/mg), for 3 
hours at 37C, followed by mechanical dissociation in Ham's F12 + 10% fetal calf 
serum (FCS). 
For DRG pellets, some of the material obtained from mechanical dissociation was 
incubated for few hours in buffer with or without NTFs, and then pelleted by 
centrifugation (200g for 4 minutes) and fixed in 4% PF. The pellets were set in 2% 
agarose, and 10[tm paraffin sections were cut for immunostaining, performed 
following the standard procedure described in section 2.2.2. 
For neuronal culture, cell suspension was plated on poly-l-lysine (20 ýtg/ml, Sigma), 
and laminin (20 [tg/ml, Sigma), coated 8 well Pennanox Labtek slides (Nalge Nunc 
Int. ). Ham's F12 (2mls) + 10% FCS, was added to all the wells, and 7sNGF 
(100ng/ml Sigma Aldrich), rhGDNF (50 ng/ml), and rhNT3 (50 ng/ml) were added 
to half the wells. The cells were incubated at 37'C in a humid environment with 8% 
C02/air for five days and the medium changed after three days. 
For calcium imaging, neuronal cultures were loaded with the calcium indicator fura- 
2 AM (Molecular Probes, UK). The absorption (or fluorescence excitation) 
maximum of fura indicators shifts from 363 nm for the Ca 
2+ 
- free chelator to about 
335 nim for the Ca 2+- bound. The ratio of the fluorescence intensities detected at 
-510 mn when using excitation at 340 and 380 nm 
for fura-2 allows accurate 
measurements of the intracellular Ca 
2+ concentration. 
Detailed methods for immunohistochemistry and calcium imaging on cultured DRG 
neurons have been published (Anand et al., 2006). 
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2.2.7 Statistical analysis 
Descriptive statistics were generated using Microsoft Excel 2000 for Windows 
(Microsoft, Redmond, WA, USA) and GraphPad Prism version 3.00 for Windows 
(GraphPad Software, San Diego California, USA). Group differences were assessed 
using the nonparametric Mann-Whitney U test (two-tailed), in GraphPad Prism. 
Statistical significance was considered when p<0.05. 
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CHAPTER 3 
TRPs receptors and pain 
3.1. Background 
The transient receptor potential (TRP) superfamily includes up to 28 distinct genes 
encoding largely Ca +2 permeable non-selective cation channels, which vary 
significantly in their selectivity and activation mechanisms. These receptors display 
most diverse biological roles (Montell, 200 1) but many TRP proteins, in particular 
those of the TRPV family, are expressed predominantly in the nervous system and 
function in sensory physiology. 
The nomenclature of the TRP family is quite complicated and has been recently 
unified. In this thesis we will use the one indicated by Montell (2005), where six 
mammalian families are described: classical (TRPCs), vanilloid (TRPVs), 
mucolipins (TRPMLs), melastatin (TRPMs), polycystins (TRPPs) and ankyrin 
(TRPA) receptors. 
This study has focused on five of these receptors: three receptors of the vanilloid 
family (TRPVI, TRPV3 and TRPV4), one from the melastatin (TRPM8) and one 
from the ankyrin (TRPA I) group. These subtypes are all present in primary sensory 
neurons and despite having multiple activation mechanisms they share a common 
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function of thennoceptors (Patapoutian et al., 2003; Torninaga and Caterina, 2004), 
each being sensitive within a specific range of temperature (figure 3.1). 
The presence of so many temperature sensitive ion channels (Gunthorpe et al., 2002) 
confers to mammalian a fine temperature sensitivity, possibly an adaptation during 
the evolution of warm-blooded animals. Those channels that are sensitive within the 
noxious range of temperatures are of particular interest for their involvement in 
thennal nociception. 
3.1.1. Structure 
TRPs receptors share significant sequence homology and predicted structural 
similarities, on which their subdivision is based (Moran et al., 2004). 
All TRP receptors have six putative transmembrane domains, with a proposed pore 
region between transmembrane domain five and six, and intracellular N- and C- 
termini (figure 3.2). Most of the subunits are thought to assemble into tetramers 
(Kedei et al., 2001) to form both hornomeric and heteromeric receptors (Hoenderop 
et al., 2003). 
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Figure 3.1 Temperature range of activation for thermoreceptors. 
Temperatures at which TRP channels are activated are shown, with the range of 
painful stimuli (heat and cold) specified. Dotted lines for activation of TRPVI and 
TRPM8 show changes of the threshold temperatures in the presence of other stimuli, 
such as mildly acidic conditions for TRPVI and sub-threshold concentrations of 
menthol for the TRIPM8 (from Tominaga and Caterina, 2004). 
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Figure 3.2 Schematic example of a TRP receptor structure. Human TRPVI 
polypeptide containing six transmembrane domains, a pore loop (P-loop) and three 
intracellular ankyrin repeats (A) in the N-terminal region (from Gunthorpe et al., 
2002). 
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3.1.2. Mechanisms of activation 
Vanilloid receptors 
The term vanilloid receptor originally described the neuronal membrane recognition 
site for capsaicin, the "burning" ingredient of chilli peppers, and other related irritant 
compounds (Szallasi and Blumberg, 1990). Cloning of the rodent functional 
vanilloid receptor VRI (TRPVI) and subsequently of its human version (Caterina et 
al., 1997; Hayes et al., 2000), was followed by numerous molecular and functional 
studies that brought a vast progress in the knowledge on this receptor family. 
TRPVI was shown to be highly expressed in nociceptive sensory neurons, and to be 
activated not only by capsaicin but also directly by noxious heat (> 42-48 OC), and by 
endogenous lipid signalling molecules such as anandamide (Van Der Stelt and Di 
Marzo, 2004). The various activating ligands have synergistic effects and the 
receptor activity is also regulated by low pH (< 6) and phosphorylation by protein 
kinase C (PKC), which both reduce the activating threshold so that for example the 
channel can be open already at RT (Tominaga et al., 1998; Vellani et al., 2001). 
Subsequent studies showed TRPV I gene disruption had minimal effect upon thermal 
nociception (Davis et al., 2000). This, together with the knowledge that the response 
of neurons to heat and capsaicin are not always identical (Nagy and Rang, 1999), 
indicates the existence of thermal receptors genetically distinct from TRPV I. 
Searches of the GenBank nucleotide databank revealed a human sequence 
homologous to TRPVI which has since been identified as a temperature- sensitive but 
capsaicin and pH insensitive, vanilloid receptor-like protein TRPV3 (Smith et al., 
2002; Xu et al., 2002). TRPV3 is responsive to noxious heat, with a threshold of 
-34-38'C, which shifts to lower temperatures with repeated warming (channel 
sensitisation), but to date there is no evidence that it can be activated by any 
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chemical ligand. The TRPV3 subunit is co-expressed with TRPVI in small diameter 
DRG neurons. Although vanilloid receptors are known to exist and function as 
homomers (Kedei et al., 2001; Szallasi and Blumberg, 1999), some evidence has 
been provided for the biochemical association of TRPV3 and TRPVl suggesting 
heteromerization (Gunthorpe et al., 2002) thus allowing a greater range of receptor 
characteristics. 
TRPV4, first described as an osmosensor, (Liedtke et al., 2000; Strotmann et al., 
2000) opening in response to hypotonic swelling of the cell, is also activated at 
temperatures above 24'C and shows strong desensitisation after repeated heating in 
contrast to the properties of other TRPVs (Benham et al., 2003; Watanabe et al., 
2002). 
TRPM8 receptor 
TRPM8 is highly expressed in neurons of DRG and TG, contributing to the sensation 
of cold temperature, since it is activated at cold temperatures below 25'C and by 
"cooling" compounds such as menthol and icilin (McKemy et al., 2002; Peier et al., 
2002a) which also shift the temperature activation threshold of the channel up to 
30'C. The receptor function shows desensitisation after repeated exposure to 
activation stimuli (McKemy et al., 2002). 
TR, PAI receptor 
TRPA I (or ANKTM1) was shown to be activated by noxious cold (T< 15'C) (Story 
et al., 2003), while another group showed its activation by mustard oils, cannabinoid 
compounds and the active compounds of garlic (Bautista et al., 2005). 
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Localisation 
Thermoreceptors are highly expressed in subsets of primary sensory neurons in 
dorsal root ganglia and trigeminal ganglia but they are also found, at lower 
expression levels, in several brain nuclei and in non-neuronal tissue (Bidaux et al., 
2005; Chung et al., 2004; Corey et al., 2004; Mezey et al., 2000; Xu et al., 2002). 
A summary of thermoreceptors' distribution in animal tissue is given in Table 3.1 at 
the end of this section. 
Primary sensory neurons 
In rats, TRPVI has been shown in a sub-population of DRG and TG small and 
medium size cells, where its expression is regulated by NGF, and also in a 
subpopulation of vagal (nodose ganglion) neurons sensitive to brain-derived 
neurotrophic factor (BDNF) (Helliwell et al., 1998) but not in sympathetic superior 
cervical ganglion. TRPVl receptor is transported from DRG neurons both 
peripherally, via C-fibres and A-delta fibres, and centrally to laminae I and 11 of the 
SC via the dorsal root (Valtschanoff et al., 2001). 
TRPV3 has been reported in sensory neurons in primates (Xu et al., 2002) but its 
expression in rodents DRG is not clear (Peier et al., 2002b). In mouse, TRIPW was 
detected in both small and large neurons (Suzuki et al., 2003). Selective expression 
of TRPVI and TRPV3 in nociceptors has been proved in human DRG where the 
receptors are thought to colocalise (Smith et al., 2002). 
In rodents, TR_PM8 and TRIPAI are also detected in sub-populations of small 
neurons. Mouse DRG mRNA shows TRPM8 does not co-express with many of the 
classical markers of nociception, included TRPVI (Peier et al., 2002a). On the 
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contrary, TRPA I is found in nociceptive sensory DRG and colocallses with TRPV 19 
CGRP and SP but not with TRPM8 in rat (Story et al., 2003; Kobayashi et al., 2005). 
Co-localisation of TRPVI and TRPM8 is however still controversial, with some 
evidence of co-expression in a proportion of TRPM8 positive neurons (Babes et al., 
2004; Okazawa et al., 2004), with the discrepancy possibly due to species difference. 
Co-expression of cold receptors with TRPVl could explain the paradoxical hot 
sensation expenenced when one is exposed to a very cold stimulus. 
Other locations 
Localisation other than the sensory nervous system indicates multiple or alternative 
physiological roles, which is corroborated by the existence of putative endogenous 
ligands and alternative mechanisms of activation. In some cases their function in 
locations other than sensory system can be still temperature related, such as for the 
TRPV4 in hypothalamus, where the receptor could be contributing to the central 
regulation of the core body temperature (Guler et al., 2002). 
Some of the TRPs receptors have been reported in keratinocytes. TRPV3 has been 
detected in rodent keratinocytes (Peier et al., 2002b). Few studies report TRPVl- 
immunoreactivity in human keratinocytes (Denda et al., 200 1; Inoue et al., 2002; 
Southall et al., 2003), where its activation by capsaicin induces the production of 
pro-inflammatory mediators such as COX2, IL8 and PGE2 (Southall et al., 2003). 
The presence of vanilloid receptors in keratinocytes thus provides a potential for 
keratinocyte-nerve interaction (Peier et al., 2002b) but these findings and their 
physiological relevance remains controversial. 
TRPV4 and TRPV3 have been localised in rodent keratynocites and may be affected 
by thermal changes (Chung et al., 2004; Guler et al., 2002). 
77 
Table 3.1 Localisation of thermal receptors from current literature 
receptor Localisation 
TRPV1 DRG: small/medium neurons (rodents) 
Peripheral fibres and dorsal rot fibres up to 
lamina I- and 11- of dorsal horn SC 
small/medium neurons in human DRG (protein) 
SKIN: human keratinocytes (KC)in culture 
Others: several brain nuclei of the CNS in rats 
TRPV3 DRG: neurons of all size (primates-mRNA) 
small/medium neurons in human DRG (protein) 
SKIN: in rodents and human by northern blot, 
IHC in rodents showed positive basal KC 
S. CORD: motoneurons and some interneurons, but not 
Dorsal horn laminae 
TRPV4 DRG: neuronal cells, all size but mostly small, (m-RNA and 
protein), in rodents 
SKIN: supra-basal KC in rodents (protein) 
Others: Hypothalamus (protein) 
TRPM8 DRG: Small/medium neurons in rodents (m-RNA) 
Others: human prostate epithelium 
TR_PA1 DRG: Small/medium neurons in rodents (m-RNA) 
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3.1.4. Involvement in pain sensation 
The involvement of TRPVI receptor in the development of pain is well recognised. 
Once activated, capsaicin- sensitive neurones evoke both the sensation of burning 
pain and the release of inflammatory mediators such as SP and CGRP from 
peripheral ten-ninals. This, together with modulation of TRPVl channel by other 
extracellular inflammatory mediators such as prostaglandin, bradykinin and ATP 
(Julius and Basbaum, 2001), provide support for TRPVl involvement in 
inflammatory pain. Also, in genetically modified mice lacking the TRPVI receptor, 
the development of thermal hypersensitivity associated with tissue inflammation is 
impaired (Caterina et al., 2000). 
Numerous studies examining the capsaicin receptor in animal models of neirve injury 
suggest that changes in the level of expression of this receptor can take part in the 
generation of neurogenic pain. TRPV I mRNA is reported to be down-regulated after 
axotomy (Michael and Priestley, 1999) but interestingly it is up-regulated in 
surviving nerves from undamaged DRG neurons after incomplete axotomy (Hudson 
et al., 2001) and it has been shown to accumulate proximal to sciatic nerve ligation 
(Guo et al., 1999). In human, the number of both TRPV3- and TRPVI- 
immunoreactive sensory neurons are increased significantly after DRG avulsion 
(Smith et al., 2002). 
Of the receptors to cold temperatures, TRPAI receptor has been related to 
development of cold hyperalgesia in rodents after inflammation or nerve injury 
(Obata et al., 2005). Use of antisense knock-down confirmed the involvement of 
TRPAI, but not TRPM8, in the induction of cold hyperalges'a after spinal nerve 
ligation in rats (Katsura et al., 2006). 
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TRPVI expression in sensory neurons is known to be regulated by neurotrophins 
(Ogun-Muylwa et al., 1999; Priestley et al., 2002; Ramer et al., 2000; Winter et al., 
1988) and so is TRPAI, which increase in rodents' pain models has been related to 
changes in NGF (Obata et al., 2005). These two receptors are co-localised and their 
up-regulation after injury and inflammation is possibly related. 
Different causes, as skin trauma, distal nerve injury or even infections, can lead to a 
shift in skin sensitivity, with numbness, hypo- or hyperalgesia and allodynia as 
common symptoms. These can be related to changes in the density of innervation, 
via processes of nerve regeneration and re-innervation of the skin. Evaluation of 
epiden-nal innervation has proven to be helpful in the assessment of diabetic 
neuropathies (Kennedy and Said, 1999; Kennedy et al., 1996). Changes in skin 
innervation have been related to states such as vulvodynia, a neurogenic pain 
syndrome of uncertain aetiology characterised by painftil burning sensation, 
mechanical allodynia and hyperalgesia in the region of the vulval vestibulus, where 
increased intraepithelial and papillary innervation has been demonstrated (McKay et 
al., 1991; Tympanidis et al., 2003). 
Evaluation of changes in the expression of TRPs channels at the tenninals of sensory 
fibres and their regulation by neurotrophic factors would be of great interest. 
As TRPV I appears to be related to generation of pain in various animal models, the 
discovery of novel drugs or naturally occurring substances that can block this 
receptor may lead to new therapies for pain. 
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3.2. Aim 
Some of the TRP receptors appear to be present mainly in small/medium diameter 
sensory neurons in rodent and also in human DRG. The involvement of some of 
these receptors, in particular TRPVI, in the emergence of pain in animal models has 
been well described but their involvement in pain mechanisms following chronic or 
acute nerve damage or in the presence of neuropathies in human is largely unknown 
and needs to be explored. 
In this chapter I have described the work done to investigate the distribution of 
vanilloid receptors TRPVl, TRPV3 and TRPV4, and the receptors to cold 
temperatures, TRPM8 and TRPAI, in peripheral nerve tissue from control subjects 
or patients with nerve lesions or different forms of neuropathy, to investigate their 
relationship with pain. 
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3.3. Materials 
Table 3.2 List of human tissues used for TRPs studies 
Tissue N Injury delay Gender Age range (years) 
Control DRG 8 male 3 41-98 
Avulsed DRG 5 Acute male 4 18-50 
6 Chronic male 6 18-30 
Control Spinal cord 
(with attached roots) 
9 
(2) 
male 3 
male 1 
59-80 
(60 and 64) 
Spinal roots 
(dorsal and ventral) 
9 4 acute 
5 chronic 
male 8 22-47 
Control nerve 8 male 6 36-81 
Prox. injured nerve 6 Acute male 5 14-34 
8 Chronic male 5 15-43 
Hyper- hypo-sensitive skin I Chronic male 46 
Finger scar I Chronic male 45 
normal arm skin, painful 
hand neuroma 
I Chronic male 31 
Control Vulvar skin 8 female 24-72 
Vulvodynia 10 Chronic female 19-67 
Non-diabetic 
neuropathic nerves 
6 N. A. N. A. N. A. 
Control calf skin 8 male 5 33-71 
Diabetic calf skin 8 Chronic male 8 36-65yr 
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3.4. Immunohistochemical studies 
The following set of results are presented: 1) Antibody specificity; 2) changes after 
brachial plexus injury in DRG, peripheral nerves and spinal roots; 3) TRPs in painful 
skin and distal painful neuroma; 4) TRPVI in subjects with vulvodynia; 5) study on 
non-diabetic neuropathic nerves; 6) TRPs in skin from subjects with diabetes. 
Most of the results here presented have been recently published (Facer et al., 2007) 
and have been summarised in Table 3.3. 
3.4.1. Antibody specificity 
Specificity of TRPVl and TRPV3 antibodies had been previously tested (Smith et 
al., 2002). 
TRPV4 Pre-incubation of primary antibodies with homologous peptide 
antigen completely prevented staining at 10-2 mg/ml diluted antibodies. 
TRPM8 Pre-incubation of TRPM8 antibodies (GSK 1323) with homologous 
antigen at 10-4 Mg/Ml of antibodies abolished immunostaining. 
TRPAI Antigen to the antibody used was not available. 
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Table 3.3 Summary of TRPS immunostaining in human nerve tissue 
Tissue TRPV1 TRPV3 TRPV4 TRPM8 TRPA1 
Spinalcord + dorsal horn - dorsal horn - dorsal horn + dorsal horn +dorsal horn 
- motoneurons + motoneurons +motoneurons - + motoneurons 
motoneurons 
Dorsal root + fibres Not detected + fibres + fibres + fibres 
Ventral root Not detected + fibres + fibres + fibres + fibres 
DRG + neurons + neurons + neurons of Rare positive + neurons 
(mainly (mainly all size small/medium (mainly 
small/medium) small/medium) No change neurons, no small/medium) 
Increased % of Increased % of with avulsion change after Increased % of 
positive cells positive cells avulsion positive cells 
after avulsion* after avulsion* after avulsion 
Peripheral + fibres, + fibres, + fibres, no + fibres, + fibres, no 
nerves increase at increase at change with fragmented change with 
injury site injury site inju at injury site injury 
Neuropathic + fibres, Not detected NA + fibres, + fibres, trend 
nerves decrease comparable to for decrease 
compared to control nerves compared to 
control nerves control nerves 
Hypersensitive + fibres, Not detected NA + fibres, 
skin increase comparable 
compared to to control 
control nerves nerve 
Vulva skin + fibres up to 
the epidermis, NA NA NA NA 
Increased with 
vulvodynia 
Calf skin + fibres up to Not detected Rare + fibres Rare + fibres Not detected 
the epidermis, in fibres +KC - KC in fibres 
decreased with +KC, with unchangedin +KC, 
diabetes trend of diabetes unchangedin 
- KC decrease with diabates 
diabetes 
KC=keratinocytes 
*= from other authors (Smith et al., 2002) 
3.4.2. Brachial plexus injury 
This section will consider changes in the expression of TRPs channels at the level of 
DRG, spinal roots and peripheral nerves after brachial plexus injury. 
0 DRG 
The distribution of TRPV4, TRPM8 and TRPAI was studied in human DRG, in 
post-mortem controls and after root avulsion. 
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TRPV4 TRPV4-immunoreactivity was detected in neurons of all sizes where 
it appeared more intense in small-medium neurons, with no significant change after 
injury [% TRPV4 small/medium cells, median (range): controls (n=8), 65.5 (57-73); 
acute (n=3), 54 (48-68); chronic (n=5), 60 (47-75); large cells: controls 63 (22-84); 
acute 56 (56-59); chronic 57 (44-78)], and therefore different from TRPVI and 
TRPV3 immunorectivity, which is present mainly in small/medium diameter neurons 
and increases after injury. 
Co-localisation (serial 'mirror-image' sections) revealed that most of the TRPV4 
positive, small/medium cells were also TRPV I and TRPV3 positive (figure 3.3). 
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Figure 3.3 Colocalisation of TRPVs receptors in sensory neurons. Sequential 
DRG section stained for TRPV3 and TRPV4 or TRPVI and TRPV4 show c 0- 
localisation. Arrows indicate parts of the same neurons that have been identified in 
two consecutive sections, and are positive for TRPV-3 and -4 or TRPV- I and -4. 
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TRPM8 Strong TRPM8-immunoreactive fibres were detected In all human 
DRG although sensory cell bodies (small/medium diameter) were very few but 
detected using antibodies from two independent sources (figure 3.4A, Q. These 
antibodies detected also few weakly positive small neurons in rat DRG (figure 3.4B). 
There was no obvious change of this pattern after chronic or acute DRG avulsion 
injury. 
Nuclear staining was observed with one of the two antibodies used (GSK, D SEL -2). 
Immunoreactivity for TRPM8 and for TRPVI in serial 'mirror-image' sections 
(figure 3.4C, D) from an avulsed DRG showed the two receptors colocalised in small 
cells. 
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Figure 3.4 TRPM8 in DRG neurons. TRPM8 in medium size neuron of human 
DRG detected using GSK (A) or Phoenix Pharmaceuticals (C) antibodies. Rare small 
neurons were observed also in rat DRG (B- GSK antibody). TRPM8 (C) and TRPVI 
(D) colocalise in some of the small sensory neurons (arrows) in an avulsed DRG. 
Scale bar = 50ýtm- 
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TRPAI Antibodies to TRPAI showed strong immunoreactivity within a 
subpopulation of small/medium sensory neurons but only medium/weak TRPAI 
immunoreactivity in some large neurons (figure 3.5A, B). The number of TRPA I 
immunoreactive (small/medium) nociceptive neurons increased significantly after 
injury [% cells, median (range): controls (n=8): 16.5 (7-23); avulsed (n=7): 46 (34- 
55); p<0.005; figure 3.5E] whilst there was no significant change in the number of 
large TRPA I -positive cells [% cells, median (range): control 19.5 (13 -3 1); injured 21 
(11-35); figure 3.5F]. 
Serial 'mirror-image' sections showed that most TRPAI-immunoreactive neurons 
were also TRPVI positive (figure 3.5C, D), except for a few large cells which 
showed TRPA I only. 
TRPAI was present in about 20% (control) and 50% (injured) of TRPVI positive 
cells. This corresponds well with animal studies that show all TRPAI-positive 
nociceptors are positive for TRPV I. 
The increase in the ratio of TRPA I+/ TRPV I+ small/medium neurons after injury is 
expected as this change reflects the large increase of TRPAI in small cells after 
injury respect to TRPv I, which is already highly expressed in control DRG (, z70% 
of small/medium cells are TRPVl positive), with a relatively small increase after 
root avulsion (--80% of small/medium cells are TRPVl positive; results from Smith 
et al., 2002). 
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Figure 3.5 TRPAI in human DRG. TRPA I- immunore activity is present in 
control (A) and injured DRG (B). TRPAI- and TR_PVl appear to co-localise in 
small/medium cells (C-D, arrows indicate corresponding parts of the same neurons 
from flip-flop serial sections that are both TRPAI and TRPVI positive). 
Scattergrams (E-F) show an increase in percentage of TRPA I -positive small/medlum 
neurons but not large ones. Scale bar = 50[im (A, B); 75[tm (C, D). 
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0 Nerve roots and spinal cord 
Thermoreceptors were studied in injured dorsal and ventral roots, collected from the 
site proximal to the DRG but which had been disconnected from the spinal cord 
since the time of injury. For comparison, uninjured post-mortem spinal cords, a few 
of which still had the uninjured roots attached, were used. 
TRPVs Uninjured, dorsal spinal roots attached to post-mortern spinal cord 
showed strong TRPV I immunoreactivity, which was maintained after either acute or 
chronic injury (figure 3.6A). No TRPVI-immunoreactivity was detected in ventral 
spinal roots or in motor neurons and fibres in the ventral horn of the spinal cord. 
TRPV4 was present in injured roots, both dorsal and ventral (figure 3.6B), but was 
weak in motoneurons and fibres in the ventral horns. There was no TRPV4 
immunostaining in the dorsal homs of post-mortem spinal cords. 
In contrast to TRPVl, strong TRPV3 immunore activity was observed in the ventral 
horn of spinal cord, in 4 out of 9 samples, both in motoneurons and fibres (figure 
3.6C). In the positive samples, counts of TRPV3 motoneurones ranged from 4- 
66% of total. In accord, strong TRPV3 immunoreactivity was shown in large calibre 
fibres in ventral spinal roots (figure 3.6D), but was not detectable in dorsal roots. 
TRPV3 immunoreactivity was observed in the rare uninjured ventral spinal roots 
available as well as in acutely injured roots but decreased and almost disappeared 
after chronic injury. 
The lack of TRPV3 immunoreactivity in dorsal roots may be due to the majority of 
the protein being transported peripherally rather than centrally or may reflect T"V3 
levels below the detection limit of the method. 
TRPM8 Antibodies to TRPM8 showed strong fibres In both dorsal (figure 
3.6E) and ventral (figure 3.6F) spinal roots, whilst no motoneurons were detected in 
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post-mortern spinal cords. Observations in peripheral nerves (see figure 3-9) indicate 
that TRPM8-immunoreactivity in fibres could be identifying Schwann cells rather 
than large diameter axons. 
TRPAI Few TRPAI-immunoreactive fibres were detected in dorsal (figure 
3.6G - arrows) and ventral spinal roots, but appeared less intense in motoneurons 
(figure 3.6H). 
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Figure 3.6 Thermo-receptors in spinal roots and cord. Immunoreactivity to 
TRPVI (A) in dorsal and TRPV4 (B) in ventral spinal roots is shown. Strong 
TRPV3 -i mmunore activity is present in motor neurons (C) and ventral roots (D). 
TRPM8-positive fibres are shown in dorsal (E) and ventral (F) spinal roots. TRPAI- 
immunoreactive fibres are shown in dorsal roots (G; arrows) and motoneurons and 
fibres (H) in the ventral horn. Scale bar =50ýtm (A-F, H); 25ýtrn (G). 
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0 Peripheral nerves 
This section shows the results obtained using control nerves from amputation and 
proximal injured segments of ruptured nerves collected during surgery for brachial 
plexus repair, therefore from location proximal to the ganglia. 
TRPVs: In control, uninjured peripheral nerves, immunore activity for TRPV1 
(figure 3.7A), TRPV3 (figure 3.7C) and TRPV4 (figure 3.7E) was detected in fine 
and medium calibre fibres, with TRPV3 immunoreactivity less intense than that for 
TRPVI or TRPV4. After nerve injury, both TRPV3 (figure 3.7D) and TRPVI 
(figure 3.7B) - immunoreactive fibres appeared to be increased in both number and 
intensity of immunostaining, whilst there was no change for TRPV4 (figure 3.7F). 
Image analysis (% immunoreactive area) showed a significant increase of both 
TRPVI and TRPV3 immunoreactivity after injury in peripheral nerves [TRPVI: 
range (median); controls (n=8): 12.1-20.6 (17.6); injured (n=14): 18.6-32.0 (24.1); 
p<0.001; TRPV3: controls 0.9-6.9 (5.3); injured 5.8-20.1 (15.0); p<0.001; figure 
3.8A, B]. 
To detennine if the change was specific or related to a general change in fibres 
density after injury, peripherin (PPN; nerve marker for fine-medium calibre fibres) 
was used. The ratio TRPVI: PPN (figure 3.8C) and TRPV3: PPN (figure 3.8D) were 
calculated and image analysis showed a highly significant increase after injury 
[TRPVI: PPN range (median); controls 32.9-82.3 (55.7); injured 63.4-100 (89.8); 
p<0.001; TRPV3: PPN; controls 2.9-19.4 (17.6); injured 25-67.9 (50.0); p<0.001, 
figure 3.8C, D], indicating the apparent increase in expression of the two receptors is 
not due to a difference in the density of fibres between control and injured nerves. 
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Figure 3.7 TRPV receptors in peripheral nerve. TRPVI (A, B), TRPV3 (C, D) 
and TRPV4 (E, F) immunoreactivity was detected in subsets of fibres in control, 
uninjured and in injured peripheral nerves. Neuronal marker (PPN) in control and 
injured nerve is shown in panel G and H respectively. Scale bar = 75ýtrn 
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Figure 3.8 Increase of TRPV3 and TRPV1 in peripheral nerves. Image 
analysis shows an increased area (%) of TRPVI (A) and TRPV3 (B) in peripheral 
nerve after injury. Comparison (ratio) with total peripherin (PPN) nerve area (%) for 
TRPV I and TRPV3 are shown in C and D respectively. 
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control injured control injured 
TRPM8 All peripheral nerves displayed immunoreactivity for TRPM8 (figure 
3.9A). After nerve injury and particularly distal to injury, TRPM8-immunoreactivity 
in nerve fibres was deteriorated and fragmented (figure 3.9B). 
TRPAI Weak TRPAI-immunoreactive fibres were present in peripheral 
nerves (figure 3.9C) but no obvious difference was observed after injury. 
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Figure 3.9 Receptors to cold temperature in peripheral nerves. Peripheral 
nerves show strong TRPM8-imunoreactivity in control samples (A) which 
deteriorates after injury (B). TRPAI-immunoreactivity is shown in injured nerve (D). 
Scale bar = 75w (A, B); 200pin (C). 
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3.4.3. Altered skin sensitivity after nerve injury 
TRPs receptors were studied in hyper- and hypo-sensitive skin specimens from 
patients with pain related to nerve injury and distal neuroma. 
Skin specimens of painful hand from a subject with partial damage at C6 root and 
complete avulsion at C7-TI, showed abundant TRPVl immunoreactive, sub- 
epidermal fibres in hypersensitive skin (figure 3.1 OA, B) but very few in an adjacent 
hyposensitive skin region (figure 3.1 OC), suggesting a correlation between pain and 
density of TRPV I positive fibres. In comparison, normal skin (figure 3.1 OD) 
showed fewer TRPV I- immunore active sub-epidermal fibres than hypersensitive 
skin. 
TRPV I -immunoreactive fibres were detected in a painful peripheral neuroma (figure 
3.1 OE) and in a nerve proximal to an area of painful scar neuritis (figure 3.1 OF). 
Frequent, TR-PM8-immunoreactive large calibre fibres were detected in the sub- 
epidermal region of hypersensitive (figure 3.1 OG) and around blood vessels in deeper 
dermal regions but not hyposensitive skin (figure 3.101-1). In these same tissue 
samples, TRPV3 and TRPAI immunostaining of peripheral fibres were below 
detection level. 
Increased TRPVI in hypersensitive regions may be due to a combination of 
increased availability of trophic factors to the remaining undamaged fibres and 
increased TRPV I -positive fibres regenerating / sprouting into the same area. 
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Figure 3.10 TRPVI and TRPM8 in hypersensitive skin. TRPVl- 
immunoreactive fibres in thenar eminence (A, B) and hypo-sensi II itive skin (C) from 
the u1nar border of distal forearin from a patient with partial damage to C6 and 
complete avulsion of C7-TI; normal skin (D); painful peripheral neuroma (E) and 
nerve proximal to an area of painful scar neuritis (F). TRPM 8- immunore active fibres 
in sub-epidermal region of the hypersensitive (G) but not in the hyposensitive skin 
(H). Scale bar=25gmA, B, D; 50ýtmE, F; 100[tm C. 
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3.4.4. Vulvodynia 
Another pathological state in which TRPVI-immunoreactive nerves appeared to be 
involved with the development of pain is vulvodynia. 
The following results have been published (Tympanidis et al., 2004). 
Patients with vulvodynia had a wide range of clinical symptoms, from coital and 
postcoital pain, to excruciating burning sensation in the absence of any mechanical or 
tactile stimulation. As matched controls, patients undergoing surgery for other 
diagnoses than vulval related diseases, such as hysterectomy, hernia repair, 
endoscopy, and vaginal prolapse repair, were available. 
Skin innervation in the biopsies from vulval vestibulus was investigated using 
antibodies to PGP9.5 as a marker for total innervation, as it detects nerve fibres up to 
the epidermis, and antibodies against TRPV I. 
TRPVI-immunoreactive fibres could be detected throughout the dermis with fine 
fibres penetrating the epidermal layer in both control (figure 3.1 IA) and vulvodynia 
skin (figure 3.11 B). 
Epidermal fibres positive for TRPVI appeared to be markedly increased on visual 
inspection in some vulvodynia specimens; however, these were sparse, fine and with 
the TRPVl immunostaining faint in a number of control specimens, so image 
analysis was not performed in this region. 
The sub-epidennal region, where fibres were robustly immunostained, was chosen 
for image analysis. Comparison of TRPVl immunoreactivity in the sub-epidermis 
showed a significant increase of fibres in the vulvodynia compared to controls, (% 
area of TRPVI immunoreactivity, median (range); controls (n=8): 0.3 (0.1 - 0.7); 
vulvodynia (n=8): 0.75 (0.3- 2.7); p<0.002; figure 3.1 IC). This increase of TRPV1 
immunoreacitivity is not attributable to an increase of fibres alone since comparison 
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by ratio with the general neuronal marker PGP was shown also to be significant, 
(TR-PV 1: PGP9.5 median (range); controls: 0.115 (0.03-0.3); vulvodynia: 0.415 (0.1 - 
0.72); p<0.02; figure 3.11 D). 
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Figure 3.11 TRPV1-positive fibres in vulvar skin. Few TR-PVI-immunoreactive 
fibres were detected in control vulvar skin (A) while these where more abundant in 
skin specimens from patients suffering from vulvodynia (B). Image analysis of % 
TRPV I- immunore active area (C) and TRPVI: PGP9.5 ratio of % area (D), both 
show a significant increase of TRPV I immunoreactivity with vulvodynia. 
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3.4.5 Neuropathic nerves 
Non-diabetic neuropathic peripheral nerves showed strong immunostaining for 
neurofilaments, with a subpopulation of strong fibres for TRPV I and few, weak, 
TRPA I -positive fibres and strong TRPM8-positive fibres throughout. 
While only a small decrease in the density of innervation (% area NF-positive) in 
neuropathic nerves compared to controls was observed, image analysis of TRPVI 
showed that the immunoreactive area (% area) for TRPVI was significantly 
decreased in virtually all neuropathic nerves, regardless of pathology [median 
(range); control (n=5): 3.3 (1.9 - 5-6); neuropathic (n=5): 0.7 (0.04 - 1.8); p<0.005; 
figure 3.12A]. 
There was no obvious change of TRPM8 immunoreactivity, while TRPAI 
immunoreactivity appeared to be decreased in neuropathic nerves in comparison with 
controls by visual assessment (figure 3.12B). 
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Figure 3.12 Image analysis of TRPVI and TRPA1 in non-diabetic 
neuropathic nerves. Non-diabetic neuropathic nerves showed decreased TRPV1- 
positive area (A). Visual assessment of TRPAI-immunoreactivity in fibres indicates 
a decrease of this subunit in neuropathic nerves (B). 
100 
Control Neuropathic 
3.4.6 Diabetic neuropathies 
Diabetes presents with a decrease of skin innervation in distal limbs. The presence 
of thermo-receptors in biopsies from leg skin was studied in tissues samples from 
patients suffering from diabetic neuropathy and compared to controls. 
0 Fibres 
TRPVI immunoreactivity was present in fibres throughout the dermis with fine 
fibres penetrating the epidermis in control (figure 3.13A - arrows) but much reduced 
in diabetic skin (figure 3.13B) . 
TRPM8-immunoreactive fibres were observed up to the sub-epidennal layer but 
were too rare for any meaningful comparison between groups. 
TRPV3- and TRPAI-immunoreactivity were not detected in nerve fibres at the skin 
level in any of the samples, while few weak TRPV4-immunopositive nerve fibres 
were observed, which did not allow any analysis or useful comparison. 
The lack of detection for TRPV3 and TRPAI could be due to a reduced peripheral 
transport respect to TRPV I and / or to a difference in quality between the antibodies 
in detecting low levels of antigen. 
Neuronal markers PPN and NF were used to compare dnsity of innervation between 
control and diabetic specimens. PPN-immunrectivity appeared to be decreased in 
diabetic skin compare to control (figure 3.13C, D), while NF-immunoreactivity did 
not show any clear difference in relation to diabetes (figure 3.13E, F). 
0 Keratinocytes 
As mentioned in paragraph 3.1.2, the presence of some of the TRPs receptors has 
been reported in cultures of human keratinocites (Denda et al., 200 1; Inoue et al., 
2002) but not in rodents (Chung et al., 2004). 
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In this study, immunoreactivity for TRIPV3, TRPV4 and TRPAI, but little or no 
immunoreactivity for TRPV I or TRPM8, were observed in human keratinocytes. 
TRPV3 immunoreactivity was detected most strongly in basal keratinocytes in 
normal skin, sometimes continuously along the length of the epidermis (figure 
3.14A), whilst diabetic skin showed weaker cells (figure 3.14B). 
Positive but patchy TRPV4 basal keratinocytes were observed (figure 3.14C), with 
strongest immunoreactivity at the cell - cell borders of groups of cells often at the 
ridges of the dermal papillae, with no apparent difference between control and 
diabetic biopsis. 
Strong TRPA I immunoreaction was detected in cells of the basal keratinocyte layer, 
at the tips of dennal papillae, (figure 3.14D). Cells in sweat glands were also 
strongly immunoreactive. No obvious difference was observed between control and 
diabetic skin. 
In diabetes, counts of TRPVl immunoreactive fibres per mm length of tissue section 
showed a significant decrease in both epidermis [median (range); controls (n=8): 1.2 
(0 - 2.6); diabetic (n=8): 0 (0 - 0.6); p<0.01)] and sub-epidermis [(controls: 4.4 (0.2 
- 11.1); diabetic: 0.4 (0 - 3.4); p<0.0 1; figure 3.15A, B]. 
In order to determine whether this decrease of TRPV I -expressing fibres is solely due 
to the denervation associated with diabetes, the number of TRPVI-immunoreactive 
fibres was correlated with immunostaining obtained with the neuronal markers NF or 
PPN, as a measure of total innervation. These markers can detect nerve fibres 
throughout the dermis and sub-epidennis, with PPN specific for fine calibre fibres, 
but not intra-epidermal fibres. 
In the sub-epidermis, peripherin- but not neurofilament-immunoreactive fibres were 
significantly reduced, suggesting the decrease in innervation regards mainly small 
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calibre fibres. Comparison of the ratio of TRPVI with peripherin showed a 
significant decrease in sub-epidermis with diabetes [TRPVI: peripherin median 
(range): controls 2.2 (0.7 - 4.2); diabetic 0.6 (0 - 1.7), p<0.01; figure 3.15C] 
indicating a decrease of TRPV I immunoreactivity occurs in addition to the decrease 
in innervation. 
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Figure 3.13 TRPVI receptor and neuronal markers in normal and diabetic 
skin. TRPVI-immunoreactive dermal and epidermal fibers (arrows) in control (A) 
and diabetic (B) skin. Sup-epidermal fibres are shown with neuronal markers PPN 
(C, D) and NF (E, F) in skin of control and diabetic patient. Scale bar = 25ýtm. 
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Figure 3.14 TRPs receptors in keratinocytes. TRPV3-immunoreactive basal 
keratinocytes in control (A) and diabetic (B) skin. TRPV4- (C) and TRPAI- (D) 
immunoreactivity in keratinocytes. Scale bar = 50ýtrn. 
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Figure 3.15 Quantification of TRPV1-immunoreactive fibres in diabetic skin 
in comparison to control. Number of TRPV I fibres per mm length skin biopsy was 
decreased in both epidermis (A) and sub-epidermis (B) in relation to diabetes (p < 
0.01). In sub-epidermis, percentage ratio of TR_PVI: PPN (C) is significantly reduced 
in diabetic skin (p < 0.01). 
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Visual assessment of the intensity of TRPV3 immunostaining in keratinocytes 
showed a trend (p = 0.05, Mann Whitney U test) for decrease in diabetic skin (figure 
3.16), while TRPV4 and TRPA I were unchanged. 
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Figure 3.16 Intensity of TRPV3 immunostaining in keratinocytes. Diabetic 
skin showed a trend for decrease in intensity of TRPV3 immunostaining in 
keratinocytes. 
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3.5. In vitro experiments 
Experiments on cultured human DRG neurons were the results of a study carried out 
in collaboration with the Cancer Research UK. For this study, avulsed DRGs from 
five male patients were used to produce cultured primary sensory neurons. 
Preparation of the neuronal cultures and IHC experiments were conducted by Dr. 
Urna Anand at the Cancer Research Unit, where I was able first to observe and then 
to help with the culture preparation. In two occasions, I used part of the tissue to 
produce DRG pellets, used to assess the condition of neurons prior to long term 
culture and to determine the effect of short duration exposure to NTFs. 
3.5.1 Summary of results observed in cultured DRG neurons 
Experiments done on cultured neurons showed a change in morphology and 
expression of TRPVl, with increased amplitude of response to capsaicin, depending 
on the inclusion of neurotrophic factors, consisting in a combination of NGF, GDNF 
and NT-3, in the incubation medium (Anand et al., 2006). 
Cultured neurons appeared as round or ellipsoid cell bodies with long, branching 
neuntes, and stained positively for the neuronal marker Gap43. Neurons cultured 
without NTFs showed neuronal sizes in the range of 20-100[im (figure 3.16 A) with 
a mean diameter of 42[tm. Neurons cultured with NTFs showed a significant shift in 
sizes, with increased cell diameters, from 20 - 120 ýtm and a significant 
increase in 
mean diameter to 62ýtm (figure 3.17A; p<0.01). 
There is a possibility that the difference seen in neuronal size is 
due to chance, to a 
in the 
casual distribution of the dissociated neurons when plating the cell suspension I 
wells. 
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However, great care was taken every time during this procedure, by thoroughly 
mixing the suspension before aliquoting a constant volume of cell suspension 
(250RL) to plate in each well. There were 8 wells in each of the slides, 4 slides per 
patient, and all cells were counted, measured and pooled for analysis. For each slide, 
half of the wells were picked at random for incubation with the extra NTFs 
component in the medium. This method should have avoided the possibility of 
observing a difference by chance. 
When changes in neuronal size were first observed, it was decided to check the 
neuronal size of the cell preparation after mechanical dissociation before plating. I 
performed IHC using the standard ABC-method with antibodies for the neuronal 
marker NF, to compare the DRG material retrieved by mechanical dissociation to 
section of standard DRGs, directly frozen after collection. This was done in order to 
check that the dissociation procedure was not causing a significant loss of any 
neuronal subtype. The pelleted DRG material, with or without short incubation in 
NTFs, showed an approximate neuronal size distribution similar to that observed in 
sections of frozen DRGs (results in the next paragraph), further indicating that the 
increased neuronal size observed in the NTFs treated cultured neurons was related to 
a long-term culture with NTFs rather than to the procedure used to prepare the 
neuronal suspension. 
Intense TRPV I- positive staining was observed in small/medium sized neurons in the 
absence of NTFs. The overall proportion of TRPVl positive neurons (as a% of all 
Gap-43 positive neurons) increased from 35+/-4% without NTFs to 71+/-4% with 
NTFs (p < 0.003). TRPVI-immunoreactivity was observed in a greater number of 
large diameter neurons with the addition of NTFs (figure 3.17B). 
108 
Some of the cultured neurons produced at the Cancer Research Unit were used by 
researchers at GSK for calcium imaging experiments. Their results are presented 
here to show the ftinctional changes that accompanied the increased TRPV- 
immunorectivity in NTFs treated neuronal cultures. Calcium imaging experiments 
measured the bound and unbound Ca +2 ratio before, during and after the addition of 
capsaicin (at 200nM, 500nM and I RM). 
Responses were given as the difference between baseline and peak change of 
intracellular Ca +2 ratio, and expressed as a percentage of the maximum response to 
I ýM capsaicin. These experiments showed that all capsaicin-sensitive neurons 
demonstrated a rapid and sustained rise in 340/380nm ratio, due to calcium influx 
when stimulated with capsaicin, which was blocked by preincubation with the 
vanilloid antagonist capsazepine (10[tM). Neurons cultured with NTFs had 
significantly increased amplitude of responses than those cultured without NTFs 
when stimulated with the same doses of capsaicin (figure 3.17C). 
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Figure 3.17 Cultured neurons morphology and activation by capsaicin. A: 
Size distribution of all Gap43 positive neurons cultured with NTFs (clear bars) and 
without NTFs (solid bars). B: Size distribution of TRPVI -positive neurons cultured 
with NTFs (clear bars) and without NTFs (solid bars). C: Graph showing percent 
changes in intracellular 340/380 excitation ratio in cells with or without NTFs, at 
200nM, 500nM and IýM capsaicin concentration (*** p<0.0001, ** p<o. 01, *p< 
0.05). 
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3.5.2. Results from DRG pellets 
Pellets from pre-digested DRG which were fixed after few hours of incubation in 
medium with or without NTFs, were used in order to test that no cell population was 
lost with digestion and mechanical dissociation, and to determine the effect of short 
duration exposure to NTFs. 
Pellet sections were immunostained with antibodies to TRPVl (figure 3.18A, B), 
TRPV3., and two non-TRPs channels., the sodium channel Nav 1.8 and the potassium 
channel hIKI, for comparison, as well as antibodies for the neuronal markers NF 
(figure 3.18C) and peripherin. Neurofilament immunostaining was also performed in 
frozen DRG sections (figure 3.18D) to compare cell sizes with pellet sections. 
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Figure 3.18 TRPV1-immunoreactivity in human DRG pellet. TRPVl- 
immunopositive neurons in sections of DRG pellets pre-treated with NTFs (A) or 
without NTFs (B). Neurofilament immunore activity in sections from hDRG pellet 
(C, without NTFs) and from post mortern hDRG (D). Scale bar = 50 [tm. 
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The percentage of positively stained cells was estimated from the total number of 
neuronal profiles in each section, separately for two main subgroups (small/medium 
versus large cells); all measurements are given as mean +/- standard error. 
TRPVI immunostaining in the pellet sections was similar to the cultured neurons, 
showing increased numbers of positive neurons, both small and large, in the presence 
of NTFs (table 3.4). No obvious change with short NTFs pre-incubation was seen 
with the other channels considered (table 3.4) except for an increased percentage of 
TRPV3-positive large neurons. 
This study shows an indication for an early positive effect of NTFs on TRPVI 
expression. However these measurements were taken from multiple sections derived 
from very few subjects and therefore it is not appropriate to make consideration 
about statistical significance. 
Table 3.4 Neurons in hDRG pellets immunopositive for the indicated ion 
channels (as % of total). 
Without NTFs With NTFs 
Marker Cell diameter 
< 50ýLM 
Cell diameter 
> 50pM 
Cell diameter 
< 50pM 
Cell diameter 
> 50pM 
TRPV1 51 ±5 6±2 73 ±2 18 ±3 
TR-PV3 57 ±2 4±2 55 ±2 16 ±4 
Na, 1.8 42 ±2 36 ±2 51 ±4 46 ±5 
IK1 62 ±2 49 ±2 61 ±2 52 ±3 
Neurofilament staining of pellet sections without NTFs showed a similar size 
distribution as post mortem DRG neurons (figure 3.19A, B). Similar results were 
seen in DRG pellets pre-incubated in NTFs for only few hours. The neuronal marker 
peripherin was selective for small/medium neurons, with around 75% of small and 
medium neurons being PPN-positive (figure 3.19C). 
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Figure 3.19 Neuronal size distribution in hDRG. Immunoreactivity to NF shows 
the size distribution of hDRG neurons from pellet sections (A: without NTFs) Is 
comparable to the size distribution of control post mortem DRG neurons (B). 
Proportion of P PN - immunore active neurons (for each size subgroup) in sections of 
hDRG pellets (without NTFs) shows most small and medium neurons are PPN- 
positive while large neurons were all negative to peripherin (Q. 
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3.6. Discussion 
The TRP family appears to have differential expression in the peripheral nervous 
system, and specific changes in peripheral neuropathies. 
DRG 
In this study we have characterised, to our knowledge for the first time, the presence 
of TRPV4, TRPM8 and TRPA I in human sensory neurons. 
While TRPV4 expression was not specific for any neuronal subtype in DRG and did 
not appear to be affected by injury in either DRG or peripheral nerves, the 
distribution of TRPAI and TRPM8 was mostly confined to a small proportion of 
small/medium neurons and an increase in the proportion of TRPA1 positive neurons 
was observed with avulsion. 
The wide distribution of TRPV4 receptor in both small and large neurons match 
observations in mice (Suzuki et al., 2003), and the specific localisation in 
small/medium neurons observed for the two cold temperature receptors is consistent 
with a previous report in rodents (Kobayashi et al., 2005). Also, the increase of 
TR-PAI but not TRPM8 seems to correspond well with results in animal models of 
nerve injury, which show a major role of TRPAI in the emergence of cold 
hyperalgesia. 
The number of TRPM8-positive neurons observed in this study was small and 
colocalisation with TRPVI was tested only in few DRG samples. Therefore it was 
not possible to quantify the frequency of co-localisation and compare it to animal 
studies, which have shown co-expression of TRPM8 with TRPVI can be species 
dependent, present only in a relatively small proportion of TRPM8-positive neurons 
114 
(Okazawa et al., 2004; Kobayashi et al., 2005). Also, the few cases in which 
colocalisation was observed occurred in avulsed DRG and therefore could have been 
a secondary effect of the TRPV I increase induced by injury. 
The co-localisation of TRPAI with TRPVI observed in human DRG corresponds 
well with results previously shown in rodents (Story et al., 2003; Kobayashi et al., 
2005). 
Roots and Spinal Cord 
A clear difference in the distribution of TRPV3 and TRPV I in spinal nerve roots was 
observed in this study. TRPVI was observed in dorsal but not in ventral roots, in 
contrast, TRPV3 was present in ventral but not observed in dorsal roots. 
The presence of TRPV I in human spinal dorsal roots shown in this study is in accord 
with rodent data (Valtschanoff et al., 2001), showing TRPV I is transported from the 
DRG neurons both peripherally and centrally to laminae I and 11 of the spinal cord 
via the dorsal root. The increase observed in dorsal roots after either acute or chronic 
injury may be due to accumulation as seen in injured peripheral nerves. TRPVI 
immunoreactivity was not detected in ventral roots, which may be expected as it was 
not detected in motor neurons. 
Strong TR-PV3-immunoreactive fibres in ventral roots correlates well with the 
presence of this receptor in adult human motoneurons, and correlates well with 
studies in monkeys showing TRPV3 m-RNA in motoneurons and other neuronal 
elements (Xu et al., 2002). The significance of TRPV3 presence in motoneurons is 
at present unknown and deserves further investigation. The TRPV3-immunoreactive 
large caliber fibres seen in control and acutely injured ventral spinal roots almost 
disappear after chronic injury. Insufficient control samples precluded a meaningful 
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quantitative comparison of vanilloid receptors in spinal roots, but the decrease of 
TRPV3 in ventral roots is most likely due to their disconnection from their source of 
TRPV3 (motoneurons). The weak TRPV3 immunoreactivity in dorsal roots is 
consistent with a preferential transport peripherally rather than centrally. It cannot be 
excluded that these observations reflect a difference in levels of TRPV3 protein or 
quality of the antibody. 
Peripheral nerves 
This study has shown that both TRIPV3 and TRPV I are increased in peripheral nerve 
proximal to the site of injury in accord with a previous study of human DRG, where 
TRPVI and TRPV3 were also increased in small neurons after avulsion (Smith et al., 
2002). 
The increase in injured nerves indicates that these receptors continue to be exported 
from the ganglion and accumulate in the nerve proximal to injury despite reduced 
support from peripheral trophic factors e. g. NGF/ GDNF from target tissue (skin). 
An increased availability of trophic factors to spared nerve fibres may be occurring, 
similar to a phenomenon described in an animal model of partial nerve injury. In this 
model it was suggested that undamaged fibres obtain more neurotrophins, made 
available because of the reduced uptake by damaged fibres (Hudson et al., 2001). 
The increased T"VI and T"V3 receptors immunostaining seen in this study, in 
combination with the presence of regenerating fibres, may be particularly relevant 
for the development and persistence of pain in chronic cases. In addition, 
inflammatory mediators and neurotrophins derived from damaged Schwann. cells or 
infiltrating macrophages at the injury site may contribute to enhance the synthesis of 
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vanilloid receptors (Hu-Tsai et al., 1996; Ramer et al., 1997; Ramer et al., 2000; 
Theodosiou et al., 1999; Tracey and Walker, 1995). 
In skin fibres or in peripheral nerve trunks at distal location, such as hand, TRPV1- 
immunoreactivity, but not TRPV3, was detected. The abundance of TRPV I -positive 
fibres observed in neuromata at distal location and in painful, hypersensitive skin 
relative to normal skin correlates well with the TRPV I involvement in mechanisms 
of pain and hyperalgesia. 
Vulvodynia 
Recent studies had shown an increase of the vulval epithelial innervation, as 
identified by increased PGP-immunoreactive fibres (McKay et al., 1991; Tympanidis 
et al., 2003), in vulvodynia. This study has shown, for the first time, an increase of 
TRPVI-immunoreactivity in fibres of the sub-epidermal region in this condition, 
with parallel change in the epidennal fibres (Tympanidis et al., 2004). Also, 
immunoreactivity to the sodium channel Navl. 8, highly expressed in un-myelinated 
fibres, showed no difference between patients with vulvodynia and controls, 
suggesting a specific increase of the vanillold receptor. 
The increased innervation and TRPVl expression could have resulted from a 
previous infection or inflammation, factors known to increase NGF expression in 
keratinocytes, which in turn may induce nerve sprouting and increase TRPVI 
expression (Ensor et al., 1996; Winter et al., 1988). 
The mechanism(s) for persistent increase of sprouting and TRPV I expression in 
vulvodynia patients, after resolution of any triggers, remains unknown. While 
increased TRPV I innervation appears to be a feature of primary vulvodynia, the 
production of symptoms may require triggers, i. e., increased levels of endogenous 
117 
ligands. These could include TRPVl agonists, such as eicosanoids, leukotrienes, and 
low pH; inflammatory cells and their products thus deserve consideration in this 
condition. 
Since increased expression of TRPV I by polymodal nociceptor fibres could mediate 
some of the symptoms in vulvodynia, TRPVI antagonists, shown to reverse 
mechanical allodynia in neuropathic and inflammatory pain in animal models 
(Walker et al., 2003), may ameliorate both thermal and mechanical hypersensitivity 
in conditions such as vulvodynia. 
Peripheral neuropathic nerves 
This study showed a clear decrease in the expression of TRPVI in subjects with non- 
diabetic neuropathies compared to controls. The cases were different, from distal 
axonal to demyelinating neuropathy. In all cases histology showed a decrease of 
nerve fibres and / or axonal atrophy. 
In skin of subjects with diabetic neuropathy, changes in the expression of TRPV 
receptors were seen both in nerve fibres and keratinocytes. 
Innervation: The present study shows that TRPVI is decreased in both intra- and 
sub-epidermal fibres in diabetes resulting in the hypo- sensitivity typical of diabetic 
neuropathy. A decrease of intra-epidermal fibres has been shown in human diabetic 
skin using the pan-neuronal marker PGP9.5 (Kennedy et al., 1996), whilst others 
have shown a decrease of TRPVI-immunoreactivity parallel to the general decrease 
in skin innervation (Lauria et al., 2006). 
The observed decrease of TRPV I may have been due simply to an overall reduction 
of innervation, a common feature of diabetes. To address this we used a neuronal 
marker for quantification of total innervation to normalise values. Comparisons were 
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made using the nerve markers NF and PPN, which do not detect epidermal fibres, 
thus limiting our normalised analysis to sub-epidermal fibres. The density of TRPV I 
sub-epidennal fibres was still clearly decreased in diabetic skin after nonnalisation 
with either PPN or NF. In addition to a loss of fibres, these results therefore suggest 
that TRPV I is down-regulated in remaining fibres. 
Keratinocytes: This study indicates that TRPV3 is present in human keratmocytes, 
which is consistent with the report of TRPV3 in rodent keratinocytes (Peier et al., 
2002b). Instead I was unable to detect TR-PV I in human keratinocytes despite 
several reports describing TRPVI in keratinocytes and other non-neuronal cells 
(Denda et al., 200 1; Dvorakova and Kummer, 200 1; Inoue et al., 2002; Southall et 
al., 2003; Veronesi et al., 1999). However these studies are performed in cultured 
keratinocytes and TRPVI expression could therefore be a consequence of culture 
conditions. It can not be excluded that the lack of TRPVI immunoreactivity in 
keratinocytes in the present study could reflect low level of expression or receptor 
confori-national changes preventing antigen-antibody recognition. 
Functional properties of vanilloid receptors in keratinocytes have been suggested to 
involve transduction between the basal keratinocytes and sub- epidermal/epiden-nal 
nerve endings (Peier et al., 2002b) or exocytosis of epidermal lamellar bodies, which 
is regulated by calcium influx (Denda et al., 2003). Recently, the activation of 
TRPV4 channels (but not TRPV3) present in keratinocytes was shown to accelerate 
barrier recovery in mice and human skin (Denda et al., 2006) indicating this receptor 
is specifically involved in epidermal pen-neability barrier homeostasis. In this study, 
no change of TRPV4 levels but a decrease of TRPV3 with diabetes was observed. 
Diabetic epiden-nis is known to be abnonnally thin, so the trend we describe for 
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decrease of TRPV3 in keratinocytes may be related to changes of neurotrophins or 
other factors controlling skin differentiation and TRPV3 expression. 
In vitro study 
Studies conducted by collaborators at the Cancer Research UK showed an effect of 
NTFs on cultured sensory neurons from avulsed human DRG. 
Neurons were cultured with and without added NTFs, nonnally synthesised in 
keratinocytes, to approach in vivo pathological and normal conditions respectively. 
The observed increase in number of TRPVl positive neurons, especially large 
neurons, in DRG cultured with NTFs, could be due to increased expression in 
TRPVI positive neurons, now within the detection limit of the method; higher 
neuronal density of this channel would be consistent with the higher calcium influx 
response observed in cultures with NTFs when channels were activated by capsaicin. 
The increase could also be due to novel expression in small and large diameter 
neurons that do not normally express this vanilloid receptor, and partly explained by 
a shift in size, i. e. neuronal hypertrophy in the presence of higher levels of NTFs, 
which has been previously described (Albers et al., 1994). 
The size- distribution analyses in neurons pelleted few hours after mechanical 
dissociation showed that there was no selective loss of any particular subset of 
neurons before plating. Even a short incubation with NTFs appears to have had a 
remarkably rapid effect on TRPV I expression in DRG neurons. TRPV3, Nav 1.8, and 
hIK I, were not significantly changed, suggesting a different mechanism of regulation 
of these ion channels, which may requIre longer duratIon or higher levels of exposure 
to NTFs. 
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When using human DRG for culture, only injured tissue can be available; also, 
harvesting neurons for culture inevitably involves a central and peripheral axotomy, 
and considerations should apply when extrapolating from in vitro to in vivo studies. 
However, these rare studies on human DRG neurons in vitro provide an extremely 
valuable model to investigate the functionality of the human TRPV I receptor, to test 
novel T"VI antagonists and to evaluate if findings from animal models are also 
valid in human sensory neurons. 
Relevance 
A change of expression and regulation of thermoreceptors is a major factor for 
dysfunction of the pain pathway and may play a role in sensory dysfunction, related 
to states of hyper/hypoalgesia. In particular, TRPV1 represents a selective target for 
pain, particularly for post-traumatic chronic hypersensitivity states, thus providing 
potential new therapies for chronic pain. 
Novel T"VI antagonists block hyperalgesia in animal models of neuropathic and 
inflammatory pain. Clinical trials with TRPV I antagonists are already in progress 
for chronic pain and hypersensitivity states, and may provide in vivo evidence of 
efficacy. 
Desensitization of capsaicin sensitive primary afferent neurons with the TRPVI 
agonist capsaicin or its powerful analogue RTX is another therapeutic possibility, as 
shown in patients with neurogenic bladder dysftinction and detrusor instability 
(Apostolidis et al., 2006). 
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Chapter 4 
P2X purinoreceptors and pain 
4.1. Background 
Purinergic P2X receptors are a ligand-gated ion channel family, which consists of 
seven receptor subtypes, named P2X, -P2X7. They form cationic channels and are 
activated by extracellular adenosine-triphosphate (ATP) (Buell et al., 1996). P2X 
subunits share 26-47% identity in amino acid sequence, with P2X7 being the most 
distinctive (Khakh et al., 200 1). 
4.1.1. Structure 
Each subunit consists of two transmembrane domains (TM I and TM2), separated by 
a long extracellular domain containing an ATP binding site, the cytoplasmic N- 
terminus and C-terminus (figure 4.1), which is longer in the P2X7 subunit compared 
to the other subtypes (Surprenant et al., 1996) and contributes to the unusual 
properties of this receptor subtype. The TM2 segment lines the pore of the channel. 
Functional P2X receptors are thought to form multimers of either three (Nicke et al., 
1998; Stoop et al., 1999) or four (Kim et al., 1997) subunits. These may be identical, 
giving rise to homo-multimeric receptors, or non-identical fonning hetero-oligomers 
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(Torres et al., 1999). For example, P2X3 can assemble in sensory neurons 
(Burnstock, 2000) fon-ning both homomeric receptors and heteromeric P2X2/3 
receptors (Virginio et al., 1998) in a subpopulation-specific way (Ueno et al., 1999), 
while the P2X7 subunit is unlikely to assemble with other P2X subunits (Torres et al., 
1999). 
C 
Figure 4.1 Representation of a P2X receptor subunit. The structure of a P2X 
subunit consists of the intracellular N- and C- tennim, two transmembrane spanning 
domains MI-M2 and a large extracellular loop containing 10 cysteine residues, 
which may form disulphide bonds (from Dunn et al., 2001). 
4.1.2. Permeability 
P2X subunits are all non-selective cation channels with almost equal pen-neability to 
Na+, K+, and significant permeability to Ca+' (Evans et al., 1996). Functional 
differences between P2X receptors subtypes (Khakh et al., 200 1; Lambrecht, 2000; 
North and Surprenant, 2000) include a different time course, ranging from rapid 
current decay during continued agonist application of P2X3 receptor, to currents 
maintained for minutes, such as the P2X7 receptor current (North, 2002). A time- 
dependent decrease in ionic selectivity has been observed in some of the P2X 
1 
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subunits. P2X7 receptor, for example, functions as a non-selective cationic channel 
following brief activation, but its prolonged or repeated activation induces increased 
permeability to larger organic cations, including some fluorescent dyes, through a 
pore dilation phenomenon (Chizh and Illes, 2001; Surprenant et al., 1996; Virginio et 
al., 1999). This is a unique biophysical phenomenon, observed only in this receptor 
and possibly linked to the C-terminus (Smart et al., 2003; Surprenant et al., 1996). 
The increased permeability, allowing large ion fluxes and leakages of small 
metabolites, is associated with cytotoxicity (Ralevic and Bumstock, 1998), and 
prolonged activation can lead to cell swelling, vacuolisation and cell death by 
necrosis or apoptosis (Dubyak and el-Moatassim, 1993). 
Localisation 
P2X receptors are found throughout the body and functional responses are seen in 
neurons, glia, epithelia, endothelia, bone, muscle, and hemopoletic tissues (Collo et 
al., 1997; North, 2002). They are abundantly distributed in the nervous system, both 
central and peripheral. P2X, -P2X6 receptors are present in populations of sensory 
neurones (Burnstock, 2000; Dunn et al., 2001; Norenberg and Illes, 2000) and in 
particular P2X3 appears to be exclusively expressed in a subgroup of nociceptors 
(Bradbury et al., 1998; Chen et al., 1995). On the other hand, the P2X7receptor, first 
cloned from rat macrophages and brain (Surprenant et al., 1996) and then from 
human monocytes (Rassendren et al., 1997), is expressed predominantly by cells of 
immune origin. It has been identified in bone marrow cells such as granulocytes, 
monocytes and B lymphocytes as well as macrophages and microglia in the brain 
(Collo et al., 1997). In the PNS, its presence has been identified in myelinating 
Schwann cells of pheripheral nerves in rats (Grafe et al., 1999) and non-neuronal cell 
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in rat DRG (Zhang et al., 2005) but not In primary sensory neurons, while a few 
studies suggest its presence in presynaptic terminals in CNS and at the 
neuromuscular junction (Deng and Fyffe, 2004; Deuchars et al., 200 1). 
4.1.4. Function and involvement in pain mechanisms 
Activation of P2X receptors occurs when ATP, present in every living cell at high 
concentration, representing the major energy source utilised in cellular metabolism, 
is released into the extracellular space. This process takes place in two distinct ways, 
by active vesicular release or by passive release after cell lysis (Hamilton and 
McMahon, 2000). ATP can be released by aggregating platelets, possibly 
contributing to migraine pain (Burnstock and Wood, 1996), or it can function as a 
neurotransmitter in the dorsal hom spinal cord (Bardoni et al., 1997) and in 
sympathetic fibres, which release ATP as a co-transmitter with noradrenalin 
(Bumstock, 1995; Bumstock, 1996), suggesting also an involvement of P2X 
receptors in sympathetically maintained pain mechanism (Ramer et al., 1999). P2X 
receptors are involved in the initiation of afferent signals in viscera (Brady et al., 
2004; Yiangou et al., 2001 a), e. g. bladder, where vesicular release of ATP has been 
detected in urothelium (Ferguson et al., 1997). Release of ATP is otherwise 
associated with cell lysis after injury and in neurodegenerative processes and 
inflammation. Bumstock (Bumstock, 1996) strongly suggested a role in nociception 
for P2X receptors, with his hypothesis that trauma, tumour, inflammation, migraine 
or visceral distortion can all result in the release of large quantities of ATP leading to 
the activation of P2X receptors and subsequent pain sensation. P2X receptors 
function as sensors of tissue-damaging and inflammatory painful stimuli (Bumstock, 
2000). Their contribution to chronic pain mechanisms following peripheral nerve 
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damage appears to involve mainly the P2X3 receptor subtype (North, 2004) in 
sensory nerves. For instance, P2X3 receptor increases in rat DRG following chronic 
constriction injury (CCI) (Eriksson et al., 1998), where the number of P2X3positive, 
medium size, sensory neurones had increased, suggesting a phenomenon of 
'phenotypic switch' (Novakovic et al., 1999). 
P2X7receptor, the only subtype of the family not found in neurons, appears to have a 
pivotal role in the inflammatory cascade (Burnstock and Williams, 2000; Illes et al., 
2000). This receptor is involved in the communication between macrophages and 
other immune cells or target cells (Dubyak and el-Moatassim, 1993; Steinberg and 
Di Virgilio, 199 1) and in the migration of leukocytes through vascular walls 
(Jamieson et al., 1996; Wiley et al., 1995). Most importantly, its activation induces 
the release of the biologically active inflammatory cytokine (IL)- IP (Ferrari et al., 
1997; Griffiths et al., 1995; Perregaux and Gabel, 1994; Solle et al., 2001), whose 
downstream effects include induction of nitric oxide synthase (NOS), COX-2 
(Samad et al., 200 1) and production of superoxide products (Parvathenani et al., 
2003) and tumour necrosis factor cc (TNF-oc) (Woolf et al., 1997), all of which 
contribute to the inflammatory state and have well described roles in the generation 
or maintenance of pain. Nociceptive effects of P2X7 receptor activation in 
inflammatory cells have been demonstrated in vivo with different animal models of 
penpheral sensitisation (Dell'Antonio et al., 2002). 
Whilst the P2X7 receptor has been linked with inflammatory pain, there is little 
evidence in the literature for its involvement with neuropathic pain. 
A recent study shows that in mice lacking this receptor, inflammatory and 
neuropathic hypersensitivity is absent to both mechanical and then-nal stimuli, whilst 
normal nociceptive processing is preserved (Chessell et al., 2005). 
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4.2. Aim 
In this study the potential involvement of purinergic P2X7 receptors in human 
neuropathic pain states was investigated by examining its expression in peripheral 
nerve tissue obtained from patients suffering from neuropathic pain and 
hypersensitivity following trauma. 
Our findings are part of a collaborative study with GSK, studying pain behaviour in 
P2X7knockout mice. Results shown here have been published (Chessell et al., 2005). 
Results from a study conducted by collegues of the Peripherl Neuropathy Unit 
investigating the involvement of persistent P2X7 activation in the pathogenesis of 
MS and ALS, diseases that present some neuroinflammation and neurodegeneration, 
are also shown (Yiangou et al., 2006). These results confinn the expected 
localisation of this receptor in human spinal cord macrophages and microglia. 
4.3. Materials 
Table 4.1 List of human tissues used for P2X71HC and WB studies 
Tissue Number Injury delay Gender Age range (years) 
Control DRG 13 4 male 34-98 
Avulsed DRG 14 2 days-4.5months 13 male 15-44 
Control nerve 21 19 male 6-77 
Prox. injured nerve II (lHQ 7 weeks -8 years 5male 26-63 
15(WB) 6 weeks -I year 12 male 15-62 
Spinal Cord control n=13 6 male 41-80 
Spinal Cord ALS n=9 5 male 41-80 
Spinal Cord MS n=10 4 male 38-79 
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4.4. Results 
4.4.1. DRG 
Immunohistochemistry 
P2X7 immunoreactivity was not detected in sensory neurons (DRG) in either post- 
mortem controls or after injury (spinal root avulsion; figure 4.2a, b) but was present 
in satellite cells surrounding neurons (inset in figure 4.2a, satellite cells red and 
neurons black, when using double immunostaining). The density of P2X7 
immunostaining was markedly increased in satellite cells of both acute and chromc 
injured DRG. The glial cell marker GFAP was used for comparison with P2X7 in 
satellite cells. In control DRG, weak GFAP immunoreactivity was observed in some 
fibres and cells surrounding neurons (figure 4.2c), however, after injury, there was a 
marked increase of both intensity and frequency of GFAP-immunoreactive cells 
(figure 4.2d) , in a very similar 
fashion to that seen with P2X7- 
In order to quantify the changes after injury, P2X7-immunoreactive area in satellite 
cells in each field analysed was related to the neuronal density of that area, calculated 
by outlining and image analysing all neuronal profiles in the field. 
P2X7 immunopositive area expressed as a ratio to neuronal area, showed a significant 
increase after injury [controls: n=10; median (range) 0.38 (0.21-0.54); injured: n=12; 
median (range) 0.60 (0.17-0.76); p<0.05; figure 4.3]. No P2X7 immunoreactivity 
was detected in neurons of human sympathetic ganglia or in motoneurons in post- 
mortern human spinal cord (data not shown). 
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Figure 4.2 P2X7- and GFAP-im mu no reactivity in DRG. P2X7- 
immunoreactivity is present in satellite cells of human control (a) and injured (b) 
DRG, [inset in (a): Double immunostaining showing P2X7-immunoreactive 
satellite/Schwann. cells (red) surrounding a neuron and axons (neurofilament-black)]. 
GFAP-immunore activity is present in control (c) and is increased in injured (d) 
DRG. Scale bar (a-d) = 50ýtm. 
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Figure 4.3 Increased P2X7 expression in satellite cells after DRG avulsion. 
Ratio between P2X7 immunopositive area in satellite cells and corresponding 
neuronal area shows a significant increase of P2X7-immunoreactivity after avulsion 
(* p<0.05). 
Immunoblotting 
Western blot of DRG protein extracts showed three bands recognised by the 
antibody, a 70kDa band, a 65kDa band, which may correspond to an unglycosylated 
form of the 70kDa band, and a larger 140kDa band, which may represent a dimer of 
a 70 kDa protein (Kim et al., 2001). 
Image analysis did not show any significant changes in the optical density for any of 
these bands. There was just a trend for increased optical density in the 70kDa band 
and decreased optical density in the 65KDa band, possibly suggesting a change in 
post-translational processes after injury (figure 4.4). 
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Figure 4.4 Quantification of P2X7-Positive bands obtained by WB from DRG 
extracts. Optical density of the 65,70 and 140kDa bands obtained from protein 
extracts of control and avulsed DRG, showing no significant changes in the protein 
amount after injury but suggesting a change in the ratio between different forms. 
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4.4.2. Peripheral nerve 
Immunohistochemistry 
P2X7 immunoreactivity was detected in peripheral nerve fibres (figure 4.5A), from 
both control and injured specimens. Results in DRG, where P2X7 antibodies did not 
show neuronal immunoreactivity, suggested glial localisation of the receptor. Serial 
tissue sections were immunostained for P2X7, GFAP or NF, to investigate if P2X7- 
immunoreactivity corresponded well with immunoreactivity for the glial/Schwann 
cell marker GFAP (figure 4.5B) or with that for the axonal marker neurofilament 
(NF) (figure 4.5Q. Co-localisation of P2X 7 and 
GFAP confirmed the presence of 
P2X7 in Schwann cells rather than in axons, correlating well with the lack of 
detection of P2X7 in the cell body of sensory neurons. 
The percentage area of P2X7- and GFAP- immunoreactivity was measured for each 
sample by image analysis and the ratio P2X7: GFAP calculated. Comparison 
between control and injured nerves, some of which were not associated with pain, 
showed a significant increase of the P2X7: GFAP ratio in painful injured nerves 
[n=l 1; median (range) 0.58 (0.26-1.78)] compared to controls [n=13; median (range) 
0.45 (0.06-0.58); p<0.05] or low pain injured nerves [n=4; median (range) 0.22 
(0.08-0.3 1); p<0.05; figure 4.5D]. 
There was no correlation between delay before surgery and P2X7 immunostaining in 
injured nerves or DRG. 
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Figure 4.5 P2X7-Positive fibres in peripheral nerve and increased expression 
with pain. Serial sections of nerve immunostained with antibodies to P2X7 (A), 
GFAP (B) or neurofilaments (C). Comparison of P2X7: GFAP ratio in painful injured 
nerves compared to control or non-painful injured nerves shows increased P2X7 
expression in painful nerves (* p<0.05). 
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Immunoblotting 
Westem blotting using the P2X7monoclonal antibody (at dilution of 1: 100,000) on a 
6% polyacrylamide gel showed in all samples of nerve extracts a 70 kDa band 
(figure 4.6A), and in some extracts a 65 kDa and a larger, approximately 140 kDa, 
band. 
The relative optical density of the 70kDa band was significantly elevated in extracts 
of painful injured nerve [n=15; median (range) = 36.0 (4.0-120)] compared to 
controls [n=8; median (range) = 11.0 (6.0-34.0); p<0.02; figure 4.6B]. 
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Figure 4.6 P2X7-Positive bands obtained by WB from peripheral nerves. A: 
Representative P2X7 western blot of peripheral nerve extracts (Lanes 1-4 are extracts 
of human control nerve and lanes 5-8 are extracts 
from painful injured nerves). B: 
Optical density of the 70kDa band is increased after injury. 
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4.4.3. Study on animal model, P2X7knockout mice 
This paragraph gives a brief summary of the behavioural studies on mice with 
disrupted P2X7 receptor, done at the GSK laboratories in Harlow (for more detailed 
description see Chessell et al., 2005). 
Mice carrying a targeted null mutation of the P2X7 gene were generated. As for 
similar P2X7 mutants (Solle et al., 2001), these mice displayed altered cytokine 
production in response to ATP and lipopolysaccharide but were overall healthy. 
Sensitivity to noxious thermal and mechanical stimuli was tested in the absence of 
any neuropathic or inflammatory insult by measuring the latency of response to an 
acute thermal stimulus (hot plate test) and to a noxious punctate stimulus (electronic 
Von Frey hair; eVFH). No difference was observed between naYve and mutants 
mice , indicating a normal nociceptive phenotype 
is preserved in mutant mice in the 
absence of ongoing inflammatory or neuropathic hypersensitivity. 
The partial nerve ligation (PNL) model for neuropathic pain and the intraplantar 
Freund's Complete Adjuvant (FCA)-induced inflammation model were used to 
assess the development of hypersensitivity in the mutant mice. 
Partial ligation of the sciatic nerve, obtained following the method described by 
(Seltzer et al., 2000), is commonly used as a valid model for neuropathic pain. 
Profound differences were found in both thermal and mechanical sensitivity between 
naYve and mutant mice. In mice lacking the P2X 7 gene, 
development of both thermal 
(figure 4.7A) and mechanical (figure 4.7B) hypersensitivity was completely absent 
following nerve ligation, whereas the naive animals developed significant thermal 
(figure 4.7A; 14 days post-ligation) and mechanical hyperalgesia, with significant 
differences in withdrawal thresholds between the two genotypes from days 3 to 21 
post-surgery (figure 4.7B). 
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The FCA-model is a well characterised (Stein et al., 1988) method, in which 
hypersensitivity is induced by subplantar injection of FCA into one hindpaw, causing 
localised inflammatory pain which reaches its peak between 2 to 3 weekes after 
injection. In this model, the difference in sensitivity between injected and uninjected 
paws of each mouse is examined, for both naYve and mutant mice, using 
determination of relative weight distribution between affected and unaffected 
hindpaws. 
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Figure 4.7 Res' onses to noxious stimuli following partial nerve ligation in 
P2X7+/+and M7_rmice. (A) Following partial nerve ligation in P2X7+/+and P2X7_ 
mice (n= 20 per group), thermal hypersensitivity developed after 3 days in P2X7+/+ 
animals, and was significantly different from pre-surgery values for at least 21 days. 
In P2X7-/- animals, hypersensitivity completely failed to develop. 
(B) Following nerve ligation in male P2X7+/+ and P2X7-/- mice (n=15 per group), 
P2X7+/+mlce developed significant mechanical hypersensitivity 3-7 days following 
ligation, which was maintained until day 21. P2X7-/- mice completely failed to 
display any significant hypersensitivity at any time point studied. 
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Analysis of the ipsilateral/contralateral weight bearing revealed a significant effect of 
genotype (p < 0.001, ANOVA), where mutant mice failed to develop significant 
hypersensitivity at any time after FCA injection, whereas the naive mice displayed a 
significant reduction in ipsilateral/contralateral ratios with most weight distributed on 
the uninjected hindpaw (figure 4.8). 
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Figure 4.8 Effect of inflammatory hypersensitivity on hindpaw weight 
bearing in P2X7+/+and P2X7 -/- mice following intraplantar FCA injection. Prior 
to FCA injection (day -1), weight was evenly distributed between both hindpaws in 
both P2X7 +/+ and P2X7-/-mice (n=15 per group). At one day after FCA injection, 
P2X7+/+mice displayed significant reduction in weight bearing on the ipsilateral 
(injected) hindpaw (** p<0.01 compared to pre-FCA baseline), which persisted for 
the duration of the study (7 days). No differences in weight bearing between 
hindpaws were observed at any timepoint in the P2X7-/-mice. 
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In conclusion, the behavioural study in mutant mice demonstrates a clear effect of 
P2X 
7 gene deletion upon responsiveness to noxious thermal or mechanical stimuli in 
conditions of both chronic neuropathic and inflammatory hypersensitivity. 
While most current research shows an apparent involvement of the P2X7 receptor in 
inflammatory pain, these results indicate the P2X 7 receptor is pivotal both in chronic 
inflammatory and in neuropathic sensitization to noxious stimuli. 
Immunohistochemistry on mice nerve tissue was performed using a commercially 
available antibody (Chernicon, ref. AB5246) which is raised against the rat form of 
the P2X7 receptor. While this antibody showed specific immunostaining in rat 
tissue, unfortunately it also showed non-specific immunostaining of blood vessels 
when using our protocol on mice tissue. The antibody used for studies in human 
tissue did not show any specific staining in rodent tissue and, to our knowledge, no 
mouse specific anti-P2X7antibody is available at the moment. 
This prevented us from obtaining any meaningful results by IHC from the transgenic 
mice tissues, which would have been of great interest by themselves and for 
comparison with the results obtained from human tissues. 
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4.4.4. Spinal Cord 
Multiple Sclerosis 
P2X7 immunoreactivity was detected mostly in white matter in cells having the 
appearance of macrophages or microglia (figure 4.9A). Immunoreactivity in 
macrophages was strongest at the cell surface membrane. Immunostaining of serial 
sections with antibodies to the macrophage marker CD68 (figure 4.9B) showed very 
similar staining patterns. MS cases showed P2X7-immunoreactive macrophages in 
plaques with an accumulation of cells in and around blood vessels. 
Immunostaining with a mixture of antibodies to ferritin (a marker for microglia) and 
to P2X7 receptor (figure 4.9C) showed that all cells with red (P2X7) immunoproduct 
also contained black immunoproduct (ferritin), indicating the presence of P2X7 in 
microglia/macrophages. 
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Figure 4.9 P2X7 and CD68 imm u no reactivity in white matter of spinal cord. 
Immunoreactivity to P2X7 (A) and CD68 (B) is shown in white matter of spinal cord. 
Double staining (C: red product for P2X7, black product for ferritin), indicates the 
presence of P2X7 in microglia/macrophages. 
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There was a significant increase of P2X7-immunoreactive area in MS cords 
compared to controls [control: n=13, % area median (range) 0.2 (0.06-0.96); MS: 
n=6,2.7 (0.01-4.9); p<0.04; figure 4.10]. 
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Figure 4.10 Quantification of P2X7-immunoreactive area (%) in control and 
MS spinal cord (white matter). The scattergrarn shows P2X7-immunoreactive area 
in white matter of NIS cords is increased compared to controls (p < 0.04). 
Am otrophic lateral sclerosis (ALS) y 
All ALS cases showed large numbers of P2X7-immunoreactive macrophages (figure 
11 , 
left panel) particularly in the dorsolateral white matter and in some cases in 
anterior columns. The macrophage marker CD68 (figure 4.11, centre) showed very 
similar staining pattern. In most controls, only occasional P2X7-immunoreactive 
macrophages were detected in contrast with diseased spinal cords, which showed 
cells in abundance. There was relatively negligible P2X7-immunoreactivity in the 
grey matter of either control or ALS cords. Double labeling with antibodies to the 
microglial marker ferritin showed P2X7present in microglial cells (figure 4.11, right 
panel). 
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Figure 4.11 P2X7- and CD68-positive macrophages in ALS spinal cord (white 
matter). Immunoreactivity to P2X7 (left) and to CD68 (centre) are shown in 
macrophages in white matter of an ALS spinal cords. Double staining (right panel: 
red product for P2X7, black product for ferritin), shows P2X7 is present in 
microglia/macrophages. 
There was a significant increase of P2X7 in the dorso-lateral white matter of ALS 
cord compared to controls [ALS (n=6): median (range) 2.4 (0.6-5.5); controls 
(n=12): 0.2 (0.06-0.96); p<0.0001; figure 4.12]. 
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Figure 4.12 Quantification of P2X7-iMmunoreactivity in control and ALS 
spinal cords. P2X7 -immunoreactive area is increased in dorso-lateral white matter 
of ALS spinal cords compared to controls (* p<0.0001). 
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4.4.5 Summary 
I have shown that P2X7 receptor has a non-neuronal distribution in PNS, being 
localised in satellite cells and nerve glia, and it is upregulated in in . ured human DRG i 
and painful injured nerves. 
In spinal cord, P2X7 immunoreactivity is locallsed mainly in activated microglia in 
the affected regions of ALS and MS spinal cord, and the receptor co-localises with 
the microglial markers CD68 (Collo et al., 1997) and ferritin (Peudenier et al., 1991). 
4.5. Discussion 
Studies in P2X7 knockout mice indicate an involvement of this receptor in both 
inflammatory and neuropathic hypersensitivity, through an impairment of IL- IP and 
IL- 10 production (Chessell et al., 2005). 
Given the role of the P2X7 receptor in triggering post-translational processing of IL- 
I P, with the resulting activation of an inflammatory cascade, it appears that the P2X7 
receptor plays a pivotal role in initiating or maintaining pathological changes as a 
result of inflammatory or neuropathic insults. The locus of action may include 
peripheral nerves, dorsal root ganglia or central pathways. Indeed, a cascade, 
initiated by release of ATP following cellular perturbation can be proposed in both 
the periphery and in the CNS. Thus, in the periphery, it is likely that inflammation or 
a neuropathic insult causes P2X7-dependent IL-10 release from mononuclear, mast 
and Schwann cells (Colomar et al., 2003), and in turn induces COX-2, nerve growth 
factor, and other algogens (Woolf et al., 1997). 
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This study shows an increased expression of P2X7 in Schwann cells of human 
injured nerves specifically when pain had developed, suggesting in some cases an 
involvement of this receptor in the induction or maintenance of human neuropathic 
pain. 
In human DRG, P2X7 receptor was detected in satellite cells but not in neurons. This 
corresponds well with the lack of neuronal P2X7 in rodent DRG and with its 
localisation in non neuronal cells obtained from culturing rat DRG, shown recently 
by Zhang et al. (2005). In animal models, peripheral nerve lesion induces an 
increase in number of GFAP-immunoreactive satellite cells, mainly around large 
diameter neurons , in a species selective way (Hu and McLachlan, 2000; Zhou et al., 
1999). This study has shown a similar increase of GFAP in human DRG satellite 
cells after central injury, which was parallel to an increase of P2X7 receptor. A 
specific function of this receptor in satellite cells, which are involved in NTFs 
production and sympathetic sprouting after nerve lesion (Zhou et al., 1999), deserve 
investigation. 
In the CNS, maturation and release of IL-10 from immune cells is able to induce 
COX-2 (Samad et al., 2001) and other mediators, many of which are thought to 
underlie increased neuronal excitability, particularly in the spinal cord. Studies in 
rodent have implicated a purinergic-signaling pathway (Schipke et al., 2002) in glial 
activation, and shown that ATP itself functions as a chemoattractant for microglia 
(Honda and Kohsaka, 2001), directing them to the source of injury, and plays a role 
in the activation (Verderio and Matteoli, 2001) of quiescent microglia, all via the 
P2X7 receptor. Also, production of superoxide in microglia mediated by P2X7 
receptor activation was up-regulated in an animal model of CNS neurodegeneration 
(Parvathenani et al., 2003), suggesting a pivotal role of microglia in degenerative 
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processes. Plastic and degenerative changes mediated by immune cells are a major 
histopathological feature in MS and ALS, suggesting that ATP activation of P2X7 
receptors could play a role in initiation of these two human neurodegenerative 
diseases. 
The experiments reported here show that P2X7 is upregulated in activated microglia 
in human MS and ALS spinal cord compared to control (Yiangou et al., 2006). 
A cascade may be postulated - cell death raises extracellular ATP (Ahmed et al., 
2000), which activates P2X7 expressed by microglia; the latter release ILI P, which in 
turn induces COX-2. ILI P and PGE2 lead to further cell death and ATP release, and 
the cycle is perpetuated. 
While constitutive expression of P2X7has been reported in different cell types in the 
brain (Beiche et al., 1998; Goppelt-Struebe and Beiche, 1997), these data suggest 
that increased expression of this receptor in MS and ALS occurs predominantly 
within activated microglia. In accord with the acknowledged role of microglia as the 
brain's endogenous immune effector cells, their presence in inflammatory and 
degenerative processes may underlie the commonality of pathological mechanisms, 
which may be targeted to modify disease progression, irrespective of the primary 
cause. 
Clinical Relevance 
In both clinical and preclinical settings there are marked differences in the efficacy of 
agents to treat inflammatory and neuropathic pain. While COX-2 inhibitors, acting 
downstream in the inflammatory cascade, are effective in treating chronic 
inflammatory pain but not clinical neuropathic pain (Wallace, 2001), drugs used for 
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the treatment of neuropathic pain are usually inadequate in the treatment of 
inflammatory pain. 
Currently used drugs effective in a broad range of pain states, such as oploids, are 
associated with tolerability, side effects and addiction issues, which limit their use. 
While a role for P2X7 in inflammatory states had already been recognised, findings 
of increased levels of this receptor in tissues from patients suffering from chronic 
neuropathic pain identify the P2X7 receptor as pivotal in neuropathic pain states, and 
suggests that therapies based on antagonism of this receptor, by interrupting the pain 
cascade upstream, may be capable of producing broad-spectrum analgesia. 
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CHAPTER 5 
Sodium channels and pain 
5.1. Background 
Voltage-gated sodium channels (VGSQ play a critical role in cell excitability. 
Their activation leads to an increase in sodium permeability, thus facilitating 
membrane depolarisation and action potential initiation in excitable cells (Goldin, 
2001; Waxman et al., 1999a). Their main involvement is not with the detection of 
pain stimuli but with their propagation. 
5.1.1. Structure and localisation 
VGSC are heteromeric channels, composed of a large (230-27OkD), pore- 
containing, cc-subunit and one or more small (about 33-36kD), auxiliary, P-subunits 
with modulatory function (Catterall, 2000; Isom, 2001; Marban et al., 1998; 
Ratcliffe et al., 200 1). A representation of a VGSC is shown in figure 5.1. 
Voltage-gated sodium channels can be distinguished by their sensitivity to 
tetrodotoxin (TTX) as TTX-sensitive, blocked by nanomolar concentrations of TTX, 
or TTX-resistant, if resistant to TTX in the micromolar concentration range. TTX 
susceptibility depends upon which subtype of the a-subunit is included in the 
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channel. All agents known to act on sodium channels, such as neurotoxins and local 
anaesthetics (Cestele and Catterall, 2000), have their receptor sites on the a- 
subunits. 
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Figure 5.1 Schematic structure of a VGSC. VGSC are composed by one alpha 
subunit, a beta-2 subunit and a second beta subunit (-I or -3), (from Baker and 
Wood, 2001). 
Alpha subunits. The (x-subunit determines the ion permeability and voltage 
sensitivity of the channel. It is an essential constituent of the channel and can 
ftinction as an homomer when transfected in a cell system (Morgan et al., 2000; 
Patton et al., 1994). 
The a-subunit is composed of four homologous domains (MV) each containing six 
transmembrane segments (S I -S6). The four domains folded together create the pore 
of the channel. Permeability to sodium cations is highly selective, by a factor of 
100: 1 over other cations, and it is due mainly to a few aminoacid residues in 
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domains III and IV (Perez-Garcia et al., 1997). Gating is related to changes in the 
conformational state of the channel, caused by a sufficient depolarisation step of 
membrane voltage. It has been demonstrated that the S4 segment, which contains 
several charged residues, functions as a sensor of change in membrane polarity 
(Yang et al., 1996), while S6 is the most accredited site for the actual activation gate 
(McPhee et al., 1995; Yarov-Yarovoy et al., 2002) and the intracellular loop 
between domains III and IV forms the inactivation gate (Catterall, 2000). 
During activation there is a passage of transient Na+ current which decays to zero 
once the channel enters an inactivated refractary state, from which it can not re-open 
until its conformation reverts back to a closed (resting) state. The interval of time 
spent in the open and in the inactivated states both depend on the composition of the 
channel, thus determining the amount of depolarising current and the speed of decay 
of this current. Neuronal capability to fire at high frequency in response to repeated 
stimuli largely depends on the properties of these channels. 
Ten cc-subunits have been cloned in human and rodent (Goldin, 2001; Goldin et al., 
2000), although one of them, known to express in glial cells (Coward et al., 2001c; 
Gautron et al., 1992) has not be functionally expressed yet and it is possible it does 
not encode for a sodium channel despite the sequence similarity with the other (x- 
subunits (Akopian et al., 1997; George et al., 1992a). 
Until a standardized nomenclature was proposed (Goldin et al., 2000), there had 
been quite a lot of confusion, with some of the subunits named in different ways 
(e. g. SNS/PN3 and NaN/SNS2). Genetic analysis shows that all the 
known 
functional cc-subunits belong to the same family and they have therefore been named 
from Na, l. I to Na, 1-9, while the functionally non defined ones have previously 
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been proposed to belong to a distinct subfamily (George et al., 1992a) and are 
named Nax. 
Of the nine functional (x-subunits, Na, 1.4 is expressed in adult skeletal muscle 
(George et al., 1992b) in both human and rodent, Na, 1.5 in cardiac muscle, human 
and rodent, but also in rat embryonic and denervated skeletal muscle (Gellens et al., 
1992; Trimmer et al., 1990). The remaining cc-subunits are found in neurons of 
CNS and/or PNS. Human and/or rodent primary sensory neurons express fast- 
activating, TTX-sensitive (TTX-S) Navl. 7 (previously known as PNI/hNE) 
(Sangameswaran et al., 1997), Na, 1.6 (Na6) (Tzoumaka et al., 2000), Na, l. I 
(Beckh, 1990), plus Na, 1.3, normally expressed during embryonic development but 
also in adult after axotomy (Black et al., 1999), and slow-inactivating TTX-resistant 
(TTX-R) sodium channels Na, 1.8 (SNS/PN3) (Sangameswaran et al., 1996) and 
Na, 1.9 (NaN/SNS2) (Dib-Hajj et al., 1999; Waxman et al., 1999b). The two TTX-R 
channel subunits are of particular interest since they are highly expressed in small, 
un-myelinated, primary sensory neurons (Black et al., 1996; Coward et al., 2000; 
Dib-Hajj et al., 1999). 
Beta subunits. The P-subunit does not appear to be essential for channel function but 
plays an important role in its modulation. When co-expressed with the (x-subunit, 
each P-subunit can modify the voltage dependence and/or the kinetics of channel 
activation and inactivation processes (Isom et al., 1995a; Isom et al., 1995b; 
McEwen et al., 2004; Patton et al., 1994; Qu et al., 2001). Different 0-subunits 
interact with matrix and cytoskeletal signalling molecules contributing to an 
increased surface expression of the channel (Isom et al., 1995b) and to its correct 
positioning within the membrane, for example in nodes of Ranvier (Isom, 2001; 
Ratcliffe et al., 2001; Salzer, 1997). 
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The P-subunit consists of a single, membrane- spanning, region with a small 
intracellular domain and a longer extracellular amino-terminus domain which is 
critical for its modulatory function (McCormick et al., 1999). Until now, five 
different sodium channel P-subunits have been characterized in rat and/or human. 
These include the non-covalently associated PI-subunit and its splice variant isoform 
PIA, a closely related P3-subunit, the disulfide-linked P2-subunit and a related P4- 
subunit (Isom, 2001; Morgan et al., 2000; Yu et al., 2003). 
A differential distribution as been observed in rat DRG, with P, andP3 confined to 
large and small neurons respectively (Shah et al., 2000). In contrast, in human 
DRG, P, andP2 are present in neurons of all sizes (Coward et al., 200 1 b), and so is 
03, as will be shown in this work (Casula et al., 2004). 
5.1.2. Post-translational modifications 
The cc-subunits provide a good substrate for phosphorylation by protein kinase C 
(PKQ and cyclic-AMP-dependent protein kinase (PKA). These enzymes, in 
combination with dephosphorylation enzymes, offer a site for pharmacological 
regulation of these channels (Cantrell and Catterall, 2001). Both PKA and PKC 
reduce the activity of subunits Na, l. I and Na, 1.2, and can be correlated with a 
reduction in activity of sodium channels in brain neurons. However, they both 
increase the activity of Navl. 8. The P-subunits are not phosphorylated. 
All sodium channel subunits undergo glycosylation, essential for the maintenance of 
cell surface expression of the channel (Zona et al., 1990). 
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5.1.3. Involvement in neuropathic pain 
Voltage-gated sodium channel expression is highly dynamic and shows plasticity at 
both the transcriptional and post-transcriptional levels (Waxman et al., 2000); they 
have been shown to be involved in the pathophysiology of pain (Waxman et al., 
1999b; Wood et al., 2004). In particular, the altered expression of specific sodium 
channel subunits, as a result of long-lasting transcriptional changes, has been related, 
in some cases, to hyperexcitability and spontaneous activity observed in rat primary 
sensory neurons after injury (Devor et al., 1992; Matzner and Devor, 1994), 
contributing to pathological pain. These changes include down-regulation of TTX-R 
subunits (Dib-Hajj et al., 1996; Dib-Hajj et al., 1998b; Sleeper et al., 2000), with 
accumulation of sodium channels at the distal tip of injured nerve axons (England et 
al., 1994), and up-regulation of the normally silent Na, 1.3 in sensory neurons after 
peripheral but not central axotomy (Black et al., 1999). This membrane remodeling 
contributes to lower the threshold of action potential generation, and to the 
insurgence of a rapidly repriming current that allows injured neurons to sustain 
higher firing frequency (Cummins and Waxman, 1997). Increasing evidence 
suggests that the subunit Na, 1.8 may play an important role in the development of 
neuropathic pain in animal models (Novakovic et al., 1998; Porreca et al., 1999). 
After spinal nerve ligation, Na, 1.8 accumulates at injured nerve endings and 
decreases in the injured DRG but also increases in the large diameter neurons of the 
ui jured adjacent DRG (Porreca et al., 1999) and in the uni Jured nerve fibres, an nin nj 
effect that could partially account for the development of neuropathic pain (Gold et 
al., 2003). 
Studies off knockout mice and the use of antisense oligonucleotides to TTX-R 
channels in rats from models of neuropathic pain show an important involvement of 
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Na, 1.8 in the development of allodynia and hyperalgesia, while the contribution of 
Na, 1.9 to the behavioural responses induced by neirve injury in these models is less 
clear (Akopian et al., 1999b; Lai et al., 2002; Porreca et al., 1999). 
Similar changes in the pattern of expression of these subunits have been observed in 
humans, validating their involvement in some human neuropathic pain states. In 
human DRG, a decrease of TTX-R (x-subunits and TTX-S Na, 1.7 was detected in 
sensory neurons after central axotomy, whilst an increase was induced by peripheral 
axotomy in nerves proximally to the site of injury (Coward et al., 2000; Coward et 
al., 2001a). However, TTX-Rsubunits were still detected in dorsal roots fibres after 
avulsion (Bucknill et al., 2002), possibly the result of translocation and 
accumulation of the pre-synthesised ion channel protein at the site of injury. 
Up-regulation of Na, 1.3 was observed in human sensory fibres after peripheral 
injury, but this subunit was not detected in soma of normal or avulsed DRG neurons 
by immunohistochernistry (Coward et al., 2001 a). 
Sodium channels were demonstrated to accumulate in human painful neuromata, 
regarded as a major cause for ectopic axonal excitability and the resulting abnormal 
sensory phenomena of pain and paresthesiae (England et al., 1996a). This work did 
not distinguish specific subtypes of the channel, but more recently, both Na, 1.7 and 
Na, 1.8 have been shown to accumulate in human neuromata, especially in painful 
ones (Kretschmer et al., 2002). In addition, tooth pulps, which have a dense sensory 
innervation originating from the trigeminal ganglion, show increased Na, 1.8 in 
fibres from subjects with dental pain (Renton et al., 2005). 
The Na, 1.7 subunit, found predominantly in peripheral sensory and sympathetic 
neurons5 has recently been shown to be implicated in specIfic 'on channelopathiesq 
hereditary conditions that usually result from dominant mutations that cause altered 
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activity of the involved ion channels, which present with pain. Primary 
erythromelalgia (PE) (Yang et al., 2004; Drenth et al., 2005) is a rare disorder of 
burning pain in the limbs provoked or aggravated by warmth or exercise. 
Paroxysmal extreme pain disorder (PEPD), previously known as familial rectal pain 
(FRP), is an inherited condition of paroxysms of rectal, ocular or submandibular pain 
with flushing (Fertleman et al., 2006). In these two conditions, mutations in SCN9A, 
the gene encoding the Na, 1.7 subunit, is associated with gain of function and causes 
two distinct painful conditions with clear differences in their clinical phenotypes, 
possibly related to the differences in the effect the mutations have on the activity of 
this sodium channel (Fertleman et al., 2006). Recently, mutations causing loss of 
function in Na, 1.7 were shown to be associated with an inherited congenital 
insensitivity to pain (Cox et al., 2006). 
While the u-subunits expressed in DRG can have a role in the pathophysiology of 
pain, the scarcity of selective compounds bring some limitation to their use as 
pharmacological targets. This has brought more attention to the function of the 0- 
subunits. 
Changes of the P-subunits have been observed also in association with nerve injury 
and in neuropathic pain models. Two different models of nerve injury in rat showed 
no significant change in the levels of P, andP2mRNA but did show an increase of 
transcript f6rP3 (Takahashi et al., 2003). Levels Of P3 m-RNA increased also in the 
chronic constriction injury (CCI) model of neuropathic pain (Shah et al., 2000) and 
in streptozocin-induced diabetic neuropathy (Shah et al., 2001 a) in rat. Changes of 
m-RNA for P-subunits were detected also in second-order neurons in dorsal horn of 
neuropathic rats (Blackbum-Munro and Fleetwood-Walker, 1999). In human DRG, 
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a decrease in the expression of PI- andP2-subunits in sensory cell bodies after spinal 
cord root avulsion was detected (Coward et al., 2001b). 
These transcriptional changes are thought to be driven, in large part, by alterations in 
availability or production of the neurotrophic factors NGF and GDNF (Black et al., 
1997; Boucher et al., 2000; Dib-Hajj et al., 1998a; Fjell et al., 1999). 
Post-translational modifications are involved in the induction of pain mainly when 
inflammation occurs. Phosphorylation of the (x-subunit by PKA appears to be 
involved in hyperalgesia (Cantrell and Catterall, 2001) and is proposed to mediate 
the neuromodulatory effect of proinflarnmatory, hyperalgesic agents such as PGE2 
on TTX-resistant subunits expressed in nociceptive sensory neurons (England et al., 
1996b). 
5.2. Aim 
Since targeting the interaction between specific cc- and P-subunits may provide a 
novel therapeutic approach for analgesia, the distribution of the novel P3-subunit in 
human DRG sensory neurons and nerves was analysed, in particular with the aim to 
determine the effect of nerve injury and/or painful conditions for which samples 
from painful and non-painful subjects were available (tooth pulp and distal 
neuroma). 
Also, a study aimed to characterise Na, 1.7 In peripheral rectal tissue from FRP 
patients in comparison to normal subjects was conducted, motivated by suggestions 
that mutation in the gene for Na, 1.7 could be linked to this condition. 
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5.3. Materials 
Table 5.1 List of human tissues used for VGSC studies 
Tissue Number Injury delay Gender Age range (yrs) 
Control DRG 8 male 4 38-98 
Avulsed DRG 8 6 acute, 2 chronic male 7 17-44 
Control nerve 14 male 10 10-77 
Prox. injured nerve 20 11 acute, 9 chronic male 17 14-43 
Neuroma no pain 2 Chronic male 1 33-37 
Neuroma, pain 4 Chronic male 2 40-57 
Tooth pulps 
with pain 
5 N. A. N. A. 22-30 
Tooth pulps 
without pain 
8 N. A. N. A. 25-54 
Control rectum 7 
FRP 2 NA male 1 10,84 
5.4. Results 
Some of the results shown here have been published in Casula et al., Neuroreport 
(2004) Vol. 15 (10): 1629-1632. 
5.4.1. Antibody specificity 
Specificity of antibodies to Na, 1.7 (GSK, K241) has been previously charactensed 
(Coward et al., 2001 a). 
The subtype-specifi city Of P3 polyclonal antibody (GSK, A53) was confirmed 
by 
immunoblot against the human Pj-, P2- and P3-subunits transiently expressed in 
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HEK293 cells (Casula et al., 2004). The P3 polyclonal antibody, used for the lHC 
experiments, specifically detects a protein of approximately 34kDa that corresponds 
to theP3-subunit. The antibody did not detect any specific proteins of similar size in 
the 01- orP2-subunit membrane preparations (data available from GSK, not shown). 
IHC controls: Immunostaining in human tissue sections was abolished completely 
by preincubation with homologous P3 pepticle antigen at 0.1 ýtg per mL of antibody 
(A53 at 0.3[tg) and returned to normal levels in the presence of I-lOng0f P3peptide 
antigen per mL of antibody. No staining was detected when primary or secondary 
antibodies were omitted or substituted with non-immune rabbit immunoglobulins. 
5.4.2. Human DRG 
P3-subunit immunoreactivity was detected in sensory neurons and nerve fibres 
within all control post mortem DRG examined (figure 5.2, left panel). 
There was no differential distribution of the receptor between the neuronal 
subpopulations (large and small diameter neurons), and very rare negative cells in 
any of the subgroups. 
The intensity of immunostaining of individual cells within a DRG was however 
quite variable. Small/medium diameter neurons were more intensely stained than 
large neurons, (dense staining in 67% of neurons with diameter > 50ýtm versus 82% 
in neurons with diameter < 50ýtm). 
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Figure 5.2 Immunoreactivity of theP3-Subunit in human DRG. Control (left) 
and avulsed (right) DRG both showP3-immunopositive cells and fibres. 
After avulsion, no significant difference with respect to control DRG was observed 
in small/medium neurons (dense P3 immunostaining in 77% of small/medium cells), 
and only a trend for decrease was detected in large neurons (46% of large cells; p< 
1; figure 5.3). 
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Figure 5.3 Percentage Of 03-Positive neurons in human DRG- The 
scattergram. shows no significant change in number Of P3-POSitive neurons 
(expressed as percentage of total) after spinal root injury, in both small/medium and 
large cells sub-population. 
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5.4.3. NGF dependency 
To investigate If P3 expression is NGF-dependent, double staining Of P3 and the 
NGF receptor trkA was performed in DRG. About half of the small/medium (S/M) 
diameter neurons expressed the high affinity NGF receptor while the percentage of 
large (L) trkA positive neurons was lower, with just a small non significant decrease 
in the number of trkA immunopositive neurons after avulsion [% neurons, median 
(range); S/M: control 46.2 (43-66.7), avulsed 41.8 (18.2-51.2); L: control 19.0 (13- 
27.8), avulsed 12 (0-40.5)]. No obvious difference in trkA immunostaining was 
seen when comparing P3-positive and P3-negative neurons but a small decrease in 
the percentage Of P3-positive neurons after avulsion appeared to happen mainly in 
the subpopulation of trkA-positive neurons, concomitant with a statistically non- 
significant decrease of trkA (figure 5.4). 
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Figure 5.4 Colocalisation of trkA and 03 in human DRG. The histograms 
show that almost half of small and a third of large beta3-positive neurons are NGF- 
dependent. These proportions do not change significantly after injury. 
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5.4.4. Peripheral nerves 
As expected from the dense expression of this subunit in primary sensory neurons, 
03-subunit immunoreactivity was observed in human peripheral nerves, both in large 
nerve trunks and in more distal locations, such as in distal neuroma and tooth pulp, 
but not in epidermis. 
Proximal injured nerves 
03-subunit immunoreactivity was present in control human nerves and maintained 
after injury in the proximal stump (figure 5.5). For comparison, sequential sections 
of all nerve samples available were immunostained with a pan-neuronal nerve 
marker (neurofilament antibody NF55), used as a positive control. 
03- and NF-immunoreactive nerve fibres were quantified by image analysis (% 
immunopositive area) and the ratioP3: NF was determined for each sample. After 
both acute and chronic injury, P3: NF was slightly but significantly increased respect 
to the control group [median (range): 0.36 (0.25-0.61) in control; 0.45 (0.31-0.58) in 
acute; 0.47 (0.33-0.57) in chronic nerve; p<0.05] (figure 5.6). 
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Figure 5.5 03- and NF-immu no reactivity in human peripheral nerves. 03- 
subunit in control (a) and proximal injured (c) nerve. NF in control (b) and injured 
(d) nerve. Scale bars = 100ýtm. 
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Figure 5.6 P3: NF percentage area in peripheral nerves. An increase Of P3- 
immunoreative fibres was observed after acute and chronic injury. 
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control acute chronic 
Neuroma 
Neuromata showed a similar increase Of P3-immunoreactivity in comparison to 
control nerves. The difference was most clear when low dilutions of antibodies, 
almost at the limit of detection level, were used. In this case, as shown in figure 5.7, 
few fibres were seen just in half of the control specimens, while all of the neuromata 
showed more fibres with intense staining, suggesting the main effect of injury to be 
an increase in intensity Of P3-immunostaining more than an increase in density of 
positive fibres. No obvious difference was seen between painful and non-painful 
neuroma but the number of specimens were too small to make any significant 
speculation. 
control painfpl-neuroma non painful neurom4 
I 
JF- 
Figure 5.7 03-iMmunoreactivity in neuromata. An Increase In IntensIty0f P3- 
immunoreactivity was observed in neuroma compared to control nerves. 
Peripheral nerves in tooth pulps 
StrongP3 immunostaining was detected in nerve fibres of human tooth pulps in all 
specimens (figure 5.8). Comparison between painful and non-painful samples by 
visual assessment did not show any difference in intensity of immunostaining or 
density of positive fibres. 
no . pain' pain 
ol 
Figure 5.8 P3-iMmunoreactivity in tooth pulps nerve fibres. Nerve fibres in 
painful and non-painful specimens do not show any difference in P3- 
immunostaining. 
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5.4.5. FRP and Na, 1.7 
Na, 1.7 immunoreactivity was not detected in rectal specimens from PEPD patients 
(figure 5.9A) while rectal specimens from control subjects (n=7) showed positive 
Na, 1.7-immunostaining in neurons of the myenteric plexus (figure 5.9B). 
lHC was repeated few times on the PEPD specimens available, showing negative 
reaction to Na, 1.7 antibodies or only weak immunoreactivity when the antibody was 
used at higher concentration respect to that normally used for control specimens. 
Immunoreactivity to other ion channels, such as Navl. 8, SKI and the potassium 
channel IK- I, was tested and no decrease in density of immunostaining for any of the 
other markers was observed. PGP9.5 immunoreactvity showed a lower number of 
neurons in the FRP specimens (C) compared to controls (D) but given the low 
number of FR-P specimens no proper comparison can be made. 
A FRP patient 
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Figure 5.9 Na, 1.7-immunoreactivity in myenteric plexus from rectum. Na, 1.7 
immunoreactvity is absent in neurons in myenteric plexus 
from an FRP patients (A) 
but present in control (B). For comparison, PGP9.5 immunoreactvIty in 
FRP (C) and 
control (D) specimens are shown. 
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5.5. Discussion 
03-Subunit 
In this thesis. ) I have shown the presence of theP3 sodium channel subunit in human 
DRG and peripheral nerves. A difference in distribution of theP3-subunit in human 
DRG with respect to other species was observed. In rat DRG, 01 andP3 subunits 
show a complementary distribution, with high levels of P, m-RNA confined to large- 
myelinated neurons and P3 m-RNA to small-unmyelinated neurons respectively 
(Shah et al., 2000). 
In contrast, I did not observe a specific distribution Of P3 in human small DRG 
neurons but both PI (Coward et al., 2001b) andP3 immunoreactivity were detected 
in all sizes of sensory cell bodies. 
Avulsion of the ganglia produced little effect on the expression Of P3 subunit in 
sensory neurons, while previous studies showed a decrease of SNS2 and PN3 a- 
subunits paralleled by that Of PI-2 (Coward et al., 2001b; Coward et al., 2000) in 
human DRG after avulsion, which may be NGF dependant (Akoplan et al., 1999a; 
Zur et al., 1995). The effect of injury onP3-immunoreactivity in sensory neurons 
indicates its expression may be regulated differently than PI-, P2- and Na, 1.8. An 
additional role of other neurotrophic factors, such as GDNF and NT-3, is suggested 
especially when taking into account the subpopulation Of P3-POSItive trk. A-negative 
neurons. 
While in rat models of pain an increase Of P3m-RNA has been detected, only a 
small increase Of P3-immunoreactivity in the proximal stump of human injured 
nerves and in neuroma was observed in this study. This increase at the injured nerve 
terminals is possibly a result of translocation and accumulation of the pre- 
165 
synthesised ion channel protein at the site of injury. The clearest change was 
observed in neuromata compared with the control nerves when low dilution of 
antibody was used, suggesting an increase of density0f P3 protein in fibres rather 
than an increase in number of fibres expressing this subunit. 
Any change in m-RNA level and synthesis Of P3 in the neuronal soma of human 
axotomised DRG can not be investigated, as these DRG are never collected but get 
repaired during surgery. 
Previous studies on human peripheral nerves demonstrate Navl. 8 redistribution 
proximal to the site of injury (Coward et al., 2000) and accumulation of Na, 1.7 and 
Na, 1.8 in neuroma (Kretschmer et al., 2002). 
Interestingly, the u-subunits Na, 1.7, Na, 1.8 and Naj. 3 do not appear to be 
modulated by PI or P2 (Cummins et al., 200 1; Sangameswaran et al., 1996; 
Sangameswaran et al., 1997). In contrast, it has been shown that theP3-subunit can 
modulate the activity of these subnits and may play a role in membrane trafficking 
of Na, 1.8, Na, 1.3 or Na, 1.2 when co-expressed in a recombinant system (John et al., 
2004; Meadows et al., 2002; Morgan et al., 2000). The small increase Of P3- 
immunoreactivity observed after nerve injury is therefore important in validating its 
role in human PNS in the modulation and trafficking of those cc-subunits expressed 
in proximal stump and neuroma (TTX-r and PN 1). 
In contrast to the other P-subunits, P3was observed during embryonic development 
in rat CNS, colocalising with Na, 1.3 (Shah et al., 2001b). This cc-subunit, known to 
be expressed during development but not in adult, is re-expressed after peripheral 
nerve injury (Black et al., 1999; Coward et al., 2001a). When re-expressed, the 
Na, 1.3 (x-subunit would be capable of forming complex with the P3-subunit, the 
intained after i 'ury in human. Na, 1.3 and P3 expression of which we show is mal inj I 
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heteromerization causes a negative shift in the voltage dependence of the 
inactivation process and slows down the rate of recovery of the human NavI. 3 
sodium channel (Meadows et al., 2002). While this would decrease cell excitability 
compared to neurons expressing Na, 1.3 alone, 03may be important in localising the 
channel within the neuron. 
In conclusion, the pattemOf 03-subunit expression in human differs from that in 
rodent. In small neurons of human DRG, the P3-subunit is possibly associated 
mainly with Na, 1.8 and Na, 1.9, the expression of which has been demonstrated to 
decrease greatly after avulsion, and with Na, 1.3, newly expressed after injury. 
Maintenance or a small increase Of 03was seen in injured peripheral nerves after 
injury or in diseased tooth pulps, but no clear difference could be detected between 
painful and non painful tissues. 
Na, 1.7 in FRP 
Fertleman et al., (2006) have shown that PEPD (or FRP), an inherited condition 
characterized by intense burning rectal, ocular, or sub-mandibular pain, with 
flushing, is caused by mutations of the Na, 1.7 channel. 
Expression of the mutant receptor in recombinant system (HEK cells) showed the 
mutations impaired fast inactivation, leading to persistent sodium currents. 
An increase in the slow-inactivation of the Navl. 7 sodium currents would sustain 
prolonged action potentials and repetitive firing in peripheral nociceptive and 
sympathetic fibres, triggering the pain associated to this condition. 
In this work, an antibody raised against a peptide corresponding to aminoacids 444 - 
449 of the human Na, 1.7 sequence, located in the first large intracellular loop 
between domains I and 11, was used to identify the presence of Na, 1.7 in rectal 
specimens from two PEPD patients. 
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One patient belong to the family were the T14611 mutation, directly adjacent to the 
highly conserved inactivation gate of the Na, 1.7 subunit, has been found to be 
causative (Fertleman et al. 2006). The second subject presents a point mutation 
resulting in a radical amino acid change (R996C) in the intracellular loop of Na, 1.7, 
between the second and the third transmembrane domain, which consequences have 
not been elucidated as yet. 
Immunohistochernistry showed a clear reduction of Na, 1.7 positive neurons in the 
myenteric plexus in rectum specimens of PEPD patients compared to controls. 
This could be an indication of reduced Na, 1.7-immunoreactivity, or correspond to a 
reduced Nav 1.7 expression. 
The antibody used in this work does not directly recognise the section of Navl. 7 
channel where the mutations occur. However, the antibody-antigen recognition in 
tissue sections depends on the three-dimensional conformation of the protein, which 
could have been altered by the mutations. 
The work of Fertleman (2006) suggests that the mutated channels considered in their 
study can express and are functional "in vivo", which is supported by the results in 
recombinant system and by the positive response of some PEPD patients to the anti- 
epileptic carbamazepine, a drug effective in reducing the persistent Na+ current in 
HEK cells. 
Therefore, the reduced immunoreactivity observed in the tissue from PEPD patients 
most probably reflects a decrease in affinity between the antibody and the antigen 
(mutated channel), but decrease in the density of this channel can not be excluded. 
It must be taken into account that the IHC results were obtained using tissues from 
only two PEPD patients and that also some control samples showed weak 
immunostaining, therefore these observations should be considered with care. 
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However these results have been important in showing the presence of Navl. 7, in the 
human intestine. This has motivated further work by other collegues in the research 
group at the Peripheral Neuropathy Unit (Hammersmith Hospital, London), which 
has shown an involvement of Navl. 7 in conditions of human rectal hypersensitivity 
(Yiangou et al., 2007). This study investigates the expression of the Navl. 7 subunit 
in rectal specimens from patients with faecal urgency and incontinence (UFI), a 
chronic, distressing condition that is difficult to treat and still poorly understood. 
An increased level of Navl. 7 subunit in nerve fibres, possibly both extrinsic primary 
sensory fibres and intrinsic fibres originating from the myenteric plexus, was 
observed in patients with rectal hypersensitivity, suggesting Navl. 7 has a role in 
rectal hypersensitivity. 
Relevance 
The presence of specific (x-subunits in nociceptive neurons and their clear 
involvement with development of painful condition makes them an important 
potential target for pain management. However, the high degree of similarity 
between all (x-subunits, together with their wide distribution in peripheral and 
central nervous system as well as in non nervous tissue, has so far stymied attempts 
to produce subtype-specific agonists/antagonists, and thus prevented an appropriate 
therapeutical use of this target for neuropathic pain. 
P3 appears not to be directly related to the development of pain but nonetheless its 
expression is fundamental for the localisation and function of those cc-subunits that 
are directly involved with the generation of pain and could be therefore interesting as 
a pharmacological tool. 
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CHAPTER 6 
Discussion 
Despite the recent great advances in the knowledge of chronic pain processes, 
neuropathic pain remains a clinical challenge, for its frequent resistance to treatment 
with currently used analgesics. Because of the lack of a well recognised treatment of 
choice, therapeutic strategies are often based on a trial-and-error method; even the 
anti-convulsive agents gabapentin and pregabalin, currently considered the gold 
standard treatment, have limited effectiveness, and can lead to side effects such as 
somnolence and dizziness. 
The last decade has seen the development of a new, mechanism-based approach to 
the classification of neuropathic pain states (Woolf et al., 1998; Woolf and Max, 
2001), which suggests that the choice of treatment should be based on a patient's 
specific pain mechanism (Woolf and Max, 2001; Dworkin et al., 2003). Evaluation 
of specific mechanisms in a given patient has proven to be difficult because of the 
complexity of pain pathophysiology, and heterogeneity between patients with a given 
syndrome, which explains variability of symptoms and unpredictability of the 
efficacy of drug treatment. This multiplicity of mechanisms is well recognised, and 
offers diversity of targets for pain management. However, it is evident that because 
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of the plurality of mechanisms and causes, and the range of potential therapies, a 
rational basis for progress is required. 
Current research has put the focus more than ever on the importance of 
understanding the connection between underlying pain mechanisms and symptoms or 
aetiology, which would help the planning of rational and effective treatment, 
including combination therapies. 
Current therapies and their limitations 
As described in the Introduction chapter, peripheral nerve and brachial plexus injury 
induce a cascade of events, with changes in phenotype of primary nociceptors, and 
central changes in spinal cord via mechanisms of wind-up, disinhibition, 
sensitization, and altered rostral processing. General chronic pain management was 
considered in Chapter 1, and common therapies for pain after nerve and brachial 
plexus injury have been reviewed. 
The therapies are of various types: some therapeutic agents have more than one site 
of action, such as tricyclic antidepressants (McQuay et al, 1996), of which 
imipramine, amitriptyline and desipramine are commonly used. These drugs are 
non-selective, acting as sodium channel blockers, and also on the descending 
inhibitory serotoninergic and noradrenergic systems. Some agents target specific ion 
channels , in particular sodium channel 
blockers, but again they do not act selectively 
on those subunits thought to be involved in chronic pain. The vanilloid agonist 
capsaicin is considered for limb hypersensitivity, possibly associated with cutaneous 
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re-innervation (Berman et al, 1998), but no TRPVI -antagonists are currently 
available for clinical treatments. 
There are few systematic studies on randomised clinical trials for pain relief in 
patients with nerve or brachial plexus injury. Using the "number needed to treat" 
(NNT) method (numbers of patients needed to treat to obtain one patient with more 
than 50% pain relief), Sindrup and Jensen (1999) evaluated the efficacy of different 
pharmacological agents used in the treatment of painful neuropathy. For 
antidepressants of all types combined, NNT of 3 was observed, with slightly better 
NNT for tricyclic antidepressants. For the ion channel blockers the NNT values 
were: carbamazepine 3.3, gabapentin 3.7, phenytoin 2.1, and mexiletine 10.0, while 
the values for other agents, dextromethorphan, tramadol, and capsaicin, were 1.9, 
3.4, and 5.9 respectively. These all indicate a relatively poor effectiveness of 
available drugs for neuropathic pain. Considering this, together with the fact that 
side-effects, which often determine the choice of drug used, are often limiting, it is 
clear that a better choice of therapy is much needed. The findings described in this 
thesis contribute to the understanding of novel ion channel involvement in 
neuropathic pain, and may support the validity of new targets for pain management. 
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6.2. Main findings and validation of novel targets in human 
0 
painful conditions. 
It is well recognised that some neuropathic positive symptoms can be related to 
changes of ion channels in nerve fibres, and the presence of particular symptoms can 
suggest the involvement of a sub-group. Presence of spontaneous pain after nerve 
injury is often related to accumulation of sodium channels in the injured axons, 
resulting in foci of ectopic activity in the axons and cell bodies of injured neurons 
(Woolf and Mannion, 1999). Many studies in animal models support the 
involvement of TRPV I in stimulus-evoked then-nal hyperalgesia and allodynia with 
inflammation or after nerve injury (Davis et al., 2000; Hudson et al., 2001) and 
TRPVl antagonists were shown to reverse thermal and mechanical allodynia in 
neuropathic and inflammatory pain animal models (Walker et al., 2003). 
Inflammatory agents are known to potentiate TRPVI responses, and while after 
peripheral nerve injury TR_PVI is down-regulated in axotomised neurons , it is up- 
regulated in the surviving spared nerve fibres of the undamaged DRG neurons. 
The identification of the appropriate target for a distinct condition or pain mechanism 
is therefore of great importance. 
This work has shown changes in the expression of novel ion channels in the 
peripheral nerve tissue in conjunction with neuropathic pain and hypersensitivity. 
After DRG avulsion, an increased expression of some of the thermo-receptors of the 
vanilloid family was observed, while after nerve injury accumulation of ion channels 
from both vanilloid and sodium channel families was observed in neuromas, and 
spared axons. Cutaneous hyper- or hypo-sensitivity after nerve injury was correlated 
with density of skin innervation and expression of the TRPVl channel in skin fibres, 
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whereas other ion channels such as subunits of the sodium channel family did not 
show any change. The relevance of these findings, of the differential changes in 
specific ion channels mediating spontaneous pain and hypersensitivity, and relevance 
for advances in pain management, is now discussed. 
6.2.1. TRPV1 and potential of TRPV1 blocking agents 
This study has shown a correspondence between increased TRPVI in skin fibres and 
hyperalgesia in some painful conditions, suggesting this receptor would be a 
selective target for treatment of chronic hypersensitivity states. Observations in 
patients with nerve injury have shown accumulation of this thermoreceptor in injured 
peripheral nerves and increased TRPVI expression in skin fibres specifically in 
hypersensitive areas. The discovery of region-specific increased expression of the 
TRPVI receptor, but not Navl. 8 sodium channel, in patients with vulvodynia, is in 
accordance with the hypothesis of a specific involvement of this receptor in 
conditions characterised by allodynia and hyperalgesia. The increased expression of 
TRPV I in polymodal nociceptor fibres could mediate these symptoms, and this study 
therefore suggests TRPVI antagonists would be a valid therapy for the treatment of 
this pathology, while the use of sodium channel antagonists for Na, 1.8 may not be 
expected to be as effective. The latter may be more effective for spontaneous, 
particularly "shooting", pain (see below). 
The use of topical TRPV I agonists has been under trial for the treatment of a number 
of chronic pain and hyper- sensitivity states (Robbins, 2000). Recently, their 
application in bladder dysfunction and detrusor over-activity has been investigated 
(Apostolidis et al., 2006; de Seze et al., 2006). A relation between increased density 
of TRPV I -positive fibres and pain was shown 
in a study on patients with neurogenic 
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detrusor over-activity (NDO) (Brady et al., 2004a). This showed an increased 
density of TRPV I fibres in NDO patients compared to controls, and a decrease of 
fibres after treatment with resiniferatoxin (RTX), restricted to those patients that 
responded to treatment. 
Topical application of capsaicin cream is used also in the treatment of diabetic 
neuropathic pain, but controlled clinical trials show conflicting results (Sindrup and 
Jensen, 1999). This could be related to trials been often too small to give substantial 
results, and to differences in compliance to the drug application protocol. Initially, 
local application of TRPV I agonists, capsaicin or RTX, is known to induce burning 
pain by activating polymodal nociceptor fibres that express TRPV I- Application of 
high doses of capsaicin, or repeated application of lower therapeutic doses (0.075%), 
is known to produce nerve tenninal degeneration, leading to functional 
desensitisation. In this way, nociceptors may lose contact with their source of NGF, 
which non-nally regulates the expression of TRPVl. If application is tenninated, 
nerve terminals can regenerate, re-innervating the NGF-rich targets, so that repeated 
application of TRPV I agonist is required for efficacy. 
In addition to TRPV1 agonists, TRPV1 antagonists could be suitable as drugs and 
could be most useful in the future. While they do not damage nerve endings, they 
can reverse hypersensitivity to thermal and also mechanical stimuli in animal models 
of inflammatory and neuropathic pain (Walker et al., 2003). This and related studies 
have addressed the problem of a species-specific efficacy of TRPVl antagonist in 
animal models of chronic pain. It clearly shown that while capsazepine inhibited 
ferent animal species (rats, mice and guinea capsaicin induced hyperalgesia in dif I 
pigs), this antagonist is only effective in other animal models of pain (such as partial 
pigs, but not i M, nerve-ligation and inflammatory models) in gui I in rats or ice. 
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These species differences in the in vivo anti -hyperal gesic effect of the TRPVI 
antagonist are consistent with previous observations from in vitro studies, which 
have shown differences in the pharmacology of rat TRPV I compared to guinea pig 
and human vanilloid receptor (McIntyre et al., 2001; Savidge et al., 2002). While 
capsaicin blocks the response to noxious heat and protons in both human and the 
guinea pig TRPV I receptors expressed in recombinant systems (HEK cells and CHO 
cells), it is not active as a blocker of heat and protons evoked currents on the rat form 
of the receptor. In summary, the activity and potency of this antagonist depends on 
the evoking stimulus used (capsaicin, heat or low pH), and its properties are different 
between species. 
The human and rat TRPVI protein sequences have 85% identity, with the trans- 
membrane and C-terminus portions being highly conserved. The identification of 
species specific effect of capsazepine has allowed, by studying the phannacological 
properties of chimeric and mutant receptors, to identify the molecular determinants 
of the activity of the antagonist capsazepine on the human TRPVI receptor (Phillips 
et al., 2004). The study showed that specific mutations in the region of the trans- 
membrane domains S3 and S4 of the rat TRPVI that mimic the human molecular 
structure of the receptor increase the effectiveness of capsazepine at inhibiting the 
receptor response to low-pH stimulus. Reciprocal mutations on the human receptor 
had the opposite effect on its functionality, tested in in vitro assays. So, despite some 
contrasting results from animal models of chronic pain due to speci es- specific 
differences , it 
has been suggested that the potency of a compound to block not only 
capsaicin but also noxious heat and protons evoked activation of the humn TRPV I 
receptor in vitro would be a good predictor of its efficacy as anti-hyperalgesic in 
clinical trials. 
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The last few years have seen the development of small molecule TRPVI antagonists 
by pharmaceutical companies, mostly tested in preclinical studies, but with some 
currently undergoing clinical trials. The published results presented in this work and 
those from other studies (Yiangou et al. 2001b; Chan et al., 2003; Tympanidis et al., 
2004; Gopinath et al. 2005; Morgan et al., 2005; Facer et al., 2007) suggest a 
potential therapeutic value of TRPV I -antagonists for pain management in a wide 
range of somatic and visceral chronic pain conditions. Hence clinical trials are under 
way with TRPVl antagonists in clinical chronic pain states in patients with over- 
expression of TRPV I in peripheral fibres, as identified in these studies. 
At present Phase I and Phase 11 clinical trials are running with the GSK compound 
SB-705498 for dental pain and migraine. This antagonist blocked TRPVl activation 
by capsaicin, low pH and heat in vitro, and reversed mechanical allodynia and 
thermal hyperalgesia in preclinical pain models (Rami et al., 2006) in guinea pigs. 
Results for this compound, from a Phase I clinical study in healthy volunteers, have 
been recently presented (Chizh et al., 2007). The study had a placebo controlled, 
single-blind, two-way cross-over design. The subjects receiving the active 
compound showed a good response. The findings in the subjects treated with the 
antagonists, such as elevation of heat pain threshold in non-sensitised skin, increased 
heat tolerance in inflamed skin (by UVB irradiation), and dose-dependent reduction 
of capsaicin-evoked skin flare, were consistent with TRPVI mediation. Most 
importantly, the incidence of side-effects was comparable between treatment groups, 
and the adverse events that presented were generally mild and unlikely to be related 
to study medication, even if the effect of using higher doses and prolonged treatment 
have yet to be investigated. Clinical efficacy in pain states is not predicted by study 
in healthy subjects, and therefore a positive outcome from the currently running 
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clinical trials for migraine and dental pain will be of great importance in supporting 
the possibility of a therapeutic use of TRPVI antagonists, and to further extend 
clinical trials to other conditions such as those mentioned above. 
6.2.2. Role of purinergic receptors 
A large number of studies have explored the role of the P2X receptor family in acute 
and chronic pain, with particular attention given to the P2X3 subunit, localized 
predominantly in small nociceptive sensory nerves, where it shows a high level of 
expression compared to the other P2X subunits (Burnstock, 2006). Involvement of 
this receptor is proposed in visceral pain via their role in mechanosensory 
transduction (Bumstock, 2001; Yiangou et al., 2001 a; Brady et al., 2004b), as well as 
in neuropathic pain after peripheral nerve injury (North, 2004). 
A major role in inflammation is attributed to the non-neuronal P2X7receptor (Illes et 
al., 2000), which activation, as discussed in Chapter 4, induces release of pro- 
inflammatory cytokine activating an inflammatory cascade. In this thesis, increased 
P2X7was shown in injured nerves in association with pain and in avulsed DRG in 
non-neuronal cells in human tissue, while P2X7 knock-out mice showed no 
development of chronic pain using both partial nerve ligation and Freund's Complete 
Adjuvant-induced models, suggesting a role for the P2X7 subunit in neuropathic as 
well as inflammatory pain (Chessell et al., 2005). A role of P2X7 in neuropathic pain 
is further supported by recent studies in animal models, which have shown that 
application of selective antagonists for this subunit reverses mechanical allodynia 
induced by spinal nerve ligation or chronic construction injury in rats (McGaraugthy 
et al-9 2007). In vitro, P2X7 selective antagonists were shown to block the calcium- 
in cultured non- influx and the release of IL- IP induced by agonist appli I 
neuronal DRG cells and macrophages respectively (McGaraugthy et al., 2007), as 
well as on recombinant systems expressing the rat or the human form of P2X7 
(Stokes et al., 2006). In vivo electrophys io logical recordings from rat spinal neurons 
in the dorsal horn showed that P2X7 antagonism reduced spinal neurons evoked and 
spontaneous activity in neuropathic rats but not in sham operated rats (McGaraugthy 
et al., 2007). Antagonism of secondary neuronal activity would support a role of this 
subunit in modulation of central sensitisation, but P2X7 mediated glial-neuronal 
interaction could be relevant at spinal as well as peripheral sites. The nonnal pain 
processing observed in the P2X7 knock-out mice (Chessell et al., 2005) and would be 
consistent with a important role in pathological states, due possibly to up-regulation 
of the receptor after injury, as we observed in peripheral human tissue specifically 
when pain had developed after nerve injury, and as observed in CNS 
neurodegenerative disoders by Yiangou et al (2006) in post mortern human spinal 
cord microglia. 
Understanding the relation between satellite cells and DRG neurons or Schwann cells 
and nerve fibres, and the sequence of the reciprocal effects between the glial and 
neuronal compartments, is fundamental to fully comprehend the role of the P2X7 
receptor in neuropathic pain. Satellite cell-derived substances, which include 
different neurotrophic factors as well as proinflammatory cytokines, have an 
important function in regulating neuronal activity. Increased P2X7 expression in the 
periphery could have a role in modulating satellite and Schwann cells under 
neuropathic conditions, but the modality of their effect needs further investigation. It 
is to be noted that the signalling mechanisms initiated by P2X7 activation have been 
observed to be cell-type dependent. For example, while P2X7 activation induces 
Ca+2 influx in satellite cells, prolonged activation of this receptor does not induce 
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formation of cytolytic pores in this cell type (Zhang et al., 2005). Also, possible 
species-specific characteristics in the functionality of the receptor should be 
considered, in view of the relatively low homology between human and rat P2X7 
receptor, which accounts for the difference in potency of a specific antagonist 
observed in the two forms of the channel (Stokes et al., 2006). 
In conclusion, studies in human tissue and pre-clinical animal models all suggest a 
role for some of the P2X subunits in chronic pain, and different specific P2X subunit 
antagonists are currently being developed (Donnelly-Roberts et al., 2008) for the 
treatment of pain. These may prove to be valuable tools for determining the different 
role of multiple P2X subunits, and for the characterization of the function of P2X7 
receptor in different compartments, central and peripheral. Pharmacological tools 
are of great importance for validating these subunits as targets for treatment of 
neuropathic pain. 
6.2.3. Sodium channels antagonists 
Voltage-gated sodium channels (VGSC) have long been considered important targets 
for pain management, due to their involvement in neuronal excitability, and since 
sodium channel antagonists are currently in widespread clinical use for treatment of 
neuropathic pain. However, all VGSC blockers currently in clinical use are non- 
selective, with this lack of specificity being a cause of their wide range of significant 
side-effects, and therefore the most limiting factor for their therapeutic use. In the 
last few years, a number of studies have shown the role of specific subunits of the 
in in pre-clinical models, and, VGSC family in the development of neuropathic pal II. 
most importantly, in human pathologic conditions (Cummins et al., 2007; Waxman, 
2007). 
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The Na, 1.7-subunit, with its selective expresslon In the perlpheral nervous system, is 
a potential interesting target, and has been shown to have a major role in 
inflammatory pain in rodents (Nassar et al., 2004) and visceral and somatic pain in 
humans (Coward et al., 2001 a; Yiangou et al., 2007). Complete deletion of Na, 1.7 in 
mice is lethal, while specific deletion confined to primary sensory neurons prevents 
development of inflammatory pain but does not eliminate neuropathic pain (Nassar et 
al., 2005). Altered function of the Na, 1.7 subunit in erythromelalgia and familial 
rectal pain (Drenth et al., 2005; Fertleman et al., 2006), and increased nerve fibres 
immunoreactive for this subunit in rectum of patients with rectal hypersensitivity 
(Yiangou et al., 2007), suggested an important role for Na, 1.7 in clinical pain states. 
Also, the increase in density of Na, 1.7 positive fibres was greater than the increase of 
the vanilloid receptor TRPVI expression previously shown in the same group of 
patients (Chan et al., 2003). In the study it is suggested that both up-regulation could 
be driven by an increase of NGF, which regulates the expression of both receptors 
(Yiangou et al., 2007). Conversely, Cox et al., (2006) reported a channelopathy 
which resulted in a complete lack of functionality of the Na, 1.7 subunit. Individuals 
with this condition appeared to be unable to experience pain, but were otherwise 
normal. This would suggest that specific antagonism at the Na, 1.7 subunit would be 
analgesic with potentially very few side-effects. 
The different clinical pattern of pain developed by patients suffering from 
erythromelalgia or Familial Rectal Pain has not been explained. Waxman (2007) has 
suggested that the interaction of the mutated Na, 1.7 subunit with other molecules 
specifically expressed in certain cells, or in a time-dependant manner, could be the 
cause behind these differences. Also, the effect of the distinct functional 
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modifications (isoforms) in the two pathologies could be specific to delimited subsets 
of neurons. 
It is clear that neuronal excitability does not depend on a single specific channel. In 
particular, the cumulative effect of Navl. 7 and Navl. 8 channels on cell excitability is 
considered most important (Cummins et al., 2007). In Yiangou work (2007) on 
rectal hypersensitivity, it was not possible to investigate the presence of Navl. 8 in 
conjunction with Na, 1.7 in the same specimen, as different methods of fixation were 
optimal for the two antibodies. 
A major role of Na, 1.7 is thus recognised in neuropathic conditions. However, the 
modulation of other sodium channel subunits or other receptors deserves attention. 
P-subunits have a functional role in channel gating, by modulating the activity of the 
associated cc-subunits, and in the expression level and cell membrane adhesion of the 
channel. The structural diversity of the beta subunits, if accompanied to selective 
association with specific alpha-subunits, would be most useful. These subunits 
would prove to be particularly good targets for specific rational drug design. 
This work described the presence of the 03 subunit in DRG neurons, which is 
maintained in DRG soma after avulsion, and increases in human peripheral nerves 
after peripheral nerve injury. The P3 subunit shows a selective distribution in small 
sensory neurons in rats, parallel to that of the TTX_R sodium channels, and was seen 
to interact with Naj-8 in the Xenopus oocytes expression system, making this 
subunit a potentially good target as an alternative to an oc-subunit antagonist 
selective for Navl. 8. It would be important to investigate which subunits associate in 
sensory fibres after nerve injury. In the sciatic nerve transection model in rat, the P3 
subunit was seen to be highly co-expressed in injured neurons with the Na, 1.3 
subunit (Takahashi et al., 2003), which is present also in human injured fibres. This 
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would support a role for P3 in coupling with Na, 1.3 after nerve injury and their 
involvement in the altered functional properties of injured sensory fibres. 
Studies of VGSCs in pain models and patients have stimulated much research in drug 
development, resulting in a series of new classes of VGSC antagonists that show 
efficacy in pre-clinical models (Krafte and Bannon, 2008), with one in particular 
showing subunit selectivity (Jarvis et al., 2007). Testing the activity of these new 
compounds in animal models, as well as in human tissues or recombinant receptors, 
will further clarify the role of specific sodium channel subunits in different pain 
states. Currently, to our knowledge, there are no selective P-subunit antagonists. 
However, despite most of the current efforts are still directed towards the use of the 
(x-subunits as a therapeutic target, the P-subunits may provide a useful and less 
difficult strategy. 
Summary 
The last few years have seen a vast progress in the knowledge of the involvement of 
ion channels in peripheral mechanisms of pain. The research discussed, including 
my contributions described in this thesis, has resulted in the identification of 
potential novel targets for neuropathic pain. The recent breakthroughs in the 
synthesis of selective compounds for some of these ion channels by the 
pharmaceutical industry will allow further progress in the understanding of 
pathological pain, and will hopefully result in much needed improvements in 
neuropathic pain management. 
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6.3. Ion channels localisation: human versus animal nerve tissue 
Many studies are conducted in animal models of neuropathic pain. As efficacy of 
novel drugs in animal models of neurogenic pain has been a poor predictor of 
success in clinical trials, localisation studies in humans, to compare to animal models 
of pain, are very important when considering potential efficacy and selectivity of 
novel drug targets. It is fundamental to confirm correspondence of patterns of ion 
channels expression between species, especially for those channels thought to be 
involved in the generation of neurogenic pain, in order to validate the use of animal 
models of chronic pain - ideally, human sensory neurons should be studied in 
common chronic pain states. 
An important result of this work has been to characterise the presence of specific ion 
channels in normal human peripheral nerve tissue and some of the changes that occur 
after injury. This allows for a comparison with known pattern of ion channels 
localisation in animal models, already well described in literature. Despite the fact 
that in humans we are clearly restricted by the kind of tissue available (for example 
human DRG from peripheral axotomy cannot be obtained at surgery), human tissues 
should be used whenever possible for validation, especially since correspondence 
with animal models is not always observed, as shown in this work. 
6.3.1. TRPs receptors 
The localisation studies in human tissue showed in this work have mostly confirmed 
what is reported in animal models, such as co-localisation of TRPVI and TRPAI 
receptors in small sensory neurons, and the increase of both thermoreceptors after 
nerve injury. The presence of TRPM8 and TRPVI in different sets of nociceptors, 
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which has been established in rodents, could not be explored properly In this study 
due to the very low number of TRPM8 positive neurons observed in human DRG 
samples. However the limited results obtained are in accordance with a possible co- 
localisation of these two receptors induced by injury. Some clear differences were 
observed. For example, while TRPVI mostly express in small sensory neurons, 
independently of species, some large cells express TRPVI in human DRG. Also, 
while a wide distribution of TRPV4 in sensory neurons of all size corresponded well 
to observations in rodents, the percentage of positive neurons in human DRG were 
higher. 
6.3.2. P2X receptors 
To my knowledge, there are no lHC studies on the localisation of P2X7 in peripheral 
nerves in mice. However, its presence has been identified in rat nerve tissue, both in 
non-neuronal DRG cells and in myelinating Schwann cells (Grafe et al., 1999; Zhang 
et al., 2005). These results are in accord with the non-neuronal distribution in human 
PNS shown in this work. The P2X7 receptor appears to have a pivotal role in the 
activation of the inflammatory cascade, and this receptor has been linked mainly with 
inflammatory pain. Its possible involvement in neuropathic pain was suggested by 
our study in human nerves and subsequently in an animal model of neuropathic 
hypersensitivity in P2X7 knock-out mice (Chessell et al., 2005). Further studies are 
needed in rodents to establish localisation with immunohistochemistry, and compare 
findings with those in humans. 
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6.3.3. Voltage gated sodium channels. 
In this work, localisation of a novel P-subunit was Investigated for the potential use 
of this subunit as selective target for neuropathic pain. A study in rat DRG showed a 
differential distribution for P, andP3 (Morgan et al., 2000) withP3 confined to small 
neurons, which suggest for the use of this subunit as a potential target to nociceptors. 
However we did not observe the same differential distribution in human DRG, 
further highlighting the need for localisation studies in human tissues. 
6.4. Limitations of IHC and WB studies 
Immunohistochernistry is widely used for research, and lHC methods have been 
greatly improved over time. However lHC has some important limitations. 
Antibody specificity needs to be proved, and negative and positive controls were 
always included, unless antigen was not available. Most important, reliability of 
results depends on the quality of primary antibodies, which can be highly variable 
regarding avidity/affinity. Our TRPVI antibodies were very good, having high 
affinity for the antigen, and were used at high dilution, giving very low background, 
enabling visualisation of not only DRG neurons but sensory fibres up to the 
epidennis. However, despite TRPV3 antibodies showing good immunostaining in 
sensory cell bodies and axons proximal to DRG, they were not able to 
detect TRPV3 
in peripheral fibres at distal locations such as skin, which may reflect their poorer 
quality compared to TRPV I antibodies. 
Although the two TRPM8 antibodies available were not used at high titre, and one of 
them showed nuclear background staining, they did show immunoreactivity in 
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peripheral nerve fibres but very few positive sensory neurons. Ventral spinal root 
fibres, but not motoneurons, were TRPM8 positive. These results could indicate a 
fast translocation of the protein along the axon. However the possibility of cross- 
immunoreactivity with other axonal protein can not be ruled out, making the 
interpretation of results observed using the TRPM8 -antibodies questionable. 
Potential limitations can arise from the condition of tissue samples. Injured nerve 
tissue samples were collected during surgery and quickly processed, while control 
tissues such as DRG were often only available up to 48 hours post mortem. During 
this time tissue damage can occur, which could degrade antigens and affect 
morphology. These limitations could not be avoided, but great care was always 
applied in the processing of the tissues, and samples which did not show a "normal" 
morphology when immuno-stained using standard neuronal markers and histology 
were discarded. 
Western Blotting was used to quantify the amount of protein of interest for 
comparison between controls and injured samples of nerve tissue. The same 
concerns as those for lHC apply in this case, with reliability of results again 
dependent upon the quality of the antibodies available and of the tissue samples. 
6.5. Further work 
Localisation studies of ion channels and receptors obtained by lHC should be 
supported when possible by functional studies. These would allow verification of 
receptor presence and its functionality at the membrane level. The ion channels 
suggested to be valid novel targets for the treatment of neurogenic pain should 
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therefore be studied in detail using functional techniques, including 
electrophysiology. In vitro studies of selected ion channel s/receptors by the use of 
cultured sensory neurons would allow research on the physiology of these channels 
and the cells where they express. Such studies would also allow assessment of the 
influence of growth factors and co-cultured targets, and the action and selectivity of 
potential agonists/antagonists. Such studies are often done in transfected cells, e. g. 
oocytes, CHO or HEK cells transfected with cDNA or RNA, over-expressing the 
receptor of interest. However these systems sometimes do not correctly represent the 
physiological conditions of the native systems, due for example to the lack in the 
experimental setting of an unknown factor normally present, which would change the 
properties of the channel studied. Human DRG would thus be better for 
physiological studies, but they are rarely obtained and only after injury. 
Despite the necessary considerations to be applied when extrapolating from in vitro 
to in vivo studies, the studies with cultured human DRG reported here are extremely 
rare, and provide a model for further neurochemical and functional studies. In 
particular, human neuronal cultures offer means to study the interaction between 
neurotrophic factors and those channels/receptors related to pain expressed in human 
sensory neurons. The studies in neuronal cultures discussed in Chapter 3 utilised a 
combination of NTFs, normally synthesised in keratinocytes, to approach in vivo 
conditions. Further similar studies with addition of individual or different 
combinations and doses of NTFs would be of interest to investigate specificity of 
neurotrophic effects. A different opportunity to study human DRG neurons in 
culture comes from the characterisation of an immortalised cell line from human 
DRG neurons (Raymon et al., 1999), which suggests its feasibility for physiological 
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studies. However, we could not find any other published work which utilises this 
cell line for functional studies. 
Conclusion 
This thesis addresses the understanding of basic and pathological biology of novel 
ion channels and receptors expressed in sensory neurons, and contributes to the 
rationale for new therapeutic strategies for chronic pain management. These ion 
channels and receptors are important novel analgesic targets for the pharmaceutical 
industry, which it is hoped will deliver great improvements for pain therapy in the 
near future. 
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Appendix-I List of chemicals 
Compound Company/code 
Acetic acid, glacial Sigma-Aldrich, Steinham, Germany / A-6283 
Ammonium cloride (NH4CI) VWR International Ltd, Poole, UK / 100 173 D 
di-Ammoniurn Nickel (11) Sulfate 6- 
hydrate 
VWR International Ltd, Poole, UK / 271894F 
Azide / Sodium azide VWR International Ltd, Poole, UK / 301114Y 
Albumin Bovine fraction V (BSA) Sigma, Gillingham, UK A-9647 
D-(+)-Glucose(C6HI206) Dextrose Sigma, Gillingham, UK G-7528 
3,3'diaminobenzidine tetra- 
hydrochloride dehydrate (DAB) 
Sigma-Aldrich, Gillingham, UK / 261890-25G 
Donor Goat serum TCS Biosciences Ltd, Botolph Claydon, UK 
GS008 
Donor Horse serum TCS Biosciences Ltd, Botolph Claydon, UK 
HAO02 
ECL Plus Western Blotting 
Detection Reagent 
Amersharn Biosciences Ltd, Little Chalfont, UK 
/ RPN2133 
Glucose Oxidase Sigma, Gillingham, UK / G-2133 
Hydrogen Peroxide solution (30%) VWR International Ltd, Poole, UK 285194F 
Methanol VWR International Ltd, Poole, UK 10 15 8 6B 
Neutral red VWR International Ltd, Poole, UK 340564A 
OCT TM Embedding Medium Raymond A Lamb, Eastbourne, UK / 4583 
Paraformaldehyde GPR VWR International Ltd, Poole, UK 294474L 
Poly-L-lysine hydrobromide Sigma, Gillingham, UK / P- 13 99 
Potassium di-hydrogen 
orthophosphate (KH2PO4) 
VWR International Ltd, Poole, UK 102034B 
Protogel National Diagnostics, Hessle, UK EC890 
Protogel Resolving Buffer National Diagnostics, Hessle, UK EC892 
Protogel Stacking Buffer National Diagnostics, Hessle, UK EC893 
20% SDS solution Ultra Pure National Diagnostics, Hessle, UK EC-974 
Sodium acetate 3-hydrate VWR International Ltd, Poole, UK / 301034J 
Sodium chloride (NaCl) VWR International Ltd, Poole, UK / 102415K 
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di-Sodiurn hydrogen orthophosphate VWR International Ltd, Poole, UK / 102494C 
anhydrous (Na2 / HP04) 
TEMED National Diagnostics, Hessle, UK / EC-503 
Tetramethylethylenediamine 
TRIS/Glycine/SDS I OX Ultra Pure National Diagnostics, Hessle, UK / EC-870 
(Electrophoresis Running Buffer) 
Vecta mount Vector Laboratories Inc, Burlingame, 
CA / H-5000 
Xylene VWR International Ltd, Poole, UK / 305756G 
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Appendix-2 List of materials and equipment 
Name Company/code 
Coverslip Cover Glass (22 x50 
mm, Thickness No. 1) 
VWR International Ltd, Poole, UK / 631-0137 
Digit-X densitometer X-Ograph Ltd, Wiltshire, UK 
DPX mounting medium RA Lamb, Eastbourne, UK / A/E020-C 
Hybond-P Membrane Amersham Biosciences Ltd, Little Chalfont, UK 
Hyperfilm ECL Amersham Biosciences Ltd, Little Chalfont, UK 
RPN3103K 
Mini-PROTEAN IITM Vertical 
Electrophoresis System 
BioRad, Hemel Hemstead, UK 
OFT 5000 Cryostat Bright Instruments Co Ltd, Huntington, UK 
Petri Dish (standard style, 
150 mm. of diameter) 
VWR International Ltd, Poole, UK 
Pipettes Gilson 
Superfrost Microscope 
Slides (76 x 26 mm) 
VWR International Ltd, Poole, 
UK (631-0117) 
Trans-blot Semi-Dry Transfer cell BioRad, Hemel Hempstead, UK 
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